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ABSTRACT OF DISSERTATION 
 
 
 
 
ANTIBIOTICS TARGETING TUBERCULOSIS: BIOSYNTHESIS OF A-
102395 AND DISCOVERY OF NOVEL ACTINOMYCINS 
 
 
The increase in antibiotic resistance of many bacterial strains including multidrug-
resistant tuberculosis (MDR-TB) due to over- and misuse of antibiotics is a serious medical 
and economical problem. Therefore discovery and development of new antibiotics are 
urgently needed. Two projects were undertaken to address the need for new anti-
tuberculosis antibiotics. 
1. Discovery of new chemical entities. A-102395, a new nucleoside inhibitor of bacterial 
MraY (translocase I, EC 2.7.8.13) that is essential for bacterial survival, was isolated from 
the culture broth of Amycolatopsis sp. SANK 60206 in 2007. Although A-102395 is a 
potent inhibitor of translocase I with IC50 of 11 nM, it contradictingly does not have any 
antibiotic activity. A-102395 is a derivative of capuramycin with a unique aromatic side 
chain. A semisynthetic derivative of capuramycin is currently in clinical trials as an anti-
tuberculosis antibiotic, suggesting potential for using A-102395 as a starting point for 
antibiotic discovery. The biosynthetic gene cluster of A-102395 was identified, including 35 
putative open reading frames responsible for biosynthesis and resistance. A series of gene 
inactivation abolished the A-102395 production, indicating those genes within the cluster are 
essential for A-102395 biosynthesis. Functional characterization of Cpr17, which has 
sequence similarity to aminoglycoside phosphotransferases, revealed that it functions as a 
phosphotransferase conferring self-resistance by using GTP as phosphate donor. 
Furthermore the enzyme is characterized by low substrate specificity, as Cpr17 was 
capable of modifying a large series of natural or semi-synthesized analogues of 
capuramycins. A series of organism-specific high-throughput screening models for potential 
antibacterial agents targeting on bacterial cell wall synthesis have been established, 
including Escherichia coli and Mycobacterium tuberculosis. For this screen ten enzymes 
were successfully used to reconstitute cell wall biosynthesis in vitro. This screening is 
expected to allow us to identify the targets of novel antibiotics rapidly and in a cost-
efficient manner 
2. Rediscovering old antibiotics. As part of our long term goal of discovering and 
 
developing novel anti-tuberculosis antibiotics, four novel actinomycins were isolated 
from the scale-up fermentation of Streptomyces sp. Gö-GS12, and their structures were 
characterized using mass spectrometry and 1D and 2D NMR. Their antibacterial activity 
against Gram-positive and Gram- negative strains were determined, as well as their 
cytotoxicity. 
Key words: capuramycins, peptidoglycan cell wall, phosphotransferase, actinomycins. 
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Chapter 1: Introduction and Background 
 
1.1 Need for new anti-tuberculosis antibiotics 
 
Despite the remarkable success of antibiotics, infectious diseases are still one of the 
highest causes of death worldwide leading to over 17 million people deaths each year 
(1). This is largely due to the continually increasing number of bacteria that are resistant 
to antibiotics as a result of both intrinsic or acquired mechanisms (2). Bacterial resistance 
to every major classes of antibiotics has been developed shortly after their first clinical 
use (3), and the emergence of multiple drug resistant pathogens (MDR) such as 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Enterococci (VRE) has become serious hospital and community threat. It was estimated 
that MDR pathogens caused over 2 million infections and 23,000 of deaths in the USA 
in 2013 alone (4). 
The rise of antibiotic resistance is typically associated with overuse and misuse of 
antibiotics. It was reported that the highest rates of antibiotic resistance were seen in 
those areas with the highest rate of antibiotic prescription (5). Along with increased drug 
resistance among pathogens, the discovery and development of new antibiotics, 
however, has dramatically declined since the “golden era” of antibiotics in 1950s when 
most classes of antibiotics were discovered. Over the past 40 years, only five new 
classes of antibiotics have been approved by FDA (6,7), and currently there are no new 
molecular entities (NME) in phase III clinical trials within the United States. Therefore 
discovery and development of new antibiotics remains a high priority. 
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Another major threat today is tuberculosis (TB) caused primarily by Mycobacterium 
tuberculosis, which is estimated to currently infect 2 billion people worldwide with 9 
million new cases diagnosed each year (8). It is likewise estimated that TB is the cause 
1.3 million deaths annually (9), making it the second largest infectious disease killer. The 
complicated mycolic acid-containing cell wall structure of M. tuberculosis makes it 
naturally resistant to most of the antibiotics such as penicillin. The cell-wall architecture 
is composed of peptidoglycan which is covalently linked to a linear galactofuran via an 
L-Rha-D-GlcNAc-P linker, and several strands of highly branched arabinofuran which is 
further attached to mycolic acids (10). The thick layer of lipid on the outer part of the cell 
protects the tuberculosis bacillus from noxious chemicals and allows the bacterium to 
survive from host’s immune system by living inside macrophages (11). Thus TB is 
difficult to treat and it usually takes six months to cure an active TB infection with a 
combination of first-line drugs (isoniazid, rifampin, ethambutol and pyrazinamide) (12). 
Like other pathogens, there has been a steady increase in reported cases of drug- 
resistant M. tuberculosis. Multidrug-resistant tuberculosis (MDR-TB) which is not 
treatable by isoniazid and rifampicin is becoming an increasing threat to public health in 
many developing countries, and extensively drug-resistant TB (XDR-TB) which is 
resistant to not only isoniazid and rifampicin but at least one additional anti-TB drug has 
been reported in more than 100 countries (9). The World Health Organization (WHO) 
estimated that 1.1 million (13%) of the TB patients worldwide were HIV-positive resulting 
360,000 deaths from HIV-associated TB in 2013 (9). MDR-TB generally requires 20-24 
months of treatment with additional five or six second-line drugs that are less effective 
and more toxic than first-line regimen (12). 
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1.2 Significance of natural products in antibiotic discovery 
 
Natural products have played an important role in the discovery of antibacterial agent 
since the introduction of penicillin in the 1940s (13). Until 2012, natural products or 
derivatives of natural products contributed about 75% of total approved antibacterial 
agents (14). Although antibiotics have been discovered from many organisms ranging 
from unicellular bacteria to eukaryotic fungi, and from plants to marine invertebrates, 
nearly 80% of the antibiotics have been discovered from Actinomycetes (15). Many 
important classes of antibiotics can only be found in those producers including polyene 
macrolides, polyether antibiotics, cyclopolylactons, most aminoglycosides, actinomycins 
and quinoxaline-peptides (16). 
In recent years, screening of natural products from microbial products has diminished 
because the discovery of novel natural products with useful antibiotic properties has 
become more expensive and laborious (17). However, it is increasingly clear that there 
is still large amount of natural products from diverse microorganisms from underexplored 
ecological niches that have yet to be identified. For example, it was estimated that 99% 
of the bacteria are “unculturable” (18) in conventional microbiology labs, and that 90-99% 
of the metagenome is not being sampled (19). Furthermore, the majority of bacteria 
operons for secondary metabolites are “silent” or cryptic under the typical growth 
conditions in the laboratory (20) while marine microbial communities have not yet been 
systematically collected and studied for bioactive secondary metabolites (17). Thus 
natural products are still promising sources for novel antibiotic discovery by applying 
new technologies including improved (21) or culture-independent molecular    methods 
(22), activating silent or cryptic biosynthetic gene clusters (23) and exploring  microbial 
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natural products and their producing organisms discovered from unique environments 
such as deep oceans (24). In addition, many “old” antibiotics were abandoned for clinic 
use due to poor pharmacokinetics or lack of activity. Researchers who now access to 
new technologies such as whole-genome sequencing can identify biosynthetic pathways 
of antibiotics and possible resistant genes, genetic engineering and computer-assisted 
drug design will be able to overcome difficulties in development of natural products 
(21,25,26). 
1.3 Current antibacterial targets 
 
There are over 200 conserved essential proteins in bacteria providing multiple targets 
for antibiotics to inhibit growth (3). Nonetheless, traditional screens used for antibiotic 
discovery have led to the identification of only a few metabolic pathways that utilize 
proteins that are able to be inhibited by small molecules leading to arrest of cell growth 
or cell death. The most successful of these pathways have been i) bacterial protein 
synthesis, ii) folic acid metabolism, iii) bacterial DNA replication and repair and iv) 
bacterial cell wall biosynthesis (27). 
Bacterial ribosomes play a key role in protein synthesis in initiation, elongation and 
termination of protein assembly (28), and have several differences compared to 
eukaryotic ribosomes, making it an important target for antibacterial agents. A large 
number of clinically used antibiotics target the complex translational ribonucleoprotein 
machinery including erythromycin (interferes with aminoacyl translocation (29)), 
tetracyclines (30) and aminoglycosides (31) targeting on the ribosomal decoding site by 
blocking the attachment of aminoacyl-RNA (27). Tetrahydrofolic acid (THF) is essential 
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for bacteria as it serves as a precursor of thymidine synthesis. Antibiotics targeting on 
different steps of the biosynthetic pathway of THF such as trimethoprim (32) and 
sulfamethoxazole (33) are used to inhibit the formation of THF and thus bacterial DNA 
synthesis. Antibiotics that inhibit DNA replication, transcription, and repair can be divided 
into two categories: those that inhibit enzymes involved in this process and those that 
directly bind to DNA. Ciprofloxacin, a member of fluoroquinolones, inhibits DNA gyrase 
by forming a complex with the enzyme and double-cleaved DNA (34) and rifampin 
inhibits bacterial DNA-dependent RNA synthesis by binding to the RNA polymerase (35). 
The antibiotics that directly interact with DNA by forming complexes with DNA or 
chemically modifying DNA usually show very low specificity, resulting in high toxicity. 
Bleomycins bind to DNA and induce scission by abstracting the hydrogen atom from the 
base, resulting multiple DNA strand breaks (36), and mitomycins covalently and 
irreversibly bind to DNA (37). Actinomycins form complexes with DNA (also known as 
intercalators), and the high toxicity limits their clinical use as antibiotics (38). Many of 
these nonspecific antibiotics, however, have instead found utility in the clinic as 
anticancer agents. 
The peptidoglycan layer of cell wall is an essential component of bacterial cell wall 
providing protection to bacterial cells from internal osmotic pressure, and thus is required 
for the survival of nearly all bacteria (39). The backbone of peptidoglycan consists of a 
β-1,4-linked polysaccharide of alternating N-acetylglucosamine (GlcNAc) and N- 
acetylmuramic acid (MurNAc) units with a pentapeptide side chain attached to each 
lactyl group of MurNAc. The backbone is conserved in all bacteria, while primarily   two 
different types of pentapeptide chain are utilized with the general structure of  L-Ala-γ- 
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D-Glu-X-D-Ala-D-Ala, where X is the variable component. Most gram-positive bacteria 
have an L-lysine (L-Lys) as the third amino acid, and a meso-diaminopimelic acid (m- 
DAP) is usually found in gram-negative bacteria (40). The peptide component of 
peptidoglycan is covalently cross-linked via transpeptidation between the ε-amino 
groups of the Lys/DAP residue and the D-Ala residue of a second strand, establishing 
the final structure of cell wall (fig 1.1). Multiple steps are required for the assembly of 
the peptidoglycan polymer that are unique to bacteria, making it an excellent target for 
many antibiotics. β-lactam-containing penicillins prevent the final transpeptidation step 
by covalently binding to transpeptidase (41,42), and the vancomycin family of 
glycopeptide antibiotics bind to the terminal D-Ala-D-Ala moiety of pentapeptide chain, 
preventing enzyme recognition of this substrate thus preventing peptidoglycan synthesis 
(42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Structure of peptidoglycan cross-linking (43). 
 
1.4 Biosynthesis of peptidoglycan cell wall 
The biosynthesis of peptidoglycan requires a minimum of 12 ubiquitous enzymatic 
reactions for both gram-positive and gram-negative bacteria (43). The earlier steps 
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proceed within the bacterial cytoplasm. The first committed step is the MurA-catalyzed 
transfer of the enolpyruvyl moiety from phosphoenolpyruvate (PEP) to uridine-5- 
diphospho-N-acetylglucosamine (UDP-GlcNAc), generating enolpyruvyl UDP-GlcNAc. 
The second step is catalyzed by MurB, a NADPH-dependent reductase that converts 
enolpyruvyl UDP-GlcNAc to UDP-N-acetylmuramic acid (UDP-MurNAc). Subsequently, 
a series of highly-conserved ATP-dependent amino acid ligases (MurC-MurF) catalyze 
the sequential addition of L-Ala, D-Glu, L-Lys (gram-positive species) or meso-DAP 
(gram-negative bacteria), and a dipeptide D-Ala-D-Ala which is formed by the ATP- 
dependent D-Ala:D-Ala ligase (Ddl), generating UDP-MurNAc-pentapeptide. A few 
inhibitors have been discovered targeting the early stages of peptidoglycan synthesis 
including fosfomycin, which selectively inactivates MurA (44),(45), and D-cycloserine, 
which targets Ddl (46) and is effective against M. tuberculosis(47). Following the 
formation of UDP-MurNAc-pentapeptide is the lipid cycle of cell wall biosynthesis, which 
is initiated by the membrane protein MraY (phospho-MurNAc-pentapeptide translocase), 
also known as translocase I. The reaction catalyzed by MraY involves the transfer of the 
MurNAC-pentapeptide unit onto a lipid carrier (undecaprenyl phosphate) to generate 
lipid I, which is then converted to lipid II by incorporating a GlcNAc sugar onto the 4’- 
hydroxyl group of MurNAc catalyzed by a glycotransferase MurG. In certain gram- 
positive strains, additional amino acids may be added to lipid II from an aminoacyl-tRNA 
donor (48). The final cytoplasmic step in peptidoglycan synthesis following disaccharide 
formation is to flip lipid II to the outer leaflet of the cytoplasmic membrane by a membrane 
protein called flippase, but the mechanism of this step is still obscure (49). On the cell 
surface,  lipid  II  undergoes  polymerization  into  nascent  peptidoglycan  strand     via 
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transglycosylation, which is then cross-linked by transpeptidation, catalyzed by a 
penicillin binding protein (PBP) (50) (fig 1.2) The undecaprenyl phosphate is released 
and recycled via dephosphorylation (48). Unlike most bacteria, the mycobacterial cell 
wall peptidoglycan has unique features including incorporation of N-glycolyl-muramic 
acid in polysaccharide chains and heavily cross-linked DAP-DAP bridge (51) and the 
ATP-dependent MurE ligase in M. tuberculosis is highly specific to m-DAP. 
 
 
 
 
 
Figure 1.2. Summary of the peptidoglycan biosynthetic pathway. L-Lys is found in 
Gram-positive bacteria while meso-DAP is found in Gram-negative strains. Antibiotics 
inhibit specific enzyme are highlighted in red (e.g. vancomycin inhibits transglycosylase 
or transpeptidase by binding to the terminal unit of peptidoglycan). 
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1.5 MraY: structure and inhibitors 
 
The transferase activity of MraY was first characterized by Neuhaus in 1965 (52). The 
integral memberane enzyme catalyzes the transfer of MurNAc-pentapeptide from UDP- 
MurNAc-pentapeptide to undecaprenyl phosphate, yielding undecaprenyl- 
pyrophosphoryl-MurNAc-pentapeptide, also known as lipid I, and UMP (fig 1.3). 
 
 
 
 
 
 
 
 
 
Figure 1.3. MraY-catalyzed reaction. 
 
MraY belongs to a subfamily of polyprenyl-phosphate N-acetyl hexosamine 1-phosphate 
transferase (PNPY) superfamily (53). Early studies on MraY led to functional 
characterization of recombinant MraY from several organisms (52), and the catalytic 
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mechanism has been proposed to proceed via either a one-step or a two-step 
mechanism. The isotopic aided experiment suggested that a two-step mechanism was 
more likely (52). Very recently the first crystal structure of MraY from Aquifex aeolicus 
(MraYAA) was reported (54). The MraYAA crystalized as a dimer with an oval-shaped 
tunnel that is surrounded by hydrophobic amino acids to accommodate lipids. Each 
subunit consists of 10 transmembrane helices (TM), an interfacial helix, an interfacial 
helix (IH), a periplasmic β hairpin (PB), a periplasmic helix (PH), and five cytoplasmic 
loops (fig 1.4). 
 
 
Figure 1.4. Structure of MraYAA (54). 
A 
B 
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The structure of MraY crystalize as a dimer in the asymmetric unit (A) with 10 
transmembrane helix (TP) highlighted in different colors (B). 
Consistent with previous mutagenesis studies of MraY from Bacillus subtilis, most of the 
14 essential amino acids are localized in the “cleft” region suggesting that this region 
serves as the active site. Mutational inactivation of three conserved aspartate residues 
as well as one histidine residue (Asp117, Asp118, Asp265 and His324) resulted in 
complete loss of activity of MraYAA, and Asp265 is possibly involved in Mg2+ binding 
while Asp117 interacts with and deprotonates the undecaprenyl phosphate. Additionally, 
an inverted-U-shaped groove within the membrane region of the enzyme could serve as 
the binding site (fig 1.5). Unfortunately crystals were only obtained in the apo-form. 
 
 
 
Figure 1.5. The active site of MraYAA (54). Amino acids important for catalysis are 
colored in red and residues essential for structural maintenance are in cyan (figure was 
redrawn using published data, PDB ID: 4J72). 
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MraY is a promising target for development of new antibiotics because the Mg2+- 
dependent reaction is essential for bacterial viability of both gram-positive and gram- 
negative bacteria and there appears to be only one copy of the gene per bacterial 
genome (55). The difficulty in assaying the MraY activity and obtaining the recombinant 
protein for characterization has hindered the identification of inhibitors. Nonetheless, 
after years of screening for inhibitors targeting MraY, there are three classes of 
structurally distinct compounds that have been discovered, which includes lysis protein 
E from bacteriophage φX174 (56), lipopeptides, and nucleoside antibiotics (43). 
The integral membrane protein E is encoded by the DNA phage φX174, and the 
overexpression of protein E leads to inhibition of MraY by forming a stable complex with 
MraY (57). It has been shown that an 18-residue region of a conserved transmembrane 
helix of protein E is required for MraY inhibitory activity, and site-directed mutagenesis 
has revealed specific residues of the helix that are important. The second class of MraY 
inhibitor consists of lipopeptides containing a lipid connected to a peptide. The 
representative member of lipopeptides is amphomycin which has been shown to form a 
complex with undecaprenyl phosphate in the presence of Ca2+ (58). The largest class of 
MraY inhibitors is formed by the nucleoside antibiotics which can be further divided into 
four structural groups: peptidyl nucleosides represented by pacidamycins (59) and 
mureidomycins (60), lipodisaccharyl nucleosides represented by tunicamycins (61) and 
streptoniridins(62), lipopeptidyl nucleosides represented by liposidomycins (63) and A- 
90289 (24), and glycosyl-peptidyl nucleosides represented by the capuramycins (64) (fig 
1.6). All nucleoside antibiotics contain an uridine or dihydrouridine moiety, and the 
variable structural component of a different group leads to slight differences in the 
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mechanism of inhibition: peptidyl, lipodisaccharyl and lipopeptidyl nucleosides are 
competitive MraY inhibitors (65) while capuramycins show a mixed-type inhibition (66). 
 
 
 
 
Figure 1.6. Representatives of different classes of MraY inhibitors. 
 
 
1.6 Targeting bacterial MraY: discovery of capuramycins 
 
Capuramycin, initially named 446-S3 in reference to the name of its producer strain 
Streptomyces griseus 446-S3, was discovered in screening programs for new antibiotics 
in 1980s (67). The structure of capuramycin contains three distinct moieties: uridine-5'- 
carboxamide (CarU), a rare unsaturated hexuronic acid, and an aminocaprolactam (L- 
ACL)   (fig   1.7).   Despite   having   good   inhibitory   activity   against  Streptococcus 
pneumoniae (MIC 12.5µg/ml) and Mycobacterium smegmatis (MIC 3.13µg/ml) (67), its 
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actual target, bacterial tranlocase I (MraY), was not elucidated until a series of 
capuramycin derivatives, known as A-500359s (1), were isolated from Streptomyces 
griseus SANK 60196 in 2003 (64). The in vitro activity (68) assay demonstrated that 
capuramycin and its methylated analogue A-500359 A (1b) showed potent inhibitory 
effect on MraY (IC50 18nM and 17nM, respectively), and the mode of action of A-500359s 
was demonstrated to be mixed type inhibition to UDP-MurNAc-pentapeptide and 
noncompetitive inhibition to undecaprenyl-phosphate. Interestingly, A-500359 E (1d) 
which lacks the L-ACL showed a slightly reduced inhibitory activity (IC50 27ng/ml), 
indicating the lack of importance of this moiety for activity (69). Shortly after that, A- 
503083s, a new series of antibiotics that are structurally related to capuramycin were 
discovered from Streptomyces sp. SANK 62799(69). The structures of A-503083s (2) 
differ from 1 in the CarU moiety, which is modified with a 2’-O-carbamoyl group. Not 
surprisingly, 2 showed excellent inhibition of MraY (e.g. IC50 38 nM for A-503083 B, 2a), 
except A-503083F (2c) that lacks the L-ACL but has a carboxylic acid in its place  (IC50 
17.9 µM). A-102395 (3), the latest member of the capuramycin family, was isolated from 
Amycolatopsis sp. SANK 60206 in 2007 (70). Unlike other capuramycin-like antibiotics, 
3 has a unique arylamine-containing polyamide instead of an ACL. Although having 
potent inhibition against MraY with IC50 11nM, 3 lacks antimicrobial activity against 
various strains due to poor permeability of bacterial membrane. 
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Figure 1.7. Structures of capuramycin-type antibiotics discussed in this 
dissertation. 
 
 
In addition to capuramycins having excellent inhibitory activity to MraY, they also have 
very low toxicity in mice (68). Due to their selective inhibitory activity against 
Mycobacterium tuberculosis, capuramycins are considered important leads for the 
development of anti-TB antibiotics. A series of semisynthetic analogues, SQ641 and 
SQ922 for example, have shown comparable MraY inhibitory activity yet better anti-TB 
activity and broader antimicrobial spectrum (71-74). Notably, not only are capuramycins 
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different from any of the current anti-TB drugs, the analogues have been shown to cause 
unique phenotypic changes in M. tuberculosis causing bacterial disintegration and loss 
of culture turbidity (75). 
 
 
1.7 Binding to DNA: a brief history of actinomycins 
 
Actinomycins are pseudo-symmetric molecules consisting of two cyclic peptides (termed 
α- and β-ring) linked to a phenoxazinone chromophore core (fig 1.8). Since the discovery 
of the first member of actinomycin by Waksman from Streptomyces antibioticus (76), 
many other actinomycins have been isolated from a variety of Streptomyces strains as 
overviewed by Bitzer et al (77). Actinomycin D, the most prominent member of the family, 
was the first natural product shown to have potent anticancer activity and it is currently 
used in the clinic as a chemotherapeutic agent for the treatment of a variety of cancers, 
including infantile kidney tumors (78), Ewing’s sarcoma (79) and gestational 
trophoblastic neoplasia (80) under the name dactinomycin since its FDA approval in 
1964. Actinomycins have also been proposed as potential anti-AIDS agents because of 
its potency of inhibiting HIV-1 minus-strand transfer (81). 
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Figure 1.8. The structure (left) and stick model (right, PDB ID: 1OVF (82)) of 
actinomycin D (right). 
 
The mechanism of action of actinomycins is associated with the inhibition of DNA- 
directed RNA synthesis (83,84), including interactions with single (85) and double- 
stranded (86) DNA as well as RNA-DNA hybrids (87), leading to inhibition of transcription 
in both prokaryotes and eukaryotes (fig 1.9). This type of non-selective action is also 
responsible for the high toxicity of actinomycins. Numerous studies have been carried 
out to elucidate the interaction of actinomycins with DNA. The actinomycin D-DNA 
complex was shown to be formed through insertion of the planar phenoxazone ring 
between the 5’-GpC-3’ sequence while pentapeptide side chains served to shield and 
stabilize the hydrogen bonds formed by the threonine units on both rings with the NH 
and CO groups to the nitrogen atoms of neighboring guanine bases (88). 
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Figure 1.9 Stereoscopic drawings of the crystal structure of the actinomycin D- 
(ATGCTGCAT)2 complex (PDB ID: 1MNV (89)). 
 
Due to the strong affinity for DNA, 7-aminoactinomycin D (7-AAD), a derivative of 
actinomycin, is widely used as a fluorescent marker for DNA in fluorescence microscopy 
and flow cytometry for cell cycle analysis and chromosome banding studies (90). 
 
There are about 30 naturally occurring actinomycins that have been reported, and they 
are grouped largely according to the organism from which they were first discovered, 
including C-type, F-type, X-type, Z-type, G-type and Y-type (77). The overall structures 
of the actinomycins are similar. The phenoxazinone core is essentially identical while 
the variations in actinomycins are mostly restricted to modifications of amino acids in the 
peptide rings. The L-Pro is the most variable position, which may undergo hydroxylation 
at the 2 position (HPro), oxidation at the 3 position (OPro), and methylation at the 4 
position (MPro). In a few cases, L-Thr at the 4 position of the β-ring is modified by 
chlorination  (ClThr) and hydroxylation  (HThr), and can undergo  cyclization  with   the 
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phenoxazinone to form an addition ring (cTHr). Other than naturally occurred 
actinomycins, about 400 analogues of actinomycins have been prepared by semi- or 
total-synthesis. Extensive modifications of actinomycins have been carried out and 
resulted in altered bioactivity. The peptide ring opening resulted in complete inactivation 
of actinomycins, and removal of methyl groups and amino group from phenoxazone also 
yielded limited activity. Thus the integrity of peptide ring and the 2-amino substituent are 
essential for biological activity (91). Structure-activity studies suggest that the L-Thr plays 
an important role in DNA binding activity since among all the naturally occurred 
actinomycins the Thr at position 1 was present, and modification of Thr resulted in 
altered bioactivity. For example, chlorine-containing actinomycins are more toxic than 
HThr-containing actinomycins (92,93). Interestingly, protactin that was structurally 
identified as a depsihexapeptide corresponding to a single ring of actinomycins was 
found from Streptomyces cucumerosporus stran L703-4, and was stated to have both 
antibiotic activity and toxicity (94). 
 
Actinomycins have been shown with potent antibacterial activity, and Actinomycins X2 
and D was reported to have potent anti-tuberculosis activity (95), but their high 
cytotoxicity hindered their development and use as anti-TB drugs. Actinomycin Y5 
containing a unique bridging macrocycle formed between an L-Thr and phenoxazinone 
core showed excellent antibacterial activity but no observable cytotoxicity (77), and 
suggested it is possible to achieve a safe antibiotic-selective actinomycin by modulating 
the chemistry at this position. 
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1.8. Aims of this study 
 
The first specific aim of this study was the identification and characterization of the 
biosynthetic gene cluster for A-102395. We will: 
 
1. Isolation of A-102395 and other capuramycin-type antibiotics. 
 
2. Generation of in-frame deletion of genes that putatively involved in the biosynthesis 
of A-102395. 
 
3. Cloning and heterologous expression of Cpr19 and Cpr25 that responsible for the 
formation of CarU core of capuramycins. 
 
4. Functional characterization of the enzyme conferring self-resistance. 
 
The second aim of this study was to discover novel actinomycins from Streptomyces sp. 
Strain Gö-GS12. This includes: 
 
1. Thorough investigation of metabolic profile of the strain. 
 
2. Isolation, purification and of structural elucidation of novel actinomycins. 
 
3. Determine the anti-microbial activity and cytotoxicity of novel actinomycins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Copyright © Wenlong Cai 2015 
21  
Chapter 2: Characterization of the biosynthetic gene cluster for A-102395 and 
reconstituting bacterial cell wall biosynthesis 
 
2.1 Background 
 
Shortly after the discovery of 1, initial evidences of building blocks for each component 
were interrogated using isotopic feeding experiments. The observed incorporation 
suggested that L-ACL originates from L-Lys, the unsaturated hexuronic acid is derived 
from D-mannose, and CarU originates from D-ribose and pyruvate. Feeding experiments 
done by the Van Lanen group have revealed that L-Thr but not pyruvate is a precursor 
of CarU (fig 2.1.1) (96-98). 
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Figure 2.1.1. Isotopic enrichment studies using the indicated 13C-labeled 
precursors. 
 
 
A series of studies have been carried out to identify the biosynthetic gene clusters of 
capuramycin-type nucleoside antibiotics from different producer strains. In 2009, 
Funabashi et. al.(99) identified the gene cluster for 1 in Streptomyces griseus 
SANK60196. In this study, an abundantly transcribed NDP-glucose dehydratase (NGDH) 
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gene in a high producing strain was first identified from the total RNA isolated from the 
mycelia by RT-PCR, which was then used as a probe to give two contiguous cosmids 
containing minimal 21 open reading frames (orfs, orf7-orf28) covering approximately 65 
kb region. Based on the sequences of orf8 and orf26, digoxigenin-labeled probes were 
designed to identify the genetic locus for 2 from Streptomyces sp. SANK 62799 and two 
genes, capB (encoding a carbamoylgtransferase) and capU (encoding a nonribosomal 
peptide synthetase) showing high similarities to the probes, were identified leading to 
the discovery of the entire gene cluster that includes 21 orfs (capA-capW). Additional 
evidence that the correct gene clusters were identified were provided by the functional 
characterization of several genes involved in 2 biosynthesis including an L-ACL:2d 
transacylase (capW), two methyltransferases (capS and capK) and a 2’-carbamoyl 
transferase (capB) (97). Unexpectedly, two orfs encoding proteins with high amino acid 
sequence similarity to a non-heme Fe(II)-dependent α-ketoglutarate:uridine-5’-UMP 
dioxygenase (LipL) (100) and a pyridoxal-5-phosphate-dependent L-Thr:uridine-5’- 
aldehyde (UA) transaldolase (LipK) (101) were also located in both gene clusters for 1 
(orf7 and orf14) and 2 (capA and capH) (97,98). 
LipL and LipK sequentially convert UMP to (5′S,6′S)-5'-C-glycyluridine (GlyU)  during 
the biosynthesis of A-90289, a member of a distinct group of MraY inhibitors that contain 
a GlyU component in the final product (fig. 2.1.2) (24,102). Homologs of LipL and LipK 
were also identified from the biosynthetic gene clusters for other GlyU-containing 
nucleoside antibiotics include liposidomycins ( 103 ) , caprazamycins( 104 ) , 
muraymycin ( 105 , 106 ) , muraminomicin (76 ) , and the recently discovered 
sphaerimicins (107). Thus, the uncovering of these  two genes within the clusters for  1 
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and 2 suggested that the biosynthesis of CarU proceeds via condensation of L-Thr with 
UA to generate GlyU as a shared pathway intermediate among nucleotide antibiotics. 
 
 
 
 
 
Figure 2.1.2. Structure and biosynthesis of A-90289, a GlyU-containing nucleoside 
antibiotic. The GlyU was converted from UMP by LipL and LipK. 
 
 
The biosynthesis of the hexuronic acid moiety is unknown. Among the shared proteins 
encoded in the capuramycin-type nucleotide antibiotics, it was proposed that a putative 
NDP-hexose 2,3-dehydratase, a putative NDP-hexose 4-epimerase/dehydratase, a 3- 
ketoreductase, a 2,3-dehytrase and a 4-epimerase are responsible for the 
biotransformation. A glycosyltransferase (ORF13 in 1 gene cluster and CapG in 2 gene 
cluster) presumably transfers the activated hexuronic acid to CarU. 
The adenylation domain of CapU in 2 biosynthetic gene cluster was tested and shown 
to activate several amino acids with a clear preference for L-Lys while a stand-alone C 
domain of NRPS CapV is also likely involved in ACL formation(97). The cyclized ACL is 
subsequently linked onto the carboxyl group on sugar moiety via an amide bond which 
occurs through an unusual ATP-independent transacylation mechanism: CapS, a 
methyltransferase, first forms a methyl ester and followed by an ester-amide exchange 
reaction catalyzed by CapW, an ACL-acyltransferase. Homologues of capS and  capW 
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were uncovered in the gene clusters of 1 (orf24 and orf28), suggesting that the amide 
bond is generated in the same manner. Additionally, two genes encoding for tailoring 
enzymes, a 2’-carbamoyl transferase (orf8 and capB) and O-methyltransferase (cpr29 
and capK) were identified. The orf8 was predicted to encode for a truncated and hence 
unfunctional carbamoyltransferase, hence explaining the observed difference in the 
chemical structures of the capuramycin-type antibiotic 1 and 2. 
Actinomycetes, like other antibiotic producing microorganisms, have developed highly 
effective self-protection mechanisms, also known as self-resistance, to prevent suicide 
from their own metabolic products. There are three commonly observed mechanisms of 
self-protection including i) chemical modification of the antibiotic by an enzyme, ii) 
physical removal from the cells by an efflux pump therefore preventing it from reaching 
a toxic concentration, and iii) modification of the normally sensitive target to render it 
insensitive (108,109). The genes conferring self-resistance are not only critical for 
protecting the antibiotic producers, but they may also potentially be acquired by other 
bacteria by horizontal gene transfer (HGT) via transduction (110), transformation (111) 
or conjugation (112). HGT is the major cause of widespread development of multi-drug 
resistance beyond spontaneous mutation. For example, the first demonstrated enzymes 
that inactivate the aminoglycoside class of antibiotics were aminoglycoside 
phosphtransferases (APHs) (113), which regio-specifically add a phosphate group to an 
aminoglycoside. Genes encoding APH have not only been found encoded within the 
biosynthetic gene cluster of aminoglycoside producing strains, but homologous genes 
have also been found within many bacterial pathogens such as Enterobacteria and 
Staphylococcus  (99).  An  understanding  of  the  self-resistance  mechanism  of     an 
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antibiotic-producer is thus important for developing novel antibiotics for clinical use. It 
provides valuable insights on the structure-activity relationship (SAR) of antibiotics (114), 
helps in predicting the potential resistance that could develop after the drug is introduced 
for clinical use (115), and offers impetus for developing derivatives of existing antibiotics 
to prolong their clinical use. 
For the capuramycins, bioinformatic analysis of the biosynthetic gene cluster for 1 
revealed a gene product (ORF21) within the locus that has sequence similarity to APH. 
The heterologous expression of orf21 provided resistance to capuramycin in two 
normally sensitive strains of Streptomyces albus and E. coli ΔtolC (99). This was the first 
study on the self-resistance of capuramycin producers. Later in 2010, CapP (114), a 
gene product encoded within the biosynthetic gene cluster for 2 with high sequence 
similarity to ORF21, was functionally characterized as an ATP-dependent 
phosphotransferase which regio-specifically transfers the γ-phosphate of ATP to the 3’’- 
hydroxyl of the unsaturated hexuronic acid moiety of 2. The 3’’-phospho-capuramycins 
lost their antibacterial activity and the IC50 in the bacterial MraY reaction increased more 
than 200-fold (98,99,114) 
To overcome the rise of antibiotic resistance and hence diminished utility of the current 
antibiotic repertoire, it is critical to keep discovering antibiotics, particularly those that 
can be considered new chemical entities. Whole cell based high-throughput screening 
(HTS) has played a vital role in the discovery of antibiotics in the past and resulted in a 
large number of bioactive compounds. This method is sometimes complicated by the 
complexity of cells, the subsequent difficulty in determining their targets, and the 
bioactive fractions can often be toxic to mammalian cells (116). Perhaps most limiting is 
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the realization that traditional whole cell based HTS has reached the point of diminishing 
returns such that the same antibiotics or family of antibiotics routinely rediscovered with 
this method. Thus a target-specific HTS model for in vitro screening offers an important 
alternative for finding novel antibiotic candidates as well as specific targets that they bind. 
The resulting hit-target pairs (116) can be further advanced by structure-based drug 
design to improve their pharmacological properties such as absorption, distribution, 
metabolism and excretion (ADME) without compromising their target-specificity. Other 
than target-specificity, species-specificity is an equally important consideration for a HTS 
model. Subtle differences in targets among different species may lead to false-positive 
screening results. Bedaquiline (117), for example, selectively inhibits the growth of 
mycobacteria but shows no activity against other bacteria because of minor differences 
in the target ATP synthase of mycobacteria and other species (3,118,119). Nevertheless, 
species-specific antibiotics are important as they typically minimize the possibility of 
adverse effects on human gut microbes, several of which are now known to be beneficial 
for human health (3). 
In this chapter, we will discuss the identification of biosynthetic gene cluster for A-102395, 
the latest member of capuramycin-type antibiotics, by bioinformatic analysis and gene 
inactivation, and the functional characterization of a phosphotransferase that confers 
self-resistance mechanism. At the end of the chapter, a validated species-specific HTS 
model of peptidoglycan cell wall biosynthesis will be reported which is expected to allow 
us to identify the novel antibiotics targeting on early stages of bacterial cell wall 
biosynthesis rapidly and in a cost-efficient manner. 
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2.2 Materials and methods 
 
 
2.2.1 Instrumentation, chemicals and reagents 
 
 
UV/Vis spectroscopy was performed with a Bio-Tek μQuant microplate reader using 
Microtest™ 96-well plates (BD Biosciences) or a Shimadzu UV/Vis-1800 
Spectrophotometer equipped with a TCC-240A thermoelectrically temperature 
controlled cell holder. PCR was performed with a Veriti® 96-well thermal cycler from 
Applied Biosystems. Analytic HPLC was performed with one of two systems: a Waters 
Alliance 2695 separation module (Milford, MA) equipped with a Waters 2998 diode array 
detector and an analytical Apollo C-18 column (250 mm x 4.6 mm, 5 µm) purchased 
from Grace (Deerfield, IL) or a Dionex Ultimate 3000 Focused separation module 
(Bannockburn, IL) equipped with a DAD-3000(RS) and MWD-3000(RS) diode array 
detector and an Acclaim 120 C-18 column (4.6 mm x 100 mm, 3 µm). Semipreparative 
HPLC was performed with a Waters 600 controller and pump (Milford, MA) equipped 
with a 996 diode array detector, 717plus autosampler, and an Apollo C-18 column (250 
mm x 10 mm, 5 µm) purchased from Grace (Deerfield, IL). LC-electrospray ionization 
(ESI)-mass spectroscopy (MS) was performed using an Agilent 6120 Quadrupole MSD 
mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an Agilent 
1200 Series Quaternary LC system and an Eclipse XDB-C18 column (150mm x 4.6 mm, 
5 µm, 80Å). LC-MS-MS analysis of 3 was carried out using a Shimadzu UFLC coupled 
with an AB Sciex 4000-Qtrap hybrid linear ion trap triple quadrupole mass spectrometer 
in multiple reaction monitoring (MRM) mode. NMR data were collected using a Varian 
Unity Inova 400 or 500 MHz spectrometer (Varian, Inc., Palo Alto, CA) or a Bruker 
AVANCE 500 MHz spectrometer (Bruker Biospin Corporation, Billerica, MA). Nanodrop 
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2000 UV-Vis spectrophotometer (Thermo Scientific, Waltham, MA) was used to 
measure concentration and purity of DNA, RNA and proteins. 
Synthetic oligonucleotides were purchased from Integrated DNA Technologies 
(Coralville, IA). Wizard® Plus SV Minipreps DNA Purification Systems,Wizard® SV Gel 
and PCR Clean-Up System were purchased from Promega (Madison, WI, USA). pET- 
30 Xa/LIC Vector Kit was purchased from Calbiochem (San Diego. CA, USA). InstaGene 
Matrix was purchased from Bio-Rad (Hercules, CA). Ni-NTA agarose was purchased 
from Qiagen (Valencia, CA). Amicon Ultra 10000 MWCO centrifugal filter was purchased 
from Millipore (Billerica, MA). PD-10 desalting column was purchased from GE 
Healthcare (Pittsburgh, PA). DNA sequencing was performed using the 
BigDye™Terminator version 3.1 Cycle Sequencing kit from Applied Biosystems, Inc. 
(Foster City, CA) and analyzed at the University of Kentucky Advanced Genetic 
Technologies Center. 
Streptomyces sp. SANK 62799 and Amycolatopsis sp. SANK 60206 were obtained from 
Daiichi Sankyo Co., Ltd (Japan). E. coli BW25113/pIJ790 and E. coli ET12567/pUZ8002 
strains were purchased from E. coli Genetic Resources at Yale University. NovaBlue 
GigaSingles Competent cells, BL21 (DE3) Competent cells were purchased from 
Invitrogen (Camarillo, CA). Takara LA taq DNA polymerase was purchased from Takara 
Bio Inc (Otsu, Shiga, Japan). Restriction enzymes were purchased from New England 
Biolabs (Ipswich, MA). Expand long template PCR system was purchased from Roche 
Applied Science (Indianapolis, IN). Phusion Green Hot Start II High-Fidelity DNA 
Polymerase was purchased from Thermo Scientific (Waltham, MA). 
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All chemicals and reagents were purchased from Sigma Aldrich expect indicated 
otherwise. 
 
 
2.2.2 Identification and characterization of A-102395 biosynthetic gene cluster 
 
2.2.2.1 Isolation of A-102395, A-503083B and A-503083F 
 
A-102395 standard was a gift from Dr. Koichi Nonaka, Daiichi-Sankyo. A-102395, A- 
503083B and A-503083F were isolated from the producing strains and purified as 
described previously (69,70). 
 
 
2.2.2.2 Amplification of disruption cassette 
 
For amplification of the disruption cassette for each gene of interest, two long primers 
were used as listed in table 2.2.1. At the 5’ end, each primer has 39 nt of homologous 
sequences matching the gene to be inactivated, and at 3’ end, each primer has a 19 nt 
or 20 nt matching the disruption cassette containing an apramycin resistant marker 
(aac(3)IV) and an origin of transfer (OriT) from pIJ773 vector (fig 2.2.1). 
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Table 2.2.1. Primers for in-frame deletion. 
 
 
 
 
Name 
 
Sequence 
Cpr19_inact 
_forward 
5’ GGCTCTCTATCGGTACGGAGAGACCAAGGACTACTC 
CGCATTCCGGGGATCCGTCGACC 3’ 
Cpr19_ inact 
_reverse 
5’ ATCGTCGGTCGCGGTGCGCAGGAAGTCCAGCGCTC 
GGCGTGTAGGCTGGAGCTGCTTC 3’ 
Cpr25_ inact 
_forward 
5’ TGGCAGTTTCGGGGCGGCCAGGACGTCGCGGAGAT 
GGAGATTCCGGGGATCCGTCGACC 3’ 
Cpr25_ inact 
_reverse 
5’ TGGCATGCCGGGAAGATCTACCTGGACGTTGACCCG 
GATTGTAGGCTGGAGCTGCTTC 3’ 
Cpr51_ inact 
_forward 
5’ ACGCTGGTGGAGGACCACACTCTCCGCCTCAACGAC 
CCGATTCCGGGGATCCGTCGACC 3’ 
Cpr51_ inact 
_reverse 
5’ CGGCGGCCAGACGAATTTGGAGTACGCCTTCTGCC 
GCGGTGTAGGCTGGAGCTGCTTC 3’ 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.1. Map of pIJ773 plasmid. Within the disruption cassette, it contains an 
apramycin resistance gene aac(3)IV (aprr, accession number: X99313) and an origin of 
transfer of plasmid RP4 (oriT, accession number: L27758). The plasmid is resistant to 
both ampicillin and apramycin. 
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Disruption cassettes were amplified by PCR using Expand Long Template PCR System 
from Roche (Indianapolis, IN) with supplied Buffer 2, 200 µM dNTPs, 5% DMSO, 10 ng 
template, 5 U DNA polymerase, and 200 nM each of the primer pairs in table 2.2.1. DNA 
template for PCR was pIJ773 plasmid. The PCR program begins at 94 °C for 2 min, 
followed by 10 cycles of 94 °C for 45 s, 50°C for 45 s and 72°C for 90 s, and then 15 
cycles of 94 °C for 45 s, 55°C for 45 s and 72°C for 90 s, and a final extension at 72°C 
for 5 min. The resulting linear PCR products were named Δcpr19-cassette, Δcpr25- 
cassette and Δcpr51-cassette. 
PCR products were purified by electrophoresis on 0.5% agarose gel, and the desired 
DNA fragment was extracted. 
 
 
2.2.2.3 Introduction of pNCap02 and pNCap04 into E. coli BW25113/pIJ790 strain 
The supercosmids pNCap02 and pNCap04, a gift from Dr. Koichi Nonaka at Daiichi 
Sankyo, were transformed into E. coli BW25113/pIJ790 by electroporation as described 
below. E. coli BW25113/pIJ790 was cultured in 10 ml LB containing chloramphenicol 
(CHL, 25 µg/ml) overnight at 30 °C, and 100 µl was used to inoculate 10 ml SOB 
containing 20 mM MgSO4 and 25 µg/ml chloramphenicol (CHL). The strain was collected 
by centrifuge at 4000 rpm for 5 min at 4 °C, and resuspended by gentle mixing in 10 ml 
ice-cold sterile 10% glycerol. Following a second centrifugation at 4000 rpm for 5 min at 
4 °C, the cell pellet was resuspended in 100 µl of 10% glycerol. 100 ng of pNCap02 or 
pNCap04 was added and mixed by pipette a few times. Electroporation was carried out 
in a 0.2 cm pre-chilled electroporation cuvette using a BioRad GenePulsor II under 
following condition: 200 Ω, 25 µF and 2.5 kV. The time constant was 4.5 ms. 1 ml ice 
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cold SOB was immediately added after electroporation, and cells were incubated 
shaking for 1h at 30 °C. The cells were spread onto LB agar containing 50 µg/ml APR 
and 25 µg/ml CHL and incubated overnight at 30 °C to yield E. coli BW- pNCap02  and 
E. coli BW- pNCap04. To confirm that the resulting single colonies harbored the correct 
cosmid, colony PCR was conducted using primers for amplification of cpr19 and cpr25 
with E. coli BW- pNCap02 as the template, and primers for amplification of cpr51 with E. 
coli BW- pNCap04 as the template (table 2.2.2). 
Table 2.2.2. Primers for amplification of cpr19, cpr25 and cpr51. 
 
 
 
Name 
 
Sequence 
cpr19_forward 5'- GGTATTGAGGGTCGCATGCAGCAGCTGCAA 
GCCG-3' 
cpr19_reverse 5'- AGAGGAGAGTTAGAGCCTCAATTGGAGGCG 
CGGGG-3' 
cpr25_forward 5'-GGTATTGAGGGTCGCATGACTGACACTAAC 
GAG-3’ 
cpr25_reverse 5'- AGAGGAGAGTTAGAGCCTCATGGGTAATCG 
ACGA-3’ 
cpr51_forward 5'- GGTATTGAGGGTCGCATGGCCAGAGGTGG 
CCTCT-3’ 
cpr51_reverse 5'- AGAGGAGAGTTAGAGCCTCAGTCGTCGATC 
  GCCTG-3’   
 
 
 
2.2.2.4 PCR targeting of supercosmids 
 
E. coli BW- pNCap02 and E. coli BW- pNCap04 were used to inoculate 10 ml of LB 
containing 50 µg/ml APR and 25 µg/ml CHL for overnight at 30 °C. Then 1 ml of each 
was transferred into 100 ml SOB containing 50 µg/ml APR, 25 µg/ml CHL and 10 mM L- 
arabinose. After growing for 3-4 h at 30 °C until OD600 reached 0.4-0.6, the cells were 
recovered by centrifuge at 4000 rpm for 5 min at 4 °C. Cell pellets were washed   twice 
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with 10 ml ice-cold 10% glycerol and resuspended in 100 µl of 10% glycerol. Then 100 
ng of the disruption cassette Δcpr19-cassette or Δcpr25-cassette was added and mixed 
with E. coli BW-pNCap02, and the Δcpr51-cassette was mixed with E. coli BW- pNCap04. 
Electroporation was carried out in a 0.2 cm pre-chilled electroporation cuvette using a 
BioRad GenePulsor II under following condition: 200 Ω, 25 µF and 2.5 kV. The time 
constant was 4.5 ms. 1 ml ice cold SOB was immediately added after electroporation, 
and cells were incubated with shaking for 1h at 37 °C before spreading onto LB agar 
containing 50 µg/ml APR and 50 µg/ml AMP. The LB agar plates were incubated at 37 °C 
for overnight. 
The double crossover gene disruption of the resulting single colonies yielded E. coli BW- 
pNCap02-Δcpr19, E. coli BW- pNCap02-cprΔ25 and E. coli BW- pNCap04-cprΔ51. The 
gene deletion and presence of disruption cassette were confirmed by PCR. The 
universal primers listed in table 2.2.3 were used to amplify the disruption cassette in 
mutant cosmids, and the primers listed in table 2.2.1 were used to compare the 
difference in sizes between wildtype (WT) and mutant genes. Mutant cosmids pNCap02- 
Δcpr19, pNCap02-Δcpr25 and pNCap04-Δcpr51 were isolated using Wizard Plus 
Minipreps DNA purification system (Promega). 
 
 
 
Table 2.2.3. Primers for amplification of disruption cassette.   
 
Name Sequence 
Disruption cassette_forward 5' ATTCCGGGGATCCGTCGACC 3' 
Disruption cassette_reverse 5' TGTAGGCTGGAGCTGCTTC 3' 
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2.2.2.5 Transfer of mutant cosmids into Amycolatopsis sp. SANK 60206 
 
Mutant cosmids pNCap02-Δcpr19, pNCap02-Δcpr25 and pNCap04-Δcpr51 were 
transformed into E. coli ET12567/pUZ8002 competent cells by heat shock. The resulting 
colonies harboring the mutant cosmids were confirmed by PCR yielding E. coli ET- 
pNCap02-Δcpr19, E. coli ET-pNCap02-Δcpr25 and E. coli ET-pNCap04-Δcpr51. 
Strains harboring the mutant cosmids were used to inoculate 50 ml LB containing 50 
 
µg/ml APR after overnight an overnight 3 mL culture and grown for ~4 h at 37 °C to an 
OD600 of 0.4 – 0.6. The cells were washed twice with fresh LB to remove APR, and 
resuspended in 1 ml of LB. 
Wild type Amycolatopsis sp. SANK 60206 was grown on ISP4 agar for 2 weeks at 28 °C 
to allow sporulation before conjugation. The spores of were collected from ISP4 agar 
and added into 50 ml of 2×YT broth. After heat shock at 50 °C for 10 min, the broth was 
allowed to cool to room temperature and centrifuged at 4000 rpm for 10 min at 4 °C. The 
pellet was resuspended in 1 ml of LB containing E. coli ET-pNCap02-Δcpr19, E. coli ET- 
pNCap02-Δcpr25 and E. coli ET-pNCap04-Δcpr51, respectively. The resuspended 
cultures were transferred onto ISP4 agar plates containing 10 mM MgCl2 without 
antibiotics. The plates were incubated at 36 °C for 16 h prior to overlaying the cells with 
1 ml sterile water containing 0.5 mg nalidixic acid and 1.25 mg APR for selection. 
Successful double crossover events were confirmed by PCR using the primers listed in 
table 2.2.2, yielding Amycolatopsis-Δcpr19, Amycolatopsis-Δcpr25 and Amycolatopsis- 
Δcpr51. 
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2.2.2.6 Isolation of genomic DNA of wild-type and mutant Amycolatopsis sp. 
SANK 60206 
 
Amycolatopsis sp. SANK 60206, Amycolatopsis-Δcpr19, Amycolatopsis-Δcpr25 and 
Amycolatopsis-Δcpr51 were grown on ISP4 plates for 2 weeks until sporulation. A 
single colony of each cell line was used to inoculate 50 ml of TSB and incubated at 28 
°C for 48 h in a rotary shaker. 1 ml of the cultured strain was used to inoculate 50 ml of 
TSB and allowed to grow for 2 additional days. Cell cultures were transferred into 
Eppendorf tubes and recovered by centrifuge at 4,000rpm for 10min, and cell pellets 
were washed twice with TE buffer. Washed cells were resuspended in 5 ml TE buffer 
and 10 mg lysosome was added and mixed gently. During incubation at 30 °C, the 
cells were checked every 15 min until 1:1 mixture of cells with 10% SDS became clear. 
1.2 ml of 0.5 M EDTA was added and mixed gently, and proteinase K was immediately 
added to a final concentration of 0.2 mg/ml. After incubation at 37 °C for 30 min, 0.7 ml 
of 10% SDS was added followed by an additional 2 h incubation at 37 °C. After 
returning the mixture to room temperature, 7 ml phenol:chloroform:isoamyl alcohol 
(25:24:1, v/v) was added and mixed by shaking at room temperature (rt) for 10 min. 
Chloroform (7 ml) was added and mixed by shaking at room temperature for 10 min. 
The supernatant was transferred into a new tube after centrifuge at 4000 rpm for 5 min. 
The phenol/chloroform extraction was repeated twice. RNase was added to a final 
concentration of 4µg/ml, and after 1 h incubation at 37 °C, 1.75 ml of 5 M NaCl was 
added and mixed by inverting the tubes. PEG6000 (4.9 ml of 30%) was added to final 
concentration of 10% and mixed by inverting the tube. DNA was precipitated and 
carefully transferred into a new tube. After dissolved in 5 ml TE buffer, 0.6 ml 3 M 
NaAc and 12 ml cold EtOH were added and mixed gently. The precipitated DNA was 
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washed with 70% EtOH, and allowed to air dry. The remaining solid was dissolved in 
5-10 ml TE buffer, and stored at 4 °C until use. 
The quality of genomic DNA was estimated by agarose gel and the ratio of absorbance 
at 260 nm and 280 nm (A260/A280) using a NanoDrop 2000C. 
 
 
2.2.2.7 PCR analysis of wild-type and mutant Amycolatopsis sp. SANK 60206 
 
PCR analysis of the genotype of wild-type and mutant Amycolatopsis sp. SANK 60206 
was carried out using LA taq DNA polymerase purchased from Takara (Mountain View, 
CA) with supplied buffer 2, 200 , 200 µM dNTPs, 5% DMSO, 10 ng template, 5 U DNA 
polymerase, and 200 nM each of the primer pairs in table 2.2.2. DNA template for WT 
strain was the genomic DNA of Amycolatopsis sp. SANK 60206, and DNA templates for 
mutant strains were genomic DNA of Amycolatopsis-Δ19, Amycolatopsis-Δ25 and 
Amycolatopsis-Δ51, respectively. The PCR program began at 97 °C for 2 min, followed 
by 20 cycles of 97 °C for 45 s, 50°C for 45 s and 72°C for 90 s, and final extension at 
72 °C for 7 min. The resulting linear PCR products were analyzed by agarose gel 
electrophoresis. 
 
 
2.2.2.8 Preparation of the DIG-labeled probes 
 
Primers for amplification were designed according to the sequences of probes for 
detection of cpr19, cpr25 and cpr51 are listed in table 2.2.4. The first amplification was 
carried out using Expand Long Template PCR System from Roche (Indianapolis, IN) 
with supplied Buffer 2, 200 µM dNTPs, 5% DMSO, 10 ng template, 5 U DNA polymerase, 
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and 200 nM each of the primer pairs. DNA template was genomic DNA of WT or the 
appropriate mutant Amycolatopsis sp. SANK 60206. The PCR program begins at 94 °C 
for 2 min, followed by 10 cycles of 94 °C for 45 s, 50°C for 45 s and 72°C for 90 s, and 
then 15 cycles of 94 °C for 45 s, 55°C for 45 s and 72°C for 90 s, and final extension at 
72 °C for 5 min. The resulting linear PCR products were purified by agarose gel 
electrophoresis. 
 
 
 
 
 
Table 2.2.4. Primers for amplification of DNA probes for Southern blot analysis. 
 
Name Sequence 
cpr19-probe-forward 5` ATTCCGGGGATCCGTCGA CC 3` 
cpr19-probe-reverse 5` TGTAGGCTGGAGCTGCTT C 3` 
cpr25-probe-forward 5` ATTCCGGGGATCCGTCGA CC 3` 
cpr25-probe-reverse 5` TGTAGGCTGGAGCTGCTT C 3` 
cpr51-probe-forward 5` ATTCCGGGGATCCGTCGA CC 3` 
cpr51-probe-reverse 5` TGTAGGCTGGAGCTGCTT C 3` 
 
 
 
 
The second amplification for DIG labeled probes was carried out using PCR Dig 
Synthesis Kit (Roche) following the provider’s protocol, and purified DNA from first PCR 
were used as templates. The PCR program was same as first amplification to yielding 
probe-Δ19, probe-Δ25 and probe-Δ51. 
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2.2.2.9 Digestion of genomic DNA 
For Southern blot analysis of Amycolatopsis-Δ19 and Amycolatopsis-Δ51, ~10 µg 
genomic DNA of WT Amycolatopsis sp. SANK 60206 and Amycolatopsis-Δ19 or 
Amycolatopsis-Δ51 were individually digested with ApaI at 37 °C overnight. For 
Southern blot analysis of Amycolatopsis-Δ25, ~10 µg genomic DNA of WT 
Amycolatopsis sp. SANK 60206 and Amycolatopsis-Δ25 were digested with BamHI at 
37 °C overnight. The digested genomic DNA was separated by 0.8% agarose gel in 
1×TAE buffer. 
 
 
2.2.2.10 DNA:DNA hybridization and detection 
Gels were soaked with denaturation solution for 30 min, then transferred into 
neutralization buffer and kept at room temperature for 30 min. Then gels were then 
soaked in 2×SSC buffer for an additional 15 min. After transferring DNA onto Nylon 
Membranes (Roche), DNA:DNA hybridization (DIG Easy Hyb Granules, Roche) and 
detection were carried out following manufacturer’s instructions. 
 
 
2.2.2.11 LC-MS analysis of production of A-102395 in mutant strains 
Amycolatopsis-Δ19, Amycolatopsis-Δ25 and Amycolatopsis-Δ51 were grown as 
described in 2.2.2.1, and MeOH was added to the supernatant to a final concentration 
of 50%. The organic solvent was evaporated and the remaining liquid was lyophilized to 
yield crude extract. Crude extracts were weighed and dissolved in 1,600 µL of 1:1 water: 
methanol and the pH was adjusted to 3-4 with concentrated HCl if necessary. 6,400 µL 
of cold acetonitrile was then added followed by sonication for a minute and centrifuged 
at 4,000 rpm for 10 min. The supernatant was then dried under nitrogen. Dried  extract 
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was resuspended in 50 µL of methanol. Analysis of 1 compound was carried out in 
multiple reaction monitoring (MRM) mode. 1 was analyzed using an Apollo C18 250   × 
4.6 mm, 5 um column (Grace) under a series of linear gradients from A (10 mM 
ammonium formate with 0.1% formic acid in H2O) to B (0.1% formic in acetonitrile) in the 
following manner (beginning time and ending time with linear increase to % B): 0-8 min, 
2% B; 8-19 min, 90% B; 19-23 min, 2% B. The flow rate was kept constant at 0.5 mL/min 
with a column temperature of 30 ⁰C. The mass spectrometer was operated in the 
negative electrospray ionization mode with optimal ion source settings determined by a 
 
standard of 1 with a declustering potential of -135 V, entrance potential of -10 V, collision 
energy of -60 V, collision cell exit potential of -7 V, curtain gas of 20 psi, ion spray voltage 
of -4200 V, ion source gas1/gas2 of 40 psi and temperature of 550 ⁰C. MRM transitions 
monitored were as follows: 763.316/189.9 and 763.316/120. Negative ESI mode    was 
 
used to analyze samples as it was more sensitive compared to positive ESI mode for 1 
 
compound. 
 
 
 
2.2.2.12 Transcriptional analysis of Δcpr19, Δcpr25 and Δcpr51 strains 
 
To isolate total mRNA of WT and mutant Amycolatopsis, strains were grown in TSB 
medium at 37 ⁰C for 2 days. Culture medium (1.5 mL) was centrifuge and washed 
twice with sterile water. The isolation procedure was carried out using TRIzol MAX 
Bacterial RNA Isolation Kit (life technologies) following the provided manual. The 
quality of total RNA was estimated by agarose gel and the ratio of absorbance at 260 
nm and 280 nm (A260/A280) using a NanoDrop 2000C. The isolated total RNA was 
immediately used for RT-PCR. 
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The first-strand cDNA of WT and mutant Amycolatopsis was synthesized using 
SuperScript III First-Strand Synthesis System (life technologies) following the provided 
manual. The quality of total RNA was estimated by agarose gel and the ratio of 
absorbance at 260 nm and 280 nm (A260/A280) using a NanoDrop 2000. The first- 
strand cDNA were kept at -20 ⁰C until use. 
The expression of inactivated and flanking genes for each mutant was examined by 
 
PCR using primers listed in table 2.2.5. For Amycolatopsis-Δ19, expression levels of 
cpr18, cpr19 and cpr20 were compared with WT. For Amycolatopsis-Δ25, expression 
levels of cpr24, cpr25 and cpr26 were compared with WT. For Amycolatopsis-Δ51, 
expression levels of cpr50, cpr51 and cpr52 were compared with WT. 
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Table 2.2.5.  Primers for transcriptional analysis of mutant and wild-type strains. 
 
 
 
 
Name Sequence 
cpr18_forward 5' ATGCAGCAGCTGCAAGCC 3' 
cpr18_reverse 5’ TCAATTGGAGGCGCGGGG 3' 
cpr19_forward 5' GTGCAGCAGCTGCAAGCC 3' 
cpr19_reverse 5’ TCAATTGGAGGCGCGGGG 3’ 
cpr20_forward 5’ ATGGAACTAC TCCTGATC 3' 
cpr20_reverse 5’ CTAGTTGTCCGCCGATGC 3' 
cpr24_forward 5’ ATGAGCAACC GACCAGTC 3' 
cpr24_reverse 5’ TCATCCACCGTGTAATTC 3' 
cpr25_forward 5’ ATGACTGACA CTAACGAG 3' 
cpr25_reverse 5’ TCATGGGTAATCGACGAA 3' 
cpr26_forward 5’ GTGGACATCG GTTCACTC 3' 
cpr26_reverse 5’ TCATGCGGGATTCGACGC 3' 
cpr50_forward 5’ GTGGAGGGCG CTGGGACC 3' 
cpr50_reverse 5’ CAACCAGGAAGCTCGGC 3' 
cpr51_forward 5’ ATGGCCAGAG GTGGCCTC 3' 
cpr51_reverse 5’ TCAGTCGTCGATCGCCTG 3' 
cpr52_forward 5’ ATGGGGAACT TGATTGAG 3' 
cpr52_reverse 5’ TCAGCTGAGCCAGCAGTTC 3' 
 
 
 
2.2.2.13 Heterologous expression and functional assignment of Cpr19 and CapH 
 
Cpr19 and CapH were heterologously expressed in E. coli BL21 (DE3) and 
Streptomyces lividans TK64, respectively, following the protocol of previous work in the 
Van Lanen lab (98). 
Native-PAGE analysis was carried out using Novex 4-12% Tris-Glycine Gel purchased 
from Life technologies. 
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2.2.3 Characterization of Cpr17 
 
2.2.3.1 Heterologous production of Cpr17 and CapP in E. coli. 
cpr17 and capP were amplified by PCR using Phusion Green Hot Start II High-Fidelity 
DNA Polymerase (Thermo Scientific) with supplied HF buffer, DMSO, 10mM dNTPs, 
DMSO, 10ng DNA template, 2U DNA polymerase, and 100nM each of the following 
primers: 
 
Table 2.2.6.  Primers for amplification of cpr17 and capP. 
 
 
 
Name 
 
Sequence 
cpr17_forward 
5' GGTATTGAGGGTCGCATGACCGAGACCGA 
GATCAC 3' 
cpr17_reverse 
5’ AGAGGAGAGTTAGAGCCCTATCCGTGGAA 
TCGGGC 3' 
capP_forward 
5' GGTATTGAGGGTCGCGTGACGGACACCGA 
AAAT 3' 
capP_reverse 
5’ AGAGGAGAGTTAGAGCCTCAGGAGTGAGT 
  CGCGGT 3'   
 
 
DNA templates for PCR were cosmid pNCap03 for cpr17 and cosmid N-1 for capP. 
The PCR program began at 94 °C for 30s, followed by 30 cycles of 94 °C for 10s, 56°C 
for 20s and 72°C for 20s, and final extension at 68°C for 7min. The PCR product was 
purified by electrophoresis on 0.5% agarose gel, and the desired DNA fragment was 
extracted with Wizard V Gel and PCR Clean-Up System (Promega). The gel-purified 
PCR product was inserted into pET-30 Xa/LIC vector (Invitrogen) following the 
manufacture’s protocol to yield pET30-cpr17 and pET30-capP. Genes ligated in pET-30 
vector were sequenced to confirm fidelity. 
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Plasmids pET30-cpr17 and pET30-capP were transformed into E. coli BL21 (DE3) by 
heat-shock, and the transformed strains were grown in SOC medium for 30 min and then 
selected on LB agar supplemented with 50 µg/mL kanamycin to yield E. coli-cpr17 and 
E. Coli-capP strains. 
 
Following an overnight incubation of culture in 10 ml of LB supplemented with 50 µg/mL 
kanamycin, the recombinant strains were grown in 500ml of LB with 50 µg/ml kanamycin 
at 37 °C until the cell density reached an OD600=0.4-0.6, then 0.1 mM 1-thio-β-D- 
galactopyranoside (IPTG) was added to induce expression. After overnight incubation 
at 18 °C, cells were collected by centrifuge at 4°C for 10min then resuspended in lysis 
buffer containing 100 mM Tris-HCl (pH=7.5) and 250 mM NaCl. Lysis of cells was 
performed using sonication for 10 rounds while the culture was kept on ice. Immediately 
after lysis, cells debris were separated from lysate by centrifuge at 10,000 rpm for 40min. 
The supernatant containing His6-tagged protein was loaded onto Ni-NTA agarose 
(Qiagen) and washed with 50 ml of washing buffer containing 100 mM Tris-HCl (pH=7.5), 
250 mM NaCl and 20 mM imidazole. The recombinant proteins were eluted with 15 ml 
of elution buffer containing 100 mM Tris-HCl (pH=7.5), 250 mM NaCl and 200 mM 
imidazole, and then concentrated with an Amicon Ultra 10,000 MWCO centrifugal filter 
(Millipore), followed by desalting of the proteins using desalting buffer containing 50mM 
Tris-HCl (pH=7.5) and 100mM NaCl. The proteins were stored in 30% glycerol at -20 °C 
until use. Size and purity of recombinant proteins were assessed by 12% acrylamide 
SDS-PAGE, and the concentration was determined by Nano Drop according to the 
predicted extinction coefficient of each protein. 
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2.2.3.2 Functional characterization of Cpr17 and CapP 
 
Reactions consisted of 50 mM Tris-HCl (pH=7.5), 10 mM MgCl2, 1 mM ATP, 1 mM 
substrates (3, 2a, 2d or 1c) and 0.3 mg/ml Cpr17 or CapP (total volume of 100 µl). 
Individual reactions were prepared and incubated at 30 °C for 12 hr and quenched by 
adding 300 µl of chloroform. Followed by centrifuge at top speed, the aqueous layers 
were used for HPLC analysis using a C-18 reversed-phase column (Grace) under a 
series of linear gradients from 0.1% TFA in 2.5% acetonitrile (A) to 0.1% TFA in 90% 
acetonitrile (B) in the following manner (beginning time and ending time with linear 
increase to % B): 0-8 min, 100% B; 8-18 min, 60% B; 18-25 min, 95%B; 25-32 min, 
95%B; and 32-35 min, 0%B. The flow rate was kept constant at 1 ml/min and elution 
was monitored at 260 nm. LC-MS analysis was performed using an Eclipse XDB-C18 
reversed-phase column (Agilent) under a series of linear gradients from 0.1% formic acid 
in H2O to 0.1% formic acid in acetonitrile over 20 min. The flow rate was kept constant 
at 0.4 ml/min and elution was monitored at 254 nm. 
The substrate specificity of Cpr17 was characterized using the identical condition as 
described above except that unnatural substrates were used (A-503083G, P1-P10 and 
P11). 
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2.2.3.3 Kinetic characterization of Cpr17 
 
The kinetic parameters (Km and kcat) for Cpr17 were determined using an enzyme- 
coupled assay monitoring the production of ADP generated by the phosphotransferase 
reaction as previously reported. The reaction (100 µL) used in determining the kinetic 
parameters for the substrate 2a contained 50 mM Tris (pH 7.5), 10 mM MgCl2, 50 mM 
KCl, 2.5 mM phosphoenol pyruvate, 0.5 mg/ml NADH, 0.5 µM Cpr17, 2 mM ATP, and 2 
mL of a pyruvate kinase/lactic dehydrogenase mixture (Sigma-Aldrich). Reactions were 
initiated with 2a at various concentrations (0, 50, 100, 250, 1000, and 2000 µM). ATP 
and GTP kinetics were determined identical to the conditions described above except 
reactions contained either varying concentrations of ATP (0, 50, 100, 250, 500, 2000 µM) 
or GTP (0, 10, 50, 75, and 100 µM) and included a constant concentration of 2a (500 
 
µM for ATP kinetics; 100 µM for GTP kinetics). All experiments were performed in 
triplicate in 96-well plates and monitored at 340 nm on a SpectraMax M5 microplate 
reader, taking measurements every 30s for 10 min. The initial rates were determined 
and the resulting data were fitted to the Michaelis-Menten equation: 
 
 
 
where v is the initial velocity, Vmax is the maximum reaction velocity, [S] is the substrate 
concentration, and KM is the Michaelis constant of the varied substrate. 
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2.2.3.4 Chemical and semi-synthesis of unnatural substrates for Cpr17 
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Scheme 2.1. Synthesis of A-503083G. 
 
To a stirred solution of the A-503083 F (100.4mg, 0.2 mmol) in anhydrous methanol (0.4 
mL) under a nitrogen atmosphere, 220 uL of 2.0 M trimethylsilyl diazomethane (0.48 
mmol) in hexanes was added slowly at 0 ℃. After stirring for 30 minutes, the reaction 
was quenched with 0.1 mL distilled water and the solvent was removed to yield A- 
 
503083 G. 
 
To prepare unnatural capuramycin derivatives, the previously established method was 
followed using a variety of alkyamines as substrates (table 2.2.7). Briefly, a 1 mL 
reaction consisted of 50 mM potassium phosphate (pH = 8.0), 2 mM 2d, 10 mM 
alkylamines (S1-S4) and 37.5 μM CapW. After incubation at 30 °C for 12 hr, reactions 
were stopped by ultracentrifuge to remove protein and analyzed by LC-MS using an 
Eclipse XDB-C18 reversed-phase column (Agilent) under a series of linear gradients 
from 0.1% formic acid in H2O to 0.1% formic acid in acetonitrile over 20 min. The flow 
rate was kept constant at 0.4 ml/min and elution was monitored at 254 nm. Purification 
of products was carried out by semi-preparative HPLC using a C-18 reversed-phase 
column. A series of linear gradients was developed from A (2.5% ACN with 0.1% TFA) 
to B (90% ACN with 0.1% TFA) in the following manner (beginning time and ending time 
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with linear increase to % B): 0-2 min, 0% B; 2-18 min, 90% B; 18-22 min, 90% B; 22-24 
min, 0% B; and 24-26 min, 0% B. The flow rate was kept constant at 3.5 mL/min, and 
elution was monitored at 260 nm. The purified products were lyophilized to yield P1-P4 
as white powder. 
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Scheme 2.2. Synthesis of P1 – P4 catalyzed by CapW as N-acyltranferase. 
 
Similar 1 mL reactions consisting of 50 mM potassium phosphate (pH = 8.0), 2 mM A- 
503083B, 10 mM alkylamines (S5–S9) and 37.5 μM CapW were carried out to yield P5- 
P10.  
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Scheme 2.3. Synthesis of P5-P10 catalyzed by CapW as a transacylase. 
S1-S4 
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Table 2.2.7. Substrates for enzymatic preparation of unnatural capuramycins*. 
 
 
Name Structures Name Structures Name Structures 
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* CapW was a gift from Dr. Xiaodong Liu of the Van Lanen lab. 
 
 
 
 
2.2.3.5 Site-directed mutagenesis of Cpr17 
 
Point mutations of Cpr17 were generated by PCR using Phusion Green Hot Start II High- 
Fidelity DNA Polymerase (Thermo Scientific) and primers listed in table 2.2.8. pET30- 
cpr17 was used as a template. Reactions were conducted according to the 
manufacturer’s protocol with supplied buffer 2, DMSO and each pair of primer. The PCR 
program began at 94 °C for 30 s, followed by 30 cycles of 94 °C for 10 s, 56°C for 20 s 
and 60 °C for 7.5 min, and final extension at 72 °C for 7 min. The template DNA was 
digested with 10 units of DpnI for 1 h at 37 °C, and the remaining PCR product was 
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transformed into E. coli Nova Blue competent cells by heat-shock. The introduction of a 
point mutation was confirmed DNA sequencing to yield pET30-cpr17_D212A. 
 
 
 
Table 2.2.8. Primers for mutagenesis of Cpr17. 
 
Name Sequence 
cpr17_ D212A_forward 
5’ ACGCTGGCGGGCGTCGTCGCCTTCGGCGCTCT 
GTTCGCCG 
cpr17_ D212A_reverse 
5’ CGGCGAACAGAGCGCCGAAGGCGACGACGCC 
  CGCCAGCGT 3’   
 
 
 
2.2.3.6 Docking of A-503083E to MraY and development of in-silico models for Cpr17 
A-503083E was manually positioned onto the reported binding pocket of MraY (128, 129) 
using AutoDock Vina (130). 
The in-silico model of Cpr17 was generated using the SWISS-MODEL (120) using APH(2’’)- 
IIIa (PDB ID: 4TDW) and APH(2’’)-IIa (PDB ID: 4ORK) as templates. The predicted Cpr17 
secondary structure was aligned with the crystal structures of templates using PyMOL. 
 
 
2.2.4 Reconstitution of bacterial cell wall biosynthesis pathway 
 
2.2.4.1 Reconstitution of E. coli cell wall biosynthesis pathway 
 
N-acetylhexosamine 1-kinase (NahK) was cloned into pET-30 Xa/LIC vector (Invitrogen) 
using genomic DNA of Bifidobacterium infantis as template yielding pET30-nahK. 
GlcNAc-1-P uridyltransferase (GlmU) was amplified from E. coli genomic DNA and 
glutamate dehydrogenase (GDH) was subcloned from Bacillus subtilis genomic   DNA. 
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MurA, MurB, MurC, MurD, MurE, MurF and Ddl in vector pCA24N were purchased from 
National Bioresource Project (Tokyo, Japan).The primers used for amplification were 
listed in table 2.2.9. 
 
 
 
Table 2.2.9.  Primers for amplification of NahK, GlmU and GDH. 
 
 
 
Name 
 
Sequence 
NahK_forward 5' GGTATTGAGGGTCGCATGAACAACACCAAT 3’ 
NahK _reverse 5' AGAGGAGAGTTAGAGCCTCACTTGGTCGTCT 3’ 
GlmU_forward 5' GGTATTGAGGGTCGC ATGTTGAATA ATGCT 3’ 
GlmU _reverse 5' AGAGGAGAGTTAGAGCCTCACTTTTTCTTTAC 3’ 
GDH _forward 5' GGTATTGAGGGTCGCATGTTGAATAATGCT 3’ 
GDH _reverse 5' AGAGGAGAGTTAGAGCCTCACTTTTTCTTTAG 3’ 
 
 
The PCR program began at 94 °C for 30 s, followed by 25-30 cycles of 94 °C for 10 s, 
56 °C for 20 s and 72 °C for 20 s per kb DNA, and final extension at 72 °C for 7 min. 
Electrophoresis with a 0.5% agarose gel was used for product purification, and the 
desired DNA fragment was extracted. The PCR products were inserted into pET-30 
Xa/LIC vector (Invitrogen) to yield pET30-nahK, pET30-glmU, and pET30-gdh. All 
plasmids were transformed into E. coli BL21 (DE3) competent cells. Induction and 
purification of recombinant proteins were carried out as described in 2.3.2.1. 
To prepare UDP-MurNAc-pentapeptide, a 10 mL solution of 50 mM Tris-HCl (pH=8.0) 
and 10 mM MgCl2, 0.1 mmol GlcNAc, 0.12 mmol ATP, 0.12 mol UTP, 0.5 mmol   PEP, 
0.1 mmol NADPH, 2 mmol glucose was prepared; subsequently 5mg NahK, 5mg GlmU, 
 
5mg MurA, 5mg MurB, 100U GDH were added. After stirring at room temperature for 2 
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h under N2, (NH4)2SO4 (final concentration at 2 mM), 0.25 mmol L-alanine, 0.25 mmol D- 
glutamic acid, 0.25 mmol diaminopemilic acid, 0.25 mmol D-alanine, 1 mmol ATP, 1 
mmol PEP, 5 mg MurB, 5 mg MurC, 5 mg MurD, 8 mg MurE, 5 mg MurF, 8 mg Ddl, 8 
mg DAP-Epi and 50U PK (pyruvate kinase) were added. The reaction was stirred at 
room temperature overnight and quenched by heating at 80 °C for 20 min. After 
centrifuge at 14, 000 rpm for 10min, the supernatant was absorbed onto pre-washed 
SEPABEADS SP207 resin (Sigma-Aldrich, USA). The resin was then washed with 1L 
0.01N HCl followed by 1.5L H2O, and UDP-Mur-Pentapeptide was eluted with 1L 20% 
methanol. The eluent was concentrated in vacuo to remove methanol and lyophilized, 
yielding 12mg of white powder. 
Further purification was carried out by semi-preparative HPLC. A series of linear 
gradients was developed from 5% methanol in 40mM NaH2PO4 (pH adjusted to 6.5 by 
TEA, A) to 20% methanol in 40mM NaH2PO4 (pH adjusted to 6.5 by TEA, B) in the 
following manner (beginning time and ending time with linear increase to % B): 0-7 min, 
0% B; 7-25 min, 30% B. The follow rate was kept constant at 3.5 ml/min, and elution was 
monitored at 365 nm. Molecular weight of purified UDP-Mur-pentapeptide was 
determined by HRMS, and purity was determined by HPLC. 
For HTS, to a 100 µL solution of 50 mM Tris-HCl (pH=8.0) and 10 mM MgCl2, 10 µM 
UDP-GlcNAc, 10 mM ATP, 20 µM PEP, 0.1 mM NADPH, 10 mM of each amino acids, 
10 mM glucose and 10mM inhibitor were added. The reaction was initiated by adding 
1U GDH, 0.5 mg MurA-MurF and 0.5 mg Ddl. The reaction was incubated at 30 °C for 3 
hours and quenched by adding 100 µL DCM. The aqueous phase was applied for HPLC 
analysis. A series of linear gradients was developed from 5% methanol in 40mM 
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NaH2PO4 (pH adjusted to 6.5 by TEA, A) to 20% methanol in 40mM NaH2PO4 (pH 
adjusted to 6.5 by TEA, B) in the following manner (beginning time and ending time with 
linear increase to % B): 0-7 min, 0% B; 7-25 min, 30% B. The follow rate was kept 
constant at 0.5 ml/min, and elution was monitored at 365 nm. 
 
 
2.2.4.2 Reconstitution of M. tuberculosis H37Rv cell wall biosynthesis pathway 
 
MurA-tb, MurB-tb, MurC-tb, MurD-tb, MurE-tb, MurF-tb and Ddl-tb were amplified using 
 
M. tuberculosis H37Rv genomic DNA as template. Primers used for cloning were listed 
in table 2.2.10. The PCR amplification, purification, protein purification and 
reconstitution of M. tuberculosis cell wall biosynthesis pathway were carried out as 
describe in 2.2.4.1. 
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Table 2.2.10.  Primers for amplification of Mur liagases from M. tuberculosis. 
 
 
 
 
Name 
 
Sequence 
MurA-tb_forward 5' GGTATTGAGGGTCGCGTGGCCGAGCGT 3’ 
MurA-tb _reverse 5' AGAGGAGAGTTAGAGCCCTAACAGCATAC 3’ 
MurB-tb _forward 5' GGTATTGAGGGTCGCATGAAACGGAGC 3’ 
MurB-tb _reverse 5' AGAGGAGAGTTAGAGCCCTACAACATGCA 3’ 
MurC-tb _forward 5' GGTATTGAGGGTCGCGTGAGCACCGAG 3’ 
MurC-tb _reverse 5' AGAGGAGAGTTAGAGCCTCATCCCAGCAC 3’ 
MurD-tb _forward 5' GGTATTGAGGGTCGCGTGCTTGACCCT 3’ 
MurD-tb _reverse 5' AGAGGAGAGTTAGAGCCCTACCGGATCAC 3’ 
MurE-tb _forward 5' GGTATTGAGGGTCGCATGATCGAGCTG 3’ 
MurE-tb _reverse 5' AGAGGAGAGTTAGAGCCTCATGGGCGCAC 3’ 
MurF-tb _forward 5' GGTATTGAGGGTCGCATGATCGAGCTG 3’ 
MurF-tb _reverse 5' AGAGGAGAGTTAGAGCCTCATGGGCGCAC 3’ 
Ddl-tb _forward 5' GGTATTGAGGGTCGCGTGAGTGCTAAC 3’ 
Ddl-tb _reverse 5' AGAGGAGAGTTAGAGCCCTAGTGCAGGCC 3’ 
54  
2.3 Results and discussion 
 
 
2.3.1 Identification and characterization of A-102395 gene cluster 
 
 
2.3.1.1 Isolation of capuramycin-type antibiotics 
 
The structure of A-102395 was confirmed using 1H-NMR and 13C-NMR data (70) (fig 
2.3.1). The HRMS data of A-503083B and A-503083F were consistent with calculated 
molecular weight. (fig 2.3.2 and fig 2.3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.1. 1H and 13C NMR spectra of A-102395 in MeOD. 
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Figure 2.3.2. HRMS of purified A-503083F. HRMS (ESI+) calcd. for [M + H]+ 503.1261; 
found 503.1247. Calcd. For [M+Na+] 525.1081; found 525.1068. 
 
 
 
Figure 2.3.3. HRMS of purified A-503083B. HRMS (ESI+) calcd. for [M + H]+ 613.2105; 
found 613.2066. 
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2.3.1.2 Identification of A-102395 gene cluster 
 
An orf encoding a protein with high amino acid sequence similarity to the transaldolase 
LipK is located within the gene clusters that have been identified for the CarU- 
containing nucleoside antibiotics: 1 (ORF14, 55/81 % identity/% similarity) and 2 (CapH, 
47/79) (107). Similarly, an orf encoding a protein with moderate sequence similarity to 
the dioxygenase LipL is found within the 1 (ORF7, 36/48) and 2 (CapA, 33/47) gene 
clusters. Previous work in the Van Lanen lab has demonstrated the direct incorporation 
of L-Thr via a transladol-like mechanism by undertaking feeding experiments with 
isotopically enriched Gly and L-Thr using the 2 producing strain. Using the previously 
designed degenerate primers based on the distinctive sequence blocks found within the 
functionally assigned L-Thr:UA transaldolases (107) as probes, we were able to identify 
three overlapping cosmids (pNCap01-03) harboring 49 complete ORFs. A 10-kb DNA 
fragment from pNCap03 was then used as another probe to identify a fourth cosmid 
pNCap04. Following DNA sequencing, bioinformatics analysis was carried out using 
Frame-plot version 4.0 and database comparison for sequence homology was 
performed using the National Center for Biotechnology Information (Bethesda, MD). A 
total of ~85 kb of contiguous DNA was identified, including 70 complete ORFs (fig 2.3.4). 
The closest homologs and putative functions of the ORFs are listed in table 2.3.1; ORFs 
predicted to be involved in the biosynthesis of 3 were annotated as cpr17-cpr51, for 
capuramycin- related nucleoside. 
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Figure 2.3.4 Cosmid map and genetic organization of the 3 biosynthetic gene 
cluster. The cpr25 gene highlighted in red encodes the putative L-Thr:uridine-5'- 
aldehyde transaldolase that was targeted for inactivation to confirm the identify the 
genetic locus. 
 
 
Not surprisingly, the genetic architecture of the clusters for 1 and 2 are virtually identical 
due to the similarity of their structures, excluding the aforementioned orf encoding a 
truncated 2'-O-carbamoyltransferase within the 1 gene cluster that leads to the sole 
structural variation between these two groups of capuramycin-type antibiotics. 
Conversely, the 16 conserved orfs within the 3 gene cluster have a different genetic 
organization than found in 1 and 2 (fig 2.3.5). Nonetheless, individual comparison of 
the gene products revealed a relatively high amino acid sequence identity,  including 
the transaldolase (Cpr 25; 79% identity with CapH) and t he non-heme Fe(II)- 
dependent αKG:UMP dioxygenase (Cpr19; 67% identity with CapA). Additional shared 
gene  products  of  note  include a phosphotransferase  Cpr17, likely  involved  in  self- 
resistance (53% identity with CapP), a carboxymethyltransferase (Cpr27; 57%  identity 
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with CapS), and a putative amide bond- forming N-transacylase (Cpr51; 65% identity 
with CapW). CapS and CapW have been shown to function sequentially to activate the 
carboxylic acid of 2c in the form of the methyl ester 2d followed by transacylation to 
incorporate the L-ACL to generate 2a( 121 ) . The uncovering of genes for Cpr27 and 
Cpr51 suggests the unusual arylamine-containing polyamide of 3 is incorporated using 
a comparable mechanism, i.e., carboxylic acid 1c → methyl ester 1d → amide 1a (Fig. 
6C), which was unexpected given the unique chemical nature of the acyl acceptors. 
 
 
 
 
 
 
Figure 2.3.5. Comparative analysis of the sequenced region of chromosomal DNA 
from the 2- and 3-producing strains. Highlighted in blue are the minimal orfs predicted 
to be essential for 3 biosynthesis, while the two orfs in black, cpr19 and cpr25, are 
predicted to encode for a non-heme Fe(II)-dependent αKG:UMP dioxygenase and L- 
ThrA-:uridine-5'-aldehyde transaldolase, respectively. 
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Table 2.3.1. Annotation of ORFs within the 3 gene cluster 
 
 
Proteina Sizeb Proposed function Homolog (accession no.)c Identity / 
Similarityd (%) 
ORF1 319 Cell-wall associated hydrolase Svir_07310 (YP_003132627) 44/58 
ORF2 363 Hypothetical protein Francci3_2715 (YP_481805) 49/59 
ORF3 855 Hypothetical protein Franean1_2549 (YP_001506885) 58/69 
ORF4 639 Type IV secretory pathway VirB4 Franean1_2548 (YP_001506884) 60/73 
ORF5 398 Hypothetical protein Franean1_2547 (YP_001506883) 57/66 
ORF6 774 Hypothetical protein Caci_4083 (YP_003114789) 46/64 
ORF7 107 Hypothetical protein Franean1_2741 (YP_001507073) 58/77 
ORF8 322 Hypothetical protein Franean1_2740 (YP_001507072) 45/56 
ORF9 247 Hypothetical protein SACE_2308 (YP_001104534) 47/56 
ORF10 350 Hypothetical protein SACE_2307 (YP_001104533) 70/80 
ORF11 233 Putative cellulase SCAB_16431 (CBG68778) 24/41 
Cpr12 259 Aminotransferase class IV Caci_2606 (YP_003113364) 45/56 
ORF13 162 Putative short chain dehydrogenase MAB_3919c (YP_001704647) 48/62 
ORF14 373 Transposase RHA1_ro08502 (YP_707704) 76/85 
ORF15 122 Transposase Svir_17380 (YP_003133592) 75/85 
ORF16 123 Transposase SSAG_01038 (ZP_04996736) 68/77 
Cpr17 305 Capuramycin 3''-phosphotransferase CapPe 53/64 
Cpr18 331 Fe2+-dependent, KG dioxygenase CapD 63/74 
Cpr19 275 Fe2+-dependent, KG:UMP dioxygenase CapA 76/88 
Cpr20 317 putative 3-ketoreductase CapC 73/81 
Cpr21 457 putative 2,3-dehydratase CapE 73/83 
Cpr22 313 putative 4-epimerase CapF 70/79 
Cpr23 378 SelA-related PLP-dependent enzyme ORF15 47/65 
Cpr24 384 Putative glycosyltransferase CapG 77/86 
Cpr25 412 L-Thr:uridine-5'-aldehyde transaldolase CapH 79/90 
Cpr26 87 Putative pyrophosphatase CapI 67/81 
Cpr27 261 Putative carboxyl methyltransferase CapS 65/79 
Cpr28 774 Putative CO dehydrogenase CapJ 75/84 
Cpr29 244 Putative O-methyltransferase CapK 71/84 
Cpr30 165 Putative CO dehydrogenase CapL 76/89 
Cpr31 289 Putative CO dehydrogenase CapM 60/72 
Cpr32 350 Luciferase-like monooxygenase LLB_0745 (ZP_06185947) 43/56 
Cpr33 234 3-oxoacyl-[acyl-carrier-protein] reductase Noca_2571 (YP_923762) 57/71 
Cpr34 391 -Ketoacyl synthase ShygA5_010100009994 (ZP_05513707) 53/63 
Cpr35 257 Hypothetical protein SCAB_69811 (CBG73975) 44/63 
Cpr36 84 Aryl carrier protein AcmD (AAD30112) 35/55 
Cpr37 466 Actinomycin synthetase I AcmA (AAD30111) 49/62 
Cpr38 663 4-amino-4-deoxychorismate synthase PabAB (P32483) 55/64 
Cpr39 521 AMP-dependent synthetase and ligase SrosN15_010100025847 (ZP_04696386) 50/61 
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Table 2.3.1 continued. 
Cpr40 311 Dehydrogenase E1, TPP-dependent Caci_5069 (YP_003115770) 55/70 
Cpr41 338 Pyruvate dehydrog. (acetyl-transferring) Sros_2206 (YP_003337932) 55/69 
Cpr42 365 Dehydrogenase Npun_F31621 (YP_001866563) 38/57 
Cpr43 433 Glycosyl transferase family 2 MicauDRAFT 1168 34/49 
Cpr44 612 Acetolactate synthase, large subunit Vapar_2048 (YP_002943959) 26/42 
Cpr45 227 Phosphatase (HAD superfamily) Yaldo0001_22190 (ZP_04621838) 39/56 
Cpr46 599 TPP-dependent  synthase/transketolase PlaT6 (ABB69756) 45/57 
Cpr47 448 Condensation domain (NRPS) MicauDRAFT_1165 (ZP_06216171) 29/42 
Cpr48 97 Acyl carrier protein SrosN15_010100019301 (ZP_04695086) 46/58 
Cpr49 314 MitI transglutaminase MitI (AAD28463) 29/48 
Cpr50 395 MitI transglutaminase MitI (AAD28463) 33/44 
Cpr51 395 Putative transacylase CapW 65/75 
Cpr52 191 Hypothetical protein SrosN15_010100025822 (ZP_04696381) 38/51 
Cpr53 381 Acyl-CoA dehydrogenase SrosN15_010100025827 (ZP_04696382) 45/57 
Cpr54 515 Long-chain-fatty-acid-CoA ligase MCAG_01785 (ZP_04605528) 75/82 
Cpr55 84 Acyl carrier protein VinL (BAD08369) 44/63 
Cpr56 424 Orn/DAP/Arg decarboxylase 2 MCAG_01775 (ZP_04605518) 74/83 
Cpr57 293 MitI transglutaminase MitI (AAD28463) 29/45 
ORF58 596 ABC transporter ATP-binding protein MCAG_02642 (ZP_04606385) 37/52 
ORF59 608 ABC transporter ATP-binding protein SghaA1_010100034323 (ZP_04690305) 53/65 
ORF60 594 ABC transporter related protein Cfla_3590 (YP_003638660) 45/62 
ORF61 663 ABC transporter related protein Cfla_3591 (YP_003638661) 44/58 
ORF62 441 MATE efflux family protein Amir_4280 (YP_003101980) 57/71 
ORF63 391 AstB/chuR/nirj-related protein SghaA1_010100036797 (ZP_04690774) 74/83 
ORF64 85 Hypothetical protein SghaA1_010100036802 (ZP_04690775) 55/72 
ORF65 352 Hypothetical protein StAA4_010100023552 (ZP_05481114) 55/63 
ORF66 320 Oxidoreductase domain protein Amir_4534 (YP_003102223) 51/63 
ORF67 219 Putative phosphotransferase StAA4_010100023547 (ZP_05481113) 50/61 
ORF68 358 Hypothetical protein StAA4_010100023542 (ZP_05481112) 53/67 
ORF69 420 Hypothetical protein Sros_6837 (YP_003342286) 29/43 
ORF70 179 Hypothetical protein StAA4_010100029435 (ZP_05482273) 57/75 
 
a Sequences deposited at NCBI (accession no. KP995196). 
b Numbers are in amino acids. 
c Given in brackets are accession numbers. 
d % sequence identity/similarity for the entire protein. 
e Putative proteins within shaded rows have homologues within the A-503083 gene cluster (accession no. AB538860) and A-500359 gene 
cluster (accession no. AB476988) 
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2.3.1.3 Characterization of the gene cluster for 3 by inactivation of cpr19, 
cpr25 and cpr51 
 
The genes cpr19 and cpr25 are proposed to be responsible for the initiation of the 
biosynthesis of CarU core of 3, while cpr51 was proposed to form the amide bond 
between hexuronic acid and the polyamide chain. To investigate the involvement of 
those genes in biosynthetic pathway of 3, both cpr19 and cpr25 were individually 
targeted for inactivation by double crossover homologous recombination, and the 
successful inactivation of each was confirmed by PCR and Southern blot analysis 
(fig 2.3.6 and fig 2.3.7). To determine if cpr51—encoding a putative N-transacylase 
with a proposed functional role comparable to CapW—was involved in the 
biosynthesis of 3, the gene was inactivated by double crossover homologous 
recombination and also confirmed by PCR and Southern blot analysis (fig 2.3.8). 
 
Table 2.3.2. Sequence comparison in % identity/% similarity among putative 
αKG:UMP dioxygenases. 
 
Gene Product LiPLa Cpz15 LpmM Mur16 SphE Mra24b ORF7 CapA Cpr19 
GlyUc LipL ---------- 86/90 81/87 39/51 25/35 26/36 36/48 33/47 39/53 
 Cpz15 ---------- ---------- 82/89 38/51 25/34 25/36 34/48 33/48 39/54 
 LpmM ---------- ---------- ---------- 37/50 24/35 27/38 36/50 33/47 37/53 
 Mur16 ---------- ---------- ---------- ---------- 25/36 29/41 43/56 42/53 47/62 
 SphE ---------- ---------- ---------- ---------- ---------- 21/32 28/40 28/40 27/39 
 Mra24 ---------- ---------- ---------- ---------- ---------- ---------- 27/37 26/35 27/41 
CarUd ORF7 ---------- ---------- ---------- ---------- ---------- ---------- ---------- 79/86 70/82 
 CapA ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- 67/78 
  Cpr19   ----------   ----------   ----------   ----------   ----------   ----------   ----------   ----------   --------   
a LipL is encoded within the biosynthetic gene cluster for A-90289, Cpz15 for caprazamycin, LpmM for liposidomycin, Mur16 
for muraymycin, SphE for sphaerimicin, Mra24 for muraminomicin, ORF7 for A-500359, CapA for A-503083, and Cpr19 for A- 
102395. 
b Mra24 appears truncated and inactive, missing 57 amino acids at the C-terminus when aligned with LipL. 
c GlyU, 5'-C-glycyluridine-containing nucleoside antibiotics. 
d CarU, uridine-5'-carboxamide-containing nucleoside antibiotics. 
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Figure 2.3.6. Inactivation of cpr19 in Amycolatopsis sp. SANK 60206. (A) Gene 
location of cpr19 in the biosynthetic gene cluster of A-102395. (B) PCR analysis of 
genomic DNA isolated from the wild-type (WT; expected 0.9 kb) and Δcpr19 mutant 
(Δ; expected 1.8 kb) strains. (C) Strategy utilized for gene inactivation of cpr19. (D) 
Southern blot analysis of ApaI-digested genomic DNA from wild-type (WT) and 
Δcpr19 mutant (Δ) strains using the indicated probe. 
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Figure 2.3.7. Inactivation of cpr25 in Amycolatopsis sp. SANK 60206. (A) Gene 
location of cpr25 in the biosynthetic gene cluster of A-102395. (B) PCR analysis of 
genomic DNA isolated from the wild-type (WT; expected 1.2 kb) and Δcpr25 mutant 
(Δ; expected 1.8 kb) strains. (C) Strategy utilized for gene inactivation of cpr25. (D) 
Southern blot analysis of BamHI-digested genomic DNA from wild-type (WT) and 
Δcpr25 mutant (Δ) strains using the indicated probe. 
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Figure 2.3.8. Inactivation of cpr51 in Amycolatopsis sp. SANK 60206. (A) Gene 
location of cpr51 in the biosynthetic gene cluster of A-102395. (B) PCR analysis of 
genomic DNA isolated from the wild-type (WT; expected 1.1 kb) and Δcpr51 mutant 
(Δ; expected 1.8 kb) strains. (C) Strategy utilized for gene inactivation of cpr51. (D) 
Southern blot analysis of PstI-digested genomic DNA from wild-type (WT) and Δcpr51 
mutant (Δ) strains using the indicated probe. 
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For comparative analysis of 3 production in the wild-type and mutant strains, extracts 
from 2 L of culture broth were used for LC-MS-MS analysis with comparison to 
authentic 3. Multiple-reaction-monitoring transitions were monitored at 763.316/189.9 
and 763.316/120. The resulting cpr19 and cpr25 mutant strains were unable to 
produce 3 (Figure 2.3.9), consistent with an essential role in the biosynthesis of 3. 
As expected, the cpr51 mutant strain was also unable to produce 3, consistent with 
an essential role in 3 biosynthesis. 
 
 
 
Figure 2.3.9. Analysis of gene inactivation in Amycolatopsis. Sp. SANK 60206. 
LC-MS-MS analysis of authentic 3 (i) and production from wild-type (ii), Δcpr19 (iii), 
Δcpr25 (iv), and Δcpr51 (v) strains. 
 
 
Gene complementation has yet to be successful in this strain, and thus to exclude a 
possible polar effect, the expression levels of the upstream and downstream  genes 
A- 
Wild 
Δcpr19 
Δcpr25 
Δcpr51 
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were analyzed by RT-PCR. Using mRNA extracted from the Δcpr25 mutant strain at 
the onset of 3 production, expression of cpr25 was not detected while genes flanking 
cpr25 were clearly expressed (fig 2.3.10). In contrast, all three genes were detected 
within the wild-type strain, suggesting there is no polar effect due to cpr25 inactivation. 
Ambiguous results were obtained with expression analysis of the Δcpr19 mutant 
strain. Utilizing mRNA extracted from the Δcpr51 mutant strain at the onset of 3 
production, expression of cpr51 was not detected while genes flanking cpr51 were 
clearly expressed (fig 2.3.10). 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.10. RT-PCR analysis of the indicated genes using mRNA isolated 
from the mutant strains or wild-type strain. M, DNA ladder. 
 
 
Ambiguous results were obtained for expression analysis of the cpr19 mutant 
strain, and hence we turned our attention to in vitro characterization to establish 
direct evidence of the involvement  of  cpr19 in the biosynthesis of   3. 
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2.3.1.4 Functional characterization of Cpr19 and CapH 
 
The gene encoding cpr19 was heterologously expressed in E. coli to obtain pure, 
recombinant protein (fig 2.3.11 B). Based on prior characterization of LipL, Cpr19 
was expected to convert UMP to UA in a reaction that is dependent upon Fe(II), O2, 
and αKG. HPLC analysis of reactions with all these components revealed a new peak 
that co-eluted with authentic UA (fig 2.3.11 C). 
After demonstrating that UA is a biosynthetic intermediate of CarU-containing 
nucleosides, the probable L-Thr:UA transaldolase, Cpr25, was targeted for 
characterization; however, soluble protein could not be obtained using multiple hosts 
and a variety of expression conditions. Instead Cpr25 was substituted with CapH that 
is encoded within the 2 biosynthetic gene cluster (69). Similarly to LipK (101), soluble 
CapH was only produced in S. lividans TK64 (fig 2.3.11 B). Enzyme assays monitored 
by HPLC revealed identical traces to LipK (fig 2.3.11 D), and the product peak was 
compared to synthetic standard (101) to demonstrate CapH is an L-Thr:UA 
transaldolase. 
The detailed characterizations of Cpr19 and CapH were carried out by Dr. Anwesha 
Goswami and Dr. Sandra Barnard-Briston. 
Interestingly, Cpr19 was a monomer instead of a dimer as TauD (fig 2.3.11C, PDB 
ID: 3SWT (110)), its closest homology, suggesting that this enzyme has a distinct 
three dimension structure compared with other αKG:taurine dioxygenase (111-113). 
Structural studies of this enzyme are ongoing. 
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Figure 2.3.11. Biosynthesis of CarU of A-102395. (A) The pathway starts with UMP 
that is converted to GlyU by the sequential reactions catalyzed by Cpr19 and Cpr25. 
(B) SDS analysis of recombinant Cpr19 and CapH. (C) Native SDS-PAGE analysis 
indicated that Cpr19 was a monomer. (D) HPLC analysis of reaction catylized by 
Cpr19 using UMP as the prime substrate with all components (i) or the omission   of 
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ascorbic acid (ii). (E) HPLC analysis of reaction catylized by CapH PLC analysis of 
the reaction without enzyme (i) or with CapH (ii) or LipK (iii). A260, absorbance at 260 
nm. 
 
 
 
 
 
 
2.3.1.5 Proposed biosynthetic pathway of α-D-mannopyranuronate moiety and 
formation of polyamide side chain for 3 
 
A glycosyltransferase, Cpr24 encoded in the 3 cluster, is proposed to attach the sugar 
moiety to the CarU core, but the formation of the unsaturated uronic acid moiety is 
still not clear. The isopotic enrichment experiments suggested the sugar unit was 
derived from mannose, thus a GDP-D-mannuronic acid is expected to be an 
intermediate. GDP-D-mannuronic acid is a building block of alginate found in other 
bacterial strains, and therefore is a reasonable precursor (122). GDP-D-mannuronic 
acid is formed from GDP-D-mannose by a GDP-mannose-6-dehydrogenase in 
alginate biosynthesis while two gene products (Cpr21, a putative NDP-hexose 2,3- 
dehydratese and Cpr22, a putative NDP-hexose 4-epimerase/dehydrodates) that are 
shared in the 1-3 gene clusters are putatively involved in this chemistry. Lastly, 4,5- 
unsaturated double bond is putatively introduced by a dehydratase reaction, possibly 
by Cpr20, a putative ketoreductase, or by Cpr21/22. Cpr29 encoded a methyl 
transferase that is required for the 3’-O-methylation is found in all capuramycin-type 
antibiotics, although the timing of methylation is still unclear. The genetic system 
established in this study should help in defining the involvement and functions of 
those gene products. 
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The arylamine-containing polyamide moiety is exclusively found in 3. Bioinformatics 
analysis of 3 gene cluster revealed that a minimum 8 ORFs are required for the side 
chain biosynthesis, including Cpr12 and Cpr32-38. Cpr38 encodes a bidomain 
protein containing an L-Gln aminotransferase and a 4-amino-4-deoxychorismate 
(ADC) synthase(123), and thus it is proposed to catalyze a two-step reaction involving 
amidohydrolysis of L-Gln and incorporation of the free ammonia into chorismic acid 
to generate ADC. The following step is putatively catalyzed by Cpr12, which is 
annotated as an ADC lyase, to form para-amino-benzoic acid (PABA) through 
elimination of pyruvate. Similar to the initial activation and loading of a 4-methyl-3- 
hydroxyanthranilic acid to a stand-alone carrier protein in biosynthesis of 
actinomycins(124), Cpr37 and Cpr36 together catalyze the formation of thioester- 
linked PABA. Adjacent Cpr34 (a ketosynthase) and Cpr35 (a chain length factor) 
catalyze the decarboxylative condensation to form a β-ketothioester via a similar 
mechanism that was proposed in hygromycin B biosynthesis (125). The following 
stereoselective reduction is proposed to be catalyzed by Cpr33, and Cpr32 likely 
catalyzes hydroxylation of C-2. The formation of the remaining two amide bond is 
proposed to involve ORFs between cpr47-cpr57, which encodes proteins with 
similarity to an adenylation domain protein (Cpr54), two carrier proteins (Cpr48 and 
Cpr55), a condensation domain protein (Cpr47) and three transglutaminase-like 
proteins. The lack of precedence for this component in metabolites makes it difficult 
to propose how the amide bonds are generated; however, the genetic system that 
was developed can now minimally be used to assess the requirement of these ORFs. 
71  
The final step for 3 biosynthesis is the formation of an amide bond between the 
polyamide side chain and the unsaturated hexuronic acid. Two genes cpr29 and 
cpr51 show high homology to capS and capW which are responsible for loading of 
ACL during the biosynthesis of 2, and gene inactivation suggested that cpr51 is 
essential for 3 biosynthesis. Unfortunately we were unable to isolate any precursors 
of 3. Nonetheless Cpr29 is proposed to activate the carboxylic acid by methylation to 
the ester and Cpr51 is proposed to catalyze the final coupling of the polyamide. 
The biosynthetic gene cluster for 3 identified in this study has enabled a thorough 
comparative analysis with gene clusters for other capuramycin-type antibiotics, 
resulting in the proposed shared biosynthetic pathway as summarized in fig 2.3.12. 
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2.3.2 Functional characterization of Cpr17 as a phosphotransferase 
 
2.3.2.1 Functional characterization of Cpr17 
 
Previous study in the Van Lanen group demonstrated that: 1) within the biosynthetic 
gene cluster for 1 exists a gene encoding for a putative aminoglycoside 3- 
phosphotransferase (Orf21) that confers selective resistance to 1 when 
heterologously expressed in Streptomyces albus (99), and 2) a similar gene, capP, 
was identified within the biosynthetic gene cluster for 2 and was functionally 
characterized in vitro as a phosphotransferase that regiospecifically transfers the - 
phosphate of ATP to the 3′′-hydroxyl of the hexuronic acid moiety of 2a leading to 
272-fold increase in the IC50 in the MraY inhibitory activity (fig 2.3.13) (114). 
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Figure 2.3.13. The ATP-dependent phosphorylation reaction catalyzed by 
CapP (114). 
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Figure 2.3.14. Resistance conferred to Streptomyces albus upon heterologous 
expression of Cpr17. The concentration of 1a is 0 µg/mL, column 1; 100 µg/mL, 
column 2; and 500 µg/mL, column 3. The upper two rows (boxed in blue) consist of 
mycelia diluted 1/10 following homogenization of a liquid culture of S. albus while 
the bottom two rows (boxed in red) consist of mycelia diluted 1/100 prior to spotting 
on ISP2 agar plates. 
 
Within the biosynthetic gene cluster of 3, a gene encoding Cpr17 was identified that 
showed high sequence similarity to Orf21 and CapP (52% identity with Orf21 and 53% 
identity with CapP). It is thus proposed that Cpr17, as same as Orf21 and CapP, 
functions as a phosphotransferase conferring self-resistance to Amycolatopsis    sp. 
SANK 60206. In order to test the hypothesized function of Cpr17, the cpr17 gene was 
cloned from Cosmid pNCap01 and heterologously expressed in S. albus. Strains 
harboring the cpr17 gene were resistant to 2a at 500 µg/mL, while growth of the 
strains containing empty vector were susceptible at 100 µg/mL (fig 2.3.14). 
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The cpr17 gene was then cloned and expressed in E. coli to yield purified protein with 
expected size (fig 2.3.15, His-tag included). As a control, CapP was also produced. 
 
 
 
 
Figure 2.3.15. Expression of recombinant CPR17 and CapP. (A) SDS-PAGE 
analysis of His6-Cpr17 (expected MW of 37.9 kD), and (B) SDS-PAGE analysis of 
His6-CapP (expected MW of 37.8 kD). 
 
 
 
In order to test the activity of Cpr17, the reaction was initially assessed by HPLC using 
2a as a potential substrate, and a new peak eluting before 2a was observed. The 
retention time of the new peak was identical when Cpr17 was substituted by CapP, 
suggesting that Cpr17 catalyzes regiospecific phosphorylation at the 3′′-OH of 2a. 
The HRMS analysis of the product revealed an [M-H]- ion at m/z = 691.1536 which is 
consistent to the expected 3′′-phospho-A-503083B (calculated [M-H]- ion at m/z = 
691.1607) (fig. 2.3.17). 
 
The authentic substrate for Cpr17, 3, was then used for the reaction as described 
above. A new peak appeared using either Cpr17 or CapP, and the analysis of the 
product revealed an [M-H]- ion at m/z = 843.0, which was consistent to the calculated 
MW of mono-phospho-3 (C31H37N6O20P, expected [M-H]-  ion at   m/z = 843.2)   (fig. 
B A 
55 KD 
37 KD 
25 KD 
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2.3.18). Although the limited availability of 3 precluded structural elucidation and 
product bioactivity analysis at the current time, the results suggested Cpr17, like 
CapP, functions as a regiospecific phosphotransferase. The shared precursor of the 
capuramycins, 2d and 2c (fig 1.7) were used as substrates. Although both Cpr17 and 
CapP were able to convert 2d into 3’’-phospho-2d, no appreciable activity was 
detected with 2c. The resulted was consistent to the previous study showing that 
CapP utilized 2c with a very low turnover of 0.2 min-1 (99) (fig 2.3.16). 
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Figure 2.3.16. HPLC analysis of the reaction catalyzed by Cpr17 and CapP. 2a 
(A), 3 (B), 2d (C) 1c (D) were used as substrates and incubated without enzyme (i), 
with Cpr17 (ii), and with CapP (iii). ▼, 3''-phospho-2a; ♦, 3''-phospho-2d; and ●, 3''- 
phospho-3. A260, absorbance at 260 nm. The asterisk (*) denotes an unidentified 
contamination peak. 
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Figure 2.3.17. HRMS analysis for the product of reactions catalyzed by Cpr17 using 
2a as substrate. (A) HRMS (ESI+) calcd. for [M + H]+ 693.1769; found 693.1742; (B) 
HRMS (ESI-) calcd. for [M - H]- 691.1612; found 691.1535. 
B 
691.1536 
A 693.1742 
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Figure 2.3.18. Mass spectrum for the products of reactions catalyzed by Cpr17. 
(A) Mass spectrum for the peak eluting at 7.7 min yielding [M-H]- = 763.3 consistent 
with the calculated MW of authentic 3. (B) Mass spectrum for the peak eluting at 7.6 
min of the reaction using 3 as substrate yielding [M-H]- = 843.0 consistent with the 
calculated MW of 3’’-phospho-3. (C) Mass spectrum for the peak eluting at 14.6 min 
of the reaction using 2d as substrate yielding [M-H]- = 595.2 consistent with the 
calculated MW of 3’’-phospho-2d. 
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2.3.2.2 Kinetic characterization of Cpr17. 
 
After identifying the function of Cpr17, single-substrate kinetic experiments were 
performed using 2a as substrate. Using near saturating ATP and variable 2a, 
standard Michaelis-Menten kinetics were observed yielding a KM  = 146 ± 13 µM and 
kcat  = 5.8 ± 0.2 min
-1 (fig.  2.3.19 A), the former constant similar to and the latter  5- 
fold lower than that reported for CapP (table 2.3.3). This result was expected since 
2a was not the authentic substrate. Single-substrate kinetic experiments with 
saturating 2a and variable ATP yielded a KM  = 1.4 ± 0.1 mM and kcat  = 10.1 ± 0.4 
min-1 (fig.  2.3.19 B). The  unexpected  high observed KM  for ATP indicated  that 
ATP is not a preferred source of phosphate. This result prompted us to test GTP as 
an alternative phosphate donor, which served as an excellent substrate for Cpr17 
yielding a KM  = 9.2 ± 1.7 µM and kcat  = 3.3 ± 0.1 min-1 (fig. 2.3.19 C), a 50-fold 
improvement in catalytic efficiency, suggesting GTP is the in vivo substrate for Cpr17. 
A similar nucleotide preference has been recently reported for certain aminoglycoside 
phosphotransferases (126-128) 
 
Table 2.3.3. Michaelis-Menten kinetic parameters of CapP and Cpr17. 
 
Enzyme  Substrate KM (µM) kcat (min-1) kcat/KM Relative efficiency 
CapPa 2a  170 ± 40 34 ± 4 2.0 x 10-1  
Cpr17 2a  146 ± 13 5.8 ± 0.2 4.0 x 10-2  
 
 
a Data taken from Ref (114). 
 ATP (1.4 ± 0.1) x 103 10.1 ± 0.4 7.2 x 10-3 1 
GTP 9.2 ± 1.7 3.3 ± 0.1 3.6 x 10-1 50 
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Figure 2.3.19. Plots for single-substrate kinetic analysis of Cpr17. (A) Single- 
substrate kinetic analysis with variable 2a. (B) Single-substrate kinetic analysis with 
variable ATP. (C) Single-substrate kinetic analysis with variable GTP. 
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2.3.2.3 Promiscuity of Cpr17 
 
 
Cpr17 phosphorylates not only its authentic substrate 3 but also other capuramycin- 
type antibiotics including 2a and 2d. This suggested a low specificity of Cpr17 for 
different substrate sidechains (fig 2.3.20). the substrate specificity of Cpr17 were 
further tested by using semi-synthetically prepared capuramycin derivatives P1 – P10 
and A-503083G as substrates (table 2.3.4). After overnight incubation with Cpr17 
along with ATP, all tested substrates were converted into their corresponding mono- 
phosphorylated products with the only exception of A-503083 G (fig 2.3.21). The lack 
of activity with A-503083G, which contains a 3’’-methyl ether instead of the hydroxyl, 
provided further evidence that Cpr17, as well as other capuramycin 
phosphotransferase, regiospecifically transfers γ–phosphate to this position. MS 
analysis of the product peaks was consistent with each product being 
monophosphorylated (fig 2.3.22). It is of worth to note that all the capuramycin 
derivatives tested here showed potent inhibitory activity against M. smegmatis MC2 
155* except A-503083 G. 
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Figure 2.3.20. Phosphorylation of unnatural capuramycin derivatives by Cpr17. 
 
 
 
* Data not yet published. 
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Table 2.3.4. Semi-synthesized substrates for Cpr17 activity assay*. Absolute 
stereo chemistry was shown. 
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* Structures of unnatural capuramycins were compared with the standards provided by Dr. Xiaodong Liu except 
for P5 (Appendix I). 
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Figure 2.3.21. HPLC analysis of reactions catalyzed by Cpr17 using unnatural 
capuramycins as substrates without enzyme (upper black traces) and with Cpr17 
(lower red traces). A260, absorbance at 260 nm. All substrates were mono- 
phosphorylated except for A-503083 G. 
A-503083G P8 P9 P7 
P6 P5 P4 
P3 P2 P1 
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Figure 2.3.22. Mass spectrum for the products of reactions catalyzed by Cpr17 
using unnatural capuramycins as substrates. Mass spectrum for the peak was 
consistent with calculated MW of mono-phospho P1-P9. 
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Functional assignment of Cpr17 as a regiospecific and substrate-promiscuis 
phosphotransferase suggests that the 3′′-OH is critical for the inhibitory activity of 
capuramycins against MraY. To elucidate the importance of 3′′-OH, I docked 2d, the 
structurally simplest but active member of capuramycins, into the proposed substrate 
binding site of MraY using the reported structure using autodock vina (129,130) (fig 
2.3.23). It is of interest to notice that 3′′-OH is interacting through a hydrogen bond 
with D117, which is one of the three catalytically important residues in the active site 
of MraY (54). A similar interaction was not observed for A-503083G on which the 3′′- 
OH was chemically protected by a methyl ether. 
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Figure 2.3.23. Docking 2d to the active site of MraY. The 3’’-OH of 2d formed a 
putative hydrogen bond to D117, one of three catalytic residues (highlighted in red 
and depicted as sticks, left). The structure used for binding and the possible 
interaction was highlighted (right). 
D117 
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2.3.2.4 Predicted structure of Cpr17 
 
 
The protein kinase (PK) superfamily which transfers the γ-phophate group from 
nucleotide to the target substrates contain a number of highly conserved catalytic 
residues related to nucleotide binding and phophoryl transfer (131). Cpr17 and CapP, 
showing highest sequence similarity to aminoglycoside phosphotransferase (APH), 
were aligned to a series of well-studied APHs including APH(2′′)-IIIa (accession 
number 3TDW_A, PDB ID: 3tdw), APH(2′′)- Ia (accession number 4ORK_D, PDB ID: 
4ORK), APH(2′′)-IIa (accession number ), APH(2′′)-IVa (accession number 3N4V_B, 
PDB ID: 3N4V), and APH(2′′)-Iva (accession number 4N57_B, PDB ID: 4N57) (fig 
2.3.24). The presence of the conserved triphosphate binding residue (highlighted in 
red), and the essential DXXXXN catalytic loop that is conserved (Asp-194 in Cpr17 
and highlighted in blue) was confirmed. The acidic glutamic acid (Glu-63, highlighted 
in green) is essential for maintaining the protein structure, and nucleotide binding 
sites (highlighted in dark green) are also conserved. The alignment indicated that 
Cpr17 and CapP share the conserved nucleotide binding site with other members of 
the APH superfamily as expected resulting in high overall sequence identity. However, 
it was quite unexpected that neither Cpr17 nor CapP contain a “gatekeeper” tyrosine 
as seen with other GTP specific APHs as reported previously (126) but instead 
contain a Val and Thr in Cpr17 and CapP, respectively, thus suggesting that the 
capuramycin phosphotransferease are nucleoside unspecific, which is inconsistent 
with the kinetics data. 
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10 20 30 
Cpr17 -------------------------VTETEITAGLIRDLLRDQHPDLADLPLREVEGGWG 
capP -----------------------MTDTENEITADLITGLLREQHPDLADLPLTFGAHGWD 
3tdv ----------------------------MKQNKLHYTTMIMTQFPDISIQSVESLGEGFR 
4ork ---------------------MEYRYDDNATNVKAMKYLIEHYFDNFKVDSIEIIGSGYD 
4dca -------------------------------MVNLDAEIYEHLNKQIKINELRYLSSGDD 
3n4v --------------------MRTYTF-------DQVEKAIEQLYPDFTINTIEISGEGND 
4N57: MGSSHHHHHHSSGLVPRGSHMRTYTF-------DQVEKAIEQLYPDFTINTIQISGKGND 
 
 
40 50 60 70 80 90 
Cpr17 NQMWRLGDELAVRIQRMDND-PQFQLRERQWLPLLAPR--LPLPIPVPVRNGAPSERFPK 
capP NQLWRLGDDLAVRLPWATEDADDLLLKEHAFLPAMASR--LPLPVPVPQRLGRPSERFPR 
3tdw NYAILVNGDWVFRFPKSQQG-ADELNKEIQLLPLLVGC--VKVNIPQYVYIGKR--SDGN 
4ork SVAYLVNNEYIFKTKFSTNK-KKGYAKEKAIYNFLNTNLETNVKIPNIEYSYI---SDEL 
4dca SDTFLCNEQYVVKVPKRDSV-RISQKREFELYRFLEN-CKLSYQIPAVVYQSD-----R- 
3n4v CIAYEINRDFIFKFPKHSRG-STNLFNEVNILKRIHNK--LPLPIPEVVFTGMPSETYQM 
4N57: CIAYEINRDFIFKFPKHSRG-STNLFNEVNILKRIHNK--LPLPIPEVVFTGMPSETYQM 
 
 
100 110 120 130 140 
Cpr17 LWTVVTWVPGLPLDQG-----SITRGDDAADTLAAFLRALHVAAPADAPV------DNDR 
capP PWIVTTWVPGEPADRA-----PATRGVEAADALSAFLKALHQPAPDDAPG------GRNR 
3tdw PFVGYRKVQGQILGEDGMAVLPDDAKDRLALQLAEFMNELSAFPVETAISAG-VPVTNLK 
4ork SILGYKEIKGTFLTPEIYSTMSEEEQNLLKRDIASFLRQMHGLDYTDISE---CTI-DNK 
4dca -FNIMKYIKGERITYEQYHKLSEKEKDALAYDEATFLKELHSIEIDCSVSLFSDALVNKK 
3n4v SFAGFTKIKGVPLTPLLLNNLPKQSQNQAAKDLARFLSELHSINISGFKS---NLVLDFR 
4N57: SFAGFTKIKGVPLTPLLLNNLPKQSQNQAAKDLARFLSELHSINISGFKS---NLVLDFR 
 
 
150 160 170 180 190 200 
Cpr17 GAHPKDSTNGFNYFLNSVDADAIGHDAADVRAVWDDAVAAPA-WEGPAMWVHGDLHPANV 
capP GGPLADADEGFEHFLKETTNRGLIPEPDTVREVWKDALAAPV-WTGPSLWLHADLHPANL 
3tdw NKILLLSEAVEDQVFP----LLDESLRDYLTLRFQSYMTHPVYTRYTPRLIHGDLSPDHF 
4ork QNVLEEYILLRETIYN----DLTDIEKDYIES-FMERLNATTVFEGKKCLCHNDFSCNHL 
4dca DKFLQDKKLLISILEKEQ--LLTDEMLEHIETIYENILNNAVLFKYTPCLVHNDFSANNM 
3n4v EKINEDNKKIKKLLSR----ELKGPQMKAVDDFYRDILENEIYFKYYPCLIHNDFSSDHI 
4N57: EKINEDNKKIKKLLSR----ELKGPQMKKVDDFYRDILENEIYFKYYPCLIHNDFSSDHI 
 
 
210 220 230 240 250 
Cpr17 VVA----DGTLAGVVDFGALFAGDPALDLSSAWVLLPAGAAA----RFFAAYADA-DEAT 
capP LTT----DGTFCGVVDFGDLCAGDPACDLAAGWHVLPDGAID----RFHQSYSSAADAAT 
3tdw LTNLNSRQTPLTGIIDFGDAAISDPDYDYVYLLEDC----GELFTRQVMAYRGEVDLDTH 
4ork LLD--G-NNRLTGIIDFGDSGIIDEYCDFIYLLEDSEEEIGTNFGEDILRMYGNIDIEKA 
4dca IFR----NNRLFGVIDFGDFNVGDPDNDFLCLLDCSTDDFGKEFGRKVLKYYQHKAPEVA 
3n4v LFD--TEKNTICGIIDFGDAAISDPDNDFISLMEDD-EEYGMEFVSKILNHYKHKDIPTV 
4N57: LFD--TEKNTICGIIDFGDAAISDPDNDFISLMEDD-EEYGMEFVSKILNHYKHKDIPTV 
 
 
260 270 280 290 300 
Cpr17 VRRARGLAALKSLFLMLMGQNGDRGLPGGKPAWGPAGRSALDRVMGERLARFHG 
capP LRRARGWAVLKALACLLIGDNGVHGRTGGKATWGPPADAALRRLTATHS----- 
3tdw IRKVSLFVTFDQVSYLL------EGLRARDQDWISEGLELLEEDKANNFGANSA 
4ork KEYQDIVEEYYPIETIV------YGIKNIKQEFIENGRKEIYKRTYKD------ 
4dca ERKAELNDVYWSIDQII------YGYERKDREMLIKGVSELLQTQAEMFIF--- 
3n4v LEKYRMKEKYWSFEKII------YGKEYGYMDWYEEGLNEIRSAKIK------- 
4N57: LEKYRMKEKYWSFEKII------YGKEYGYMDWYEEGLNEIRSIKIK------- 
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Figure 2.3.24. Sequence alignment of Cpr17, CapP to APHs (126) using Clustal 
Omega. The conserved residues involved in triphosphate binding were highlighted 
in red and the catalytic loop HGDXXXN was in blue. The glutamic acid in green is 
responsible for electrostatic interaction with surrounding basic residues. The 
“gatekeeper” residues in black, together with nucleoside binding residues highlighted 
in dark green, determines ATP or GTP is preferred (125). 
 
 
 
The structure of Cpr17 was predicted using SWISS MODEL based on a GTP specific 
APH(2′′)-IIIa (PBD ID 3TDW) and a nucleotide unspecific APH(2′′)-IIa (PBD ID 4DCA), 
and showed considerable similarity to the template (fig 2.3.25). The conserved 
residues involved in nucleoside binding and the catalytic residues superimposed 
perfectly between models and templates (fig 2.3.26 while the “gatekeeper” tyrosine 
residue was not found in the putative nucleoside binding site of Cpr17. Based on this 
model, a D212A mutant were prepared and expressed in E. coli BL21 strains to yield 
soluble proteins. HPLC analysis results indicated that D212A_Cpr17 showed no 
activity with 2a, which was consistent to the proposed function of D212 (fig 2.3.27). 
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Figure 2.3.25. Structure comparison of APH and predicted Cpr17. (A) 
comparison of the structures of APH(2’’)-IIIa, APH(2’’)-IIa and the predicted structure 
of Cpr17. (A) The predicted structure of Cpr17 (blue, left) was imposed onto the 
template APH(2’’)-IIIa. (B) The predicted structure of Cpr17 (blue, left) was imposed 
onto the template APH(2’’)-IIa. 
A 
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Gly 97/ 
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Figure 2.3.26. Alignment of GTP binding site of APH(2’’)-IIIa (light blue) and 
Cpr17 (green). 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.27. Mutant Cpr17 exhibited altered activity. CPR17_D212A resulted 
complete loss of activity (i) compared to wild-type Cpr17 (ii). 
3’’-phospho-2a 
ii 
2a 
i 
Tyr 92/ 
Val 96 
Arg 45/ 
Arg 48 
Glu 59/ 
Glu 62 
GDP 
Asp 218/ 
Asp 212 
His 201/ 
Asn 199 
Asp 196/ 
Asp 195 
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Even though several APHs of the phosphotransferase/kinase family have been 
crystalized, it is still difficult to precisely predict the capuramycin binding site in Cpr17 
because of the significant difference in structures between capuramycins and 
aminoglycosides. We subsequently attempted to crystalize Cpr17 and co-crystalize 
Cpr17 along with its substrates capuramycin, AMPPNP and magnesium ion. 
Although crystals of Cpr17 have been obtained (fig 2.3.28), further optimization of 
the conditions for crystallization in order to acquire decent structural information by 
X-ray diffraction is still ongoing. 
 
 
 
 
 
 
 
Figure 2.3.28. Crystal of Cpr17 obtained from high throughput screening. 
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2.3.3. Reconstitution of bacterial cell wall biosynthesis in vitro. 
 
The genes encoded for MurA-MurF and Ddl that are involved in E. coli cell wall 
biosynthesis were cloned and expressed in E. coli (BL21) DE3 strains to yield soluble 
proteins (fig 2.3.29). Two additional genes were added to the reaction to avoid using 
expensive UDP-GlcNAc (132): N-acetylhexosamine 1-kinase (NahK (133), 
subcloned from Bifidobacterium infantis ATCC 15697) that converts GlcNAc to N- 
acetyl-glucosamine 1-phosphate (GIcNAc-1P) by using ATP as the phosphate donor; 
and a bifunctional enzyme GlmU (134) (subcloned from E. coli BL21) that converts 
GlcNAc-1P into UDP-GlcNAc using UMP as the co-substrate (fig 2.3.30). When 
preparing the UDP-MurNAc-pentapeptide (12), another two enzymes including a 
glutamate dehydrogenase (GDH, subcloned from Bacillus subtilis strain 168) that 
recycles the NAPDH while oxidizing glucose into glucono-1,5-lactone (135), and a 
pyruvate kinase (purchased from Sigma-Aldrich) that regenerates nucleotides were 
added to the reaction. The one pot reaction containing all of the enzymes and 
supplemented with the appropriate substrates (fig 2.3.31) was incubated at rt for 
overnight, and the product was purified as described in Methods section. The 
production of UDP-MurNAc-pentapeptide (12), which is the final product of the Mur 
ligases, was purified using SEPABEADS SP207 resin and semi-preparative HPLC. 
The purity of 12 was 95% based on HPLC and the molecular weight was confirmed 
by HRMS (fig 2.3.32) 
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Figure 2.3.29. Expression of MurA-MurF and Ddl involed in E. coli cell wall 
synthesis. 
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Figure 2.3.30. NahK and GlmU convert GlcNAc to UDP-GlcNAc. (i) Reaction with 
NahK and GlmU, (ii) without NahK and (iii) without GlmU. 
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Figure 2.3.32. HPLC and HRMS analysis of UDP-MurNAc-pentapeptide (12). (A) 
HPLC analysis of purified 12. (B) HRMS analysis of purified 12, calcd. for [M - H]- 
1192.3414; found 1192.3337. 
B A 
Figure 2.3.31. Enzymatic synthesis of UDP-MurNAc-pentapeptide. 
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A similar one pot reaction was used to establish a rapid and cost-efficient HTS model 
for discovery of antibiotics targeting on the Mur liagases. In short, candidate inhibitors 
would be expected to stop the flux when a Mur ligase is inhibited. Firstly, the reactions 
were carried out individually for each enzymatic step, and the HPLC traces revealed 
that the reactions can be monitored stepwise (fig 2.3.33). To validate this model, a 
known inhibitor targeting Ddl (cycloserine, purchased from Sigma-Aldrich) was added 
to reactions at a concentration of 10 mM. After the reaction was quenched after 3 h, 
the HPCL results indicated that the reactions containing cycloserine stopped at the 
expected step leading to the accumulation of 11 (fig 2.3.33). 
97  
 
 
 
 
 
 
 
 
ii 
 
 
 
 
 
 
Figure 2.3.33. Reconstituting E. coli bacterial cell wall biosynthesis. HPLC 
analysis of reactions carried out using individual enzymes (MurA-MurF and Ddl) 
with appropriate substrates (traces i - vi). When 10 mM cycloserine was added, the 
reaction stopped at MurE step (last vii). 
7 8   9  11 10 12 
UDP-GlcNAc 
MurA i 
MurB 
MurC iii 
MurD iv 
MurE v 
Ddl and MurF vi 
MurA-F, 
10 mM cycloserine vii 
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The MurA-MurF and Ddl in M. tuberculosis (Mur_tb and Ddl_tb) showed only 
moderate identity/similarity to those in E. coli, suggesting possible structural 
differences between isoenzymes from different species (table 2.3.5). Thus a species- 
specific HTS model is necessary to avoid false-negative results. To expand the 
system beyond detecting inhibitors for the E. coli recombinant enzymes, the 
homologous genes from M. tuberculosis R37v were cloned and expressed. All 
proteins from M. tuberculosis were soluble excluding MurD_tb, which failed to 
express in E. coli BL21 (DE3) and therefore E. coli MurD was purified and used 
instead (fig 2.3.33). HPLC traces of the reactions catalyzed by Mur ligases from M. 
tuberculosis were compared with the ones from E. coli. The final product 12 was 
purified using SEPABEADS SP207 resin. The product after purification was 
confirmed as authentic 12 by LC-MS (fig 2.3.34). 
 
 
 
Table 2.3.5. Sequence comparison of MurA-MurF from different species in % 
identity/% similarity. 
 
Protein 
E. coli BL21(DE3) 
Protein 
M. tuberculosis 
  H37Rv   
Identity/ 
Similarity (%) 
MurA MurA-tb 45/60 
MurB MurB-tb 34/50 
MurC MurC-tb 36/51 
MurD MurD-tb 31/44 
MurE MurE-tb 39/53 
MurF MurF-tb 31/46 
  DdlA   DdlA-tb   37/54   
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Figure 2.3.34. Reconstituting M. tuberculosis bacterial cell wall biosynthesis. 
(A) Expression of MurA-MurF and Ddl involed in M. tuberculosis cell wall synthesis. 
(B) One pot reaction of MurA-MurF and Ddl from M. tuberculosis (i) and E. coli (ii). 
(C Mass spectrum for the peak eluting at 13.5 min yielding [M-H]- = 1192.3 
consistent with the calculated MW of authentic 12. (D) Mass spectrum for the peak 
eluting at 13.5 min yielding [M+H]+ = 1194.4 consistent with the calculated MW of 
authentic 12. The asterisk (*) denotes an unidentified contamination peak. 
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MurB_tb has not been functionally characterized from this Mycobacteria before, and 
the HPLC results suggest this enzyme is indeed an UDP-N- 
acetylenolpyruvoylglucosamine reductase (fig 2.3.35), the same activity of the E. coli 
MurB. 
 
 
 
 
 
 
 
Figure 2.3.35. HPLC analysis of the reaction catalyzed MurB. (A) Reactions were 
carried out using authentic 7 (iii) incubacted with MurB from M. tuberculosis (i) and E. 
coli (ii). 
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2.4 Conclusion 
 
In summary, the biosynthetic gene cluster of 3 was identified by using a pair of 
degenerate primers based on the possible involvement of an L-Thr:UA transaldolase 
in CarU biosynthesis, and a total of 70 ORFs were identified to be responsible for the 
biosynthesis of 3. Unlike the producing strains for 1 and 2, which have not been 
amenable to genetic manipulation, gene inactivation was possible with the 3 
producing strain, thus enabling the first in vivo analysis of the gene clusters for the 
capuramycin-type antibiotics to validate our proposed gene cluster. A series of gene 
inactivations were carried out. Three orfs cpr19, cpr25 and cpr51 were chosen and 
individually replaced by a resistant marker on the genome of 3 producer, and no 
mutant strains were able to produce 3 as determined by LC-MS-MS analysis. 
Functional characterization of CapH and Cpr19 indicated that they catalyze identical 
reactions as LipK and LipL, suggesting a shared biosynthetic paradigm for CarU in 
capuramycin-type antibiotics and (5′S,6′S)-5'-C-glycyluridine (GlyU) in uridyl 
lipopeptide antibiotics (136,137): uridine-5'-monophophate (UMP) is oxidized to 
uridine-5'-aldehyde (UA) in a reaction catalyzed by a a non-heme, Fe(II)-dependent 
α-ketoglutarate:UMP dioxygenase and UA is subsequently converted to GlyU through 
an aldol-type condensation in a reaction catalyzed by an L-threonine:uridine-5'- 
aldehyde transaldolase. The final step(s) to furnish CarU from GlyU, however, 
remains unclear. 
We have functionally and kinetically characterized Cpr17 as a phosphotransferase 
conferring self-resistance to 3, and explored its substrate promiscuity toward 
capuramycins. Cpr17 has a similar amino acid sequence to ORF21 and CapP  from 
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the biosynthetic gene clusters for 1 and 2, respectively, and was demonstrated to 
function as a phosphotransferase that converts 3 to 3′′-monophosphate-3 using a γ- 
phosphate group from a nucleotide donor. The kinetic characterization revealed 
Cpr17 has similar kinetic parameters as CapP including an unexpectedly high 
apparent KM for ATP indicated that Cpr17 probably utilizes a different nucleotide as 
the phosphate donor. GTP was therefore tested with Cpr17, resulting in a 50-fold 
increase of catalytic efficiency suggested that GTP is the authentic substrate in vivo. 
Cpr17 was also shown to phosphorylate other capuramycins including 2a and 2d. 
The only exception among the natural capuramycins was 2c, which neither Cap17 
nor CapP was able to modify under the conditions employed here. This substrate 
promiscuity of Cpr17 caught our interest and led us to explore the substrate flexibility 
in more detail. We chemically and chemo-enzymatically synthesized a series of 
unnatural capuramycins using CapW as a biocatalyst. As expected, A-503083 G, the 
3′′-methoxy capuramycin was not phosphorylated. On the other hand, however, all 
the unnatural capuramycins were phosphorylated by Cpr17 regardless of the side 
chain structures. Finally, the conserved amino acid residues in Cpr17 involving in 
nucleotide triphosphate binding and catalytic residues were confirmed by global 
sequence alignment with representative aminoglycoside phosphotransferase, 
homologous modeling and small molecule docking. The abolishment of activity of 
D212A_Cpr17 testified that the aspartate is a key residue involved in triphosphate 
binding. Interestingly, the “gatekeeper” tyrosine residue which determines the 
preference of nucleotide in aminoglycoside phosphotransferase was absent, but 
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Cpr17 is selective to GTP over ATP. Future crystal structure of Cpr17 may reveal the 
mechanism of nucleoside selectivity. 
Lastly, a target- and species-specific HTS model was established and validated by 
using cycloserine, a known inhibitor targeting on Ddl which is one of the key enzymes 
in cell wall biosynthesis. The one pot reaction also allowed us to accumulate 
expensive intermediates that occur in the pathway. In the future, this model will be 
optimized to determine the most suitable concentration of starting material, best 
incubation time and so on. It is envisioned that this HTS model can eventually be 
utilized to screen natural products and their derivatives and synthetic libraries to 
identify new antibacterial therapeutics. 
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Chapter 3: Discovery of novel actinomycins as potential anti-tuberculosis 
agents* 
 
3.1 Background 
 
Previous studies revealed that the mechanism of action of actinomycin involves 
intercalation of the phenoxazinone between a GC base pair of double-stranded DNA 
with each peptide ring orienting in opposite directions to bind within the minor groove 
(138). While the phenoxazinone moiety has been demonstrated to be essential for 
the activity of actinomycins, the strength and specificity of binding is highly dependent 
on amino acid composition of the peptides (77,92,93,139). In 2009, several new 
actinomycin congeners were identified (termed Y-type actinomycins) from the 
fermentation broth of Streptomyces sp. Strain Gö-GS12. Actinomycin Y5, which 
contains a unique bridging macrocycle between L-Thr on the β-ring and the 
phenoxazinone core, had potent antibacterial activity against Staphylococcus aureus 
and Bacillus subtilis while no apparent cytotoxicity against tested human cancer cell 
lines HM02 (gastric adenocarcinoma), HepG2 (hepatocellular carcinoma), and MCF7 
(breast adenocarcinoma) (77) (fig 3.1.1). The improved selectivity of the fascinating 
structures of the newly discovered Y-type actinomycins suggested a possible 
antibiotic-selective actinomycin. Our group initiated studies aimed at identifying 
additional novel actinomycins with potential anti-tuberculosis activity by thoroughly 
investigating the metabolite profile of the producer strain for Y-type actinomycins. 
Consequently, this would allow us to isolate more actinomycin Y5 for further 
characterization. 
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*This chapter was carried out in collaboration with Dr. Xiachang Wang (structural elucidation), Drs. 
Larissa.Ponomareva and Sherif Elshahawi (bioactivity assays), Center for Pharmaceutical Research and 
Innovation (CPRI). 
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Figure 3.1.1. Structure of actinomycin Y5. 
 
 
 
In this chapter, structures of four novel actinomycins isolated from Streptomyces sp. 
Strain Gö-GS12 (actinomycins Y6-Y9, 1-4) and a known semisynthetic compound 
actinomycin Zp (5) which for the first time, isolated from Streptomyces as a natural 
product will be discussed. The new members of actinomycins provided more details 
into structure-activity relationship. The unstable actinomycin Y6 (1) containing an 
additional ring structure between β-ring and chromophore underwent ring opening 
under acidic conditions, suggesting that biosynthesis of the bridging macrocycle is 
potentially due to nucleophilic attack of the amino group of the chromophore to C-4 
of HThr. 
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3.2 Materials and methods 
 
3.2.1 Instrumentation, chemicals and bacterial strains 
 
UV spectra were recorded on an Ultrospec 8000 spectrometer (GE, Pittsburgh, PA, 
USA). CD spectra were obtained on a Jasco J-810 spectropolarimeter (Jasco, Easton, 
MD). All NMR data was recorded at 500 MHz or 400 MHz for 1H and 100 MHz for 13C 
with Varian Inova NMR spectrometers (Agilent, Santa Clara, CA). LC-MS was 
conducted with an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent 
Technologies, Santa Clara, CA) equipped with an Agilent 1200 Series Quaternary LC 
system and an Eclipse XDB-C18 column (150 × 4.6 mm, 5 µm). HR-ESI-MS spectra 
were recorded on an AB SCIEX Triple TOF 5600 System (AB Sciex, Framingham, 
MA, USA). Analytic HPLC was performed with one of two systems: a Waters Alliance 
2695 separation module (Milford, MA) equipped with a Waters 2998 diode array 
detector and an analytical Apollo C-18 column(250 mm x 4.6 mm, 5 µm). 
Semipreparative HPLC was performed with a Waters 600 controller and pump 
(Milford, MA) equipped with a 996 diode array detector, 717plus autosampler, and an 
Apollo C-18 column (250 × 10 mm, 5 µm) purchased from Grace (Deerfield, IL). All 
solvents used were of ACS grade and purchased from Pharmco-AAPER (Brookfield, 
CT). Sephadex LH-20 (25 ~ 100 μm) was purchased from GE Healthcare (Little 
Chalfont, United Kingdom). TLC silica gel plates (60 F254) were purchased from EMD 
Chemicals Inc. (Darmstadt, Germany). Celite (TM) was purchased from Fisher 
Scientific (Pittsburgh, PA). Amino acids and marfey’s reagent were purchased from 
Sigma Aldrich (St. Louis, MO). 
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Streptomyces sp. Strain Gö-GS12 was provided by Dr. Stephanie Grond (University 
of Göttingen). 
 
 
3.2.2 Isolation of actinomycins 
 
Streptomyces sp. Strain Gö-GS12 was cultivated in three 250 mL Erlenmeyer flasks, 
each containing 50 mL of oatmeal medium (20 g/L) enhanced with trace elements 
solution (CaCl2·2 H2O 3 g/L , Fe(III)-citrate 1 g/L, MnSO4 0.2 g/L, ZnCl2 0.1 g/L, 
CuSO4·5 H2O 25 mg/L, Na2B4O7 ·10 H2O 20 mg/L, CoCl2 4 mg/L, Na2MoO4·2 H2O 
10 mg/L). After three days of incubation at 28°C with 200 rpm agitation, the cultures 
were used to inoculate 50 flasks (250 mL), each containing 100 mL of oatmeal 
medium (77). The fermentation was continued for seven days at 28°C with 200 rpm 
agitation. 
All culture flasks were combined, mixed with 300 g of celite follwed by filteration under 
vacum to seperate the mycelium and culutre broth. The mycelial cake-celite portion 
was extracted with acetone (3 × 500 mL) by sonnication, filltered off and the organic 
phase was evaporated to afford 2g of a dark red crude extract. The supernatant was 
extracted with CH2Cl2 (3 × 1 L). The organic phase was dried in vacuo to afford 3 g 
of dark red crude extract. 
Crude extract from mycelium and supernatant was combined and subjected to a silica 
gel colunm chromatography using a gradient of CHCl3-MeOH (100:0 ~ 90:10) to yield 
four fractions, I-IV. Fraction I was applied to Sephadex LH-20 column 
chromatography and then semi-preparative HPLC (CH3CN/H2O, 0.01% TFA; flow 
rate: 3.5 mL/min) to offer 5 (10 mg). Compounds Y1 (30 mg), 3 (10 mg) and 4 (15 mg) 
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were isolated from fractions II, III by applying Sephadex LH-20 and then semi- 
preparative HPLC (CH3CN/H2O, 0.1% TFA; flow rate: 3.5 mL/min). Similarly, 1 (2 mg), 
2 (10 mg) and Y4 (10 mg) were purified from fraction IV. Since 1 was unstable under 
acidic condition, 0.1‰ THF was used during HPLC purification for fraction IV, and 
solvent was rapidly dried in vacuo (fig 3.2.1). 
 
 
 
Figure 3.2.1. Isolation scheme for actinomycins from 5 L fermentation broth. 
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3.2.3. Determination of amino acids configuration 
 
The absolute configuration of each amino acid residue was determined following 
Marfey’s method (140). 2.0 mg of 1 were hydrolyzed in 6 N HCl (1 ml) at 110 °C for 
4 h. After drying under nitrogen, the corresponding hydrolysate was dissolved in 2 ml 
of EtOAc-H2O (1:1). The aqueous layer was dried in vacuo, to which a solution of 1% 
Marfey’s reagent in acetone (200 ml) was subsequently added, followed by 1 M 
NaHCO3 (50 ml). The reaction was incubated at 40 °C for 1 h, then allowed to cool. 
It was then acidified with 25 ml of 2 N HCl. The reaction mixture was diluted with 
MeOH (0.5 ml) and analyzed by HPLC using the following gradient: 0–55 min, linear 
gradient from 10–55% CH3CN in 50 mM triethylammonium phosphate buffer 
(Phenomenex C18 column, 250*4.6 mm). The flow rate was kept constant at 1 ml/min 
and elution was monitored at 430 nm. Derivatized standards were prepared from the 
authentic D- and L-valine, L-sarcosine, L-threonine and L-methyl valine (50 ml of a 50 
mM stock) following an identical procedure. 
 
 
3.2.4. ynthesis of Fmoc-depsipeptide and 2-amino-3-hydroxy-4- 
methylbenzamide 
The Fmoc-depsipeptide (6) was synthesized through a combination of solid- and 
liquid-phase peptide synthesis (Scheme 3.1). 
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Scheme 3.1. Synthesis of Fmoc-depsipeptide (6). 
Under a nitrogen atmosphere, a filter column was charged with 2-chlorotrityl chloride 
resin (1 equiv., 100 mg, 0.15 mmol, 100-200 mesh). The resin was washed with DCM 
(3 × 10 mL) and swollen with DMF/CH2Cl2 (5:1, 10mL) for 20 min. susequently, a 
solution of Fmoc-N-Me-Val-OH (2 equiv., 102 mg, 0.3 mmol) in DMF/ DCM (5:1, 3 
mL) was added, followed by DIPEA (6 equiv., 158 µl, 0.9 mmol). The suspended resin 
was stirred at rt for 1 h. The resin was drained and washed with DCM (3 × 20 mL), 
DMF (3 × 20 mL), IPA (3 × 20 mL),and DCM (3 × 20 mL). The first loading and 
washing was performed twice. 5 mL of 20% piperidine in DCM was added and 
O 
NH 
N 
H 
O 
O 
N 
O O 
NH 
NHFmoc 
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resuspended resin was stirred for 20 min to remove Fmoc protectin group, and same 
washing procedure was followed to afford resin-bond C1. 
Then a solution of Fmoc-Sar-OH (2 equiv., 90 mg, 0.3 mmol), HATU (2 equiv.,  115 
 
mg, 0.3 mmol) and DIPEA (4 equiv., 105 µl, 0.6 mmol) in DMF/DCM (5:1, 1.5 mL) 
was added. The reaction was stirred at rt for 1 h, and washed as described above. 
The reaction was repeated twice, and resin was drained to yield resin-bond C2. 
Successive condensation with Fmoc-Pro-OH, Fmoc-D-Val and Fmoc-Thr(tBu)-OH 
was carried out as described above to give resin-bound C5. 
The resin-bound C5 was released by adding 4 mL of 40% TFA in DCM containing 
2.5% TIPS, and the resin was drained and washed with DCM (3 × 20 mL). The filtrate 
was dried in vacuo and purified by flash silica-gel chromatography purification 
(DCM/MeOH) to afford 103 mg of C6 as white powder. 
C6 (1 equiv., 103 mg, 0.15 mmol) was dissolved in DMF/DCM (1:1, 10 mL) and HOAt 
 
(6 equiv., 123 mg, 0.9 mmol), DIPEA (6 equiv., 161 µl, 0.9 mmol) was added and 
stirred until solution was clear. Then DIC (2 equiv., 48 µl, 0.3 mmol) and DMAP (0.1 
equiv., 1.8mg, 0.015 mmol) was added and stirred at rt for 3 h. The reaction was 
susequently washed with saturated NH4Cl, NaHCO3 and borine. The orgainc solvent 
was dried in vacuo, and remaining substances were purified by flash silica-gel 
chromatography purification (DCM/MeOH) to afford 33 mg of 6 as oily liquid. 
The overall yield was 16%. 
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Table 3.2.1. NMR data of 6 in CDCl3 (1H: 400 MHz, 13C: 100 MHz, J in Hz) 
 
 
Pentapeptidolactones 
α-ring positions δC δH β-ring positions δC δH 
Thr 1 170.0  Gly 1 171.5  
 2 57.2 4.54 (dd, 9.3, 
2.2) 
 2 42.7 4.44, 3.64 (d, 4.2) 
 3 71.9 5.28 (m)  NH  7.00 (brs) 
 4 15.9 1.24 (d, 6.2) L-Val 1 167.4  
 NH  5.64 (d, 9.3)  2 56.2 4.61 (dd, 9.9, 5.2) 
D-Val 1 169.3   3 28.8 2.28 (m) 
 2 58.1 4.06 (dd, 7.3, 
3.1) 
 4 17.5 0.93 (d, 7.0) 
 3 29.9 1.96 (m)  5 19.6 0.95 (d, 6.8) 
 4 18.9 0.97 (d, 6.9)  NH  7.36 (d, 8.2) 
 5 18.7 1.01 (d, 6.6)     
 NH  7.02 (brs)     
Pro 1 171.6      
 2 61.4 4.44 (m)     
 3 29.3 2.17 (m), 
1.22 (m) 
    
 4 24.5 2.03 (m)     
 5 47.9 3.96, 3.55 
(m) 
    
Chromophore 
δH 7.74 (d, 7.5, 2H, 4/5-H), 7.59 (t, 7.2, 2H, 1/8-H), 7.37 (t, 7.6, 2H, 3/6-H), 7.29 (t, 7.4, 2H, 
2/7-H), 4.37 (d, 7.6, 2H, 10-H), 4.22 (m, 1H, 9-H). 
δC 125.4 (CH, C-1/8), 127.6 (CH, C-2/7), 127.7 (CH, C-3/6), 119.9 (CH, C-4/5), 47.0 (CH, 
  C-9), 67.5 (CH2, C-10), 143.7 (qC, C-11/14), 141.2 (qC, C-12/13).   
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2-amino-3-hydroxy-4-methylbenzamide (Phenol-4) was synthesized as described 
below: 
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Scheme 3.2. Synthesis of phenol-4. 
 
 
 
A solution of 3-hydroxy-4-methyl-2-nitrobenzoic acid (1.97 g, 10 mmol) and oxalyl 
chloride (10 mL) was refluxed at 60 °C until clear. After cooling to rt, solvent was 
evaporated to give 3-hydroxy-4-methyl-2-nitrobenzoyl chloride. Ammonium 
hydroxide (20 mL) was added dropwise within 5 min at 0 °C. The mixture was 
stirred at 0 °C for 30 min, and at room temperature for an additional 30 min. 30 mL 
of water was added to the mixture. After the white precipitate was filtered, the 
aqueous solution was adjusted to pH 3 and then extracted with ethyl acetate. The 
organic solution was dried with Na2SO4, and evaporated to give 1.4 g of 3-hydroxy- 
4-methyl-2-nitrobenzamide (Phenol-3) as a white solid. 
To a solution of 3-hydroxy-4-methyl-2-nitrobenzamide (1.96 g, 10 mmol) in 20 mL 
methanol, Pd/C (0.19 g) was added and reaction was stirred under hydrogen 
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atmosphere at room temperature for 4 h. The insoluble particles were filtered, and 
organic solution was concentrated to give 1.56 g of 2-amino-3-hydroxy-4- 
methylbenzamide (Phenol-4) as brown powder. 
The overall yield was 93%. 
 
3.2.5 Cytotoxicity assay* 
 
A resazurin-based cytotoxicity assay, also known as AlamarBlue assay, was used to 
assess the cytotoxicity of agents against the human lung non-small cell carcinoma 
cell line A549 and human prostate cancer cell lines PC3 where the degree of 
cytotoxicity was based upon residual metabolic activity as assessed via reduction of 
resazurin (7-hydroxy-10-oxido-phenoxazin-10-ium-3-one) to its fluorescent product 
resorufin. A549 and PC3 cells, purchased from ATCC (Manassas, VA, USA), were 
grown in DMEM/F-12 Kaighn’s modification and MEM/EBSS media, respectively 
(Thermo scientific HyClone, Logan, UT, USA), with 10% heat-inactivated fetal bovine 
serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine. Cells 
were seeded at a density 2 × 103 cells per well onto 96-well culture plates with a clear 
bottom (Corning, NY, USA), incubated 24 hrs at 37 oC in a humidified atmosphere 
containing 5% CO2 and were exposed to test agents for 2 days (positive controls: 1.5 
mM hydrogen peroxide, 10 µg/ml actinomycin D). Resazurin (150 µM final 
concentration) was subsequently added to each well and the plates were shaken 
briefly for 10 seconds and were incubated for another 3 h at 37 oC to allow viable 
cells to convert resazurin into resorufin. The fluorescence intensity for resorufin was 
detected on a scanning microplate spectrofluorometer FLUOstar Omega (BMG 
LABTECH GmbH, Ortenberg, Germany) using an excitation wavelength of 560   nm 
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and an emission wavelength of 590 nm. The assay was repeated in 3 independent 
experimental replications. In each replication, the emission of fluorescence of 
resorufin values in treated cells were normalized to, and expressed as a percent of, 
the mean resorufin emission values of untreated control (metabolically active cells; 
100%, all cells are viable). 
 
 
3.2.6 Antibacterial activity assay** 
 
The protocol used for the determination of the minimum inhibitory concentration (MIC) 
was as that described previously with minor modifications (141,142). The bacterial 
strains Staphylococcus aureus ATCC 6538, Micrococcus luteus ATCC 15307, 
Bacillus subtilis ATCC 6633, Salmonella enterica ATCC 10708, Escherichia coli 
ATCC 12435, Mycobacterium aurum ATCC 23366, in addition to the fungal strain 
Saccharomyces cerevisiae ATCC 204508 were used as model strains for 
antimicrobial susceptibility assays. All strains were grown in appropriate liquid or on 
agar plates using tryptic soy broth (BD211825) for S. aureus and M. luteus, LB 
medium (BD244620) for B. subtilis and E. coli, nutrient broth (BD 234000) for S. 
enterica, Middlebrook 7H9 with OADC enrichment (Sigma-Aldrich M0178-500G) for 
M. aurum, and YAPD (ATCC medium number 1069) for S. cerevisiae. Individual 
strains were grown in 5 mL of medium for 16 h at 37 °C with shaking (250 rpm). An 
aliquot of a fully grown culture (100 μL) was diluted to using sterile liquid medium to 
OD600 ~ 0.1. Aliquots (160 μL) of each diluted culture were then transferred into the 
individual wells of a 96-well plate supplied with 2 μL of the tested compound. Various 
concentrations with maximum concentration 120 μM were maintained to assess the 
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antimicrobial activities and compared to the negative control containing vehicle 
(DMSO) alone and positive controls (rifampicin and ciprofloxacin for M. aurum, 
amphotericin B for S. cerevisiae, and kanamycin for the other microorganisms. The 
culture plates was incubated at 28-37 °C for 16-48 h with shaking (160 rpm), and then 
the OD600 of each well measured using a FLUOstar Omega scanning microplate 
spectrofluorometer (BMG Labtech). The acquired OD600 values were normalized to 
the negative control wells (100% viability). The minimal concentration of the tested 
compound that caused growth inhibition was recorded as the MIC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Cytotoxicity assay was carried out by Dr. Larissa.Ponomareva, CPRI. 
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**Antibacterial activity assay was carried out by Dr. Sherif Elshahawi, CPRI. 
 
3.3 Results and discussion 
 
3.3.1 Isolation of actinomycins from S. sp. Strain Gö-GS12 
 
3.3.1.1 Isolation of actinomycin Y1, Y3 and Y4 
 
Our initial goal was to isolate and accumulate known Y-type actinomycins for 
additional bioactivity studies, and Y1, Y3 and Y4 were successfully identified from the 
culture medium. Their 1H and 13C NMR spectrum was identical to reported data (77). 
Because the yield of Y2 and Y5 was very low, it was difficult to purify sufficient amounts 
for NMR analysis, even though the HRMS results suggested the presence Y2 and Y5. 
During these studies, several additional, novel actinomycins were identified; analysis 
of these new compounds is described below. 
 
 
3.3.1.2 Structural elucidation of 1 
 
Compound 1 was obtained as red amorphous powder. The molecular formula of   1 
 
was established as C61H80N12O18 on the basis of (+)-HRESIMS at m/z 1269.5816 [M 
 
+ H]+ (calcd for C61H81N12O18, 1269.5792). It was recognized as a member of 
actinomycin family due to the high molecular weight around 1300, the presence of 
twelve nitrogen atoms, and its UV spectrum (λmax 238 and 429 nm) that indicated 
typical features of actinomycins containing an aminophenoxazinone chromophore. 
An additional absorption max at 309 nm was observed, which is also found in 
actinomycin Y5, suggesting that 1 may contain a third ring. Initially we thought that it 
was actinomycin Y5 because of the same molecular weight and UV absorption profile. 
However, the NMR spectrum of 1 in CD3OD was not consistent with Y5. Furthermore, 
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the molecular weight of 1 did not correspond to any other chomopeptide, indicating 
that 1 was a new member of actinomycins. 
The 1H NMR spectrum (table 3.3.1) of 1 showed characteristic features of 
actinomcyins, including four N-methyl groups resonating at δH 2.84 (s), 2.88 (s), 2.92 
(s) and 3.05 (s), two phenylmethyl groups at δH 2.25 (s) and 2.55 (s), and two adjacent 
protons attached to a phenyl group with resonances at δH 7.45 (d, J=7.8) and δH 7.50 
(d, J=7.9). The 13C-NMR also showed typical features with actinomycins,   including 
12 aromatic carbons on the phenoxazinone chromophore, and 12 amide/acid 
carbonyl carbons at δC 165.5, 167.8, 168.5 (two overlapping signals), 169.1, 169.7, 
170.6, 171.8, 172.5, 174.9, 175.6 and 177.2, which were consistent with the identify 
as a peptide-containing compound. 
Correlations obtained from COSY, HMBC and HMQC and TOCSY experiments of 1 
were used to establish the structure. The methyl group (δC 17.2 and δH 1.26, d, J=5.9) 
was chosen as a start point from TOCSY analysis, which showed correlations with 
two methines at δH 5.34 (m) and at δH 4.80. The COSY experiments revealed 
correlations between the methyl (δH 1.26) and the CH at δH 5.34, and between δH 
5.34 and δH 4.80. Additionally, HMBC correlation was observed from δH 4.80 to a 
quaternary carbon resonating at δC 171.8. The independent spin system of 
XCHCHCH3 indicated the presence of the first threonine and it was named Thrα. 
Similarly, the second fragment was identified. In contrast to Thrα, the chemical shift at 
the β-position (δC 64.0, δH 5.68) and the γ-position (δC 71.5, δH 4.94, d, J=12.6, and 
5.22, d, J=12.6) suggested that there was a significant conformational change 
including a C-N bond at C-3 and an oxygen-substituted C-4 whereby comparison of 
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HN 
3 
carbon chemical shift with actinomycin G3 and G5 (77). The second fragment was 
thereby a 4-hydroxylthreonine, and named as HThrβ. 
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An active hydrogen resonating at δH 7.88 (d, J=5.5) showed TOCSY correlations 
between δH 3.77 (m), δH 2.04 (m), δH 0.92 (d, J=6.7), and δH 1.10 (d, J=6.7) revealed 
that they were clustered together. The COSY experiment indicated that the two 
methyl groups (δH 0.92, d, J=7.1, and 1.10, d, J=6.7) were linked via a CH at δH 2.04. 
Additional COSY correlations were observed between δH 2.04 and δH 3.77, and 
between δH 3.77 and δH 7.88. The HMBC correlations further confirmed the structure 
with an independent spin system of XCHCH(CH3)2, which indicated the presence of 
a valine and it was named Valα. Similarly, the other active hydrogen resonating at δH 
8.78 (d, J=5.3) resulted in another valine (Valβ) moiety from 2D NMR analysis. 
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A methyl group resonating at δH 1.48 (d, J=6.0) was chosen as a start point for the 
next fragment. It showed TOCSY correlations between δH 4.23 (m), δH 1.97/2.13 (m) 
and δH 6.29 (s), and a COSY correlation between δH 4.23. Further COSY correlations 
were observed between δH 4.23 and δH 1.97/2.12, between δH 1.97/2.12 and δH 4.27. 
The methyl group also showed HMBC correlations to a methine at δC 40.4 (δH 1.97, 
m, 2.12, m) and a methine at δC 55.4 (δH 4.23, m), while other key HMBC correlations 
were observed from δH 6.29 to methines at δC 40.4 and δC 74.8, and to a quaternary 
carbon at δC 172.5, which further confirmed a XCHCHCH2CHX’CH3 spin system and 
suggested the presence of a methyl proline. The chemical shift of C-3 (δC 74.8) 
indicated that it was attached to a hydroxyl group. Thus the structure of this fragment 
was a 3-hydoxyl-5-methyl proline (HMPro). The relative conformation of HMPro was 
determined as 3-OH trans because 2-H at δH 6.29 was a singlet (indicating a 90° 
dihedral angle to 3-H at δH 4.27) and there was no COSY correlation between 2-H 
and 3-H.  
HO 
4.27 
74.8 
1.97 
 
O 
172.5 
6.29 
69.4 
2.12  40.4 
N 
4.23  55.4 
1.48  18.9 
 
HMPro 
 
 
A diagnostic 13C NMR signal at δC 209.5 was observed in the 13C NMR spectrum, to 
which five key HMBC correlations were observed from δH 3.94 (d, J=19.0), δH 4.40 
(d, J=19.0), δH 2.38 (m), δH 3.42 (m) and δH 6.68 (d, J=7.2). Additional HMBC 
correlations  from  δH  2.38  to  δC  174.9  revealed  an  independent  spin  system of 
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XCHCH2CCH2X’ as a 4-oxoproline (OPro) which was also present in Z and G type 
actinomycins. 
 
 
 
O 
 
 
OPro 
 
 
Two remaining CH2 groups resonating at δC 52.9 (δH 4.09, d, J=17.8 and δH 4.80, d, 
J=17.8), and δC 52.8 (δH 4.09, d, J=17.8 and δH 4.66, J=17.8) did not have COSY 
nor TOCSY correlations to other protons, suggested the presence of glycine 
moieties. The CH2 groups showed HMBC correlations to carbonyl carbons at δC 
168.53 and δC 168.52, respectively. The correlations from CH2 groups to N-methyl 
groups at δC 35.7 (δH 2.84, s) and at δC 35.4 (δH 2.88, s) indicated two sarcosines 
(Sarα and Sarβ) instead of glycines. Those sarcosines were named Sarα, and Sarβ. 
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Similar to the Val discussed earlier, an extra valine was identified using the methyl 
group resonating at δC 19.6 (δH 0.82, d, J=6.9) as a starting point. This valine, different 
from the other two, has an additional HMBC correlation from the methine resonating 
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at δH 3.07 to a methyl group resonating at δC 39.6 (δH 3.05, s) indicating that this 
valine contained a N-methyl group. This fragment was named MeVal. 
1.01 21.8 
 
2 
 
 
 
 
MeVal 
 
 
The HMBC and COSY correlations observed from the very last methyl group 
resonating at δC 13.7 (δH 1.43, d, J=6.8) revealed the presence of an alanine with a 
spin system of XCHCH3. The HMBC correlation from the CH resonating at δH     3.76 
(m) to a N-methyl group revealed the structure of a methyl alanine, and this fragment 
was named MeAla. 
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The chromophore core of 1 was identified by 2D NMR and the comparison of the 
measured 13C data with that obtained for known actinomycins, where actinomcyin Y5 
was especially helpful.  
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The remaining analysis was aimed at connecting the fragments to give an overall 
structure of 1. For the α-ring, Thrα could be connected to Valα through the amide 
hydrogen at δH 7.87 which showed a HMBC correlation to C-1 of Thrα at δC 171.8. 
The carbonyl carbon of Val at δC 177.2 contained a HMBC correlation from the 
methine at δH 6.29, thus the HMPro was attached to Valα. The Sarα was connected 
to HMPro due to the HMBC correlation from the N-methyl group at δH 2.84 (s) to the 
carbonyl of HMPro at δC 172.5. The last amino acid, MeVal was joined to Sarα 
according to the HMBC correlation from the N-methyl group at δH 3.05 (s) to the 
carbonyl of Sarα at δC 168.53. The key HMBC correlation from the CH at Thrα (δH 
5.34) to the carbonyl at δC 169.7 of MeVal helped to establish the first pentapeptide 
ring (α-ring) as cyclo-(-Thr-Val-HMPro-Sar-MeVal-). The β-ring was established as 
cyclo-(-HThr-Val-OPro-Sar-MeAla-) by a similar manner as the α-ring. The major 
difference between α- and β-ring was that the Thr in the β-ring was connected to 
MeAla via an amide bond instead of an ester. This type of “rearrangement” was also 
observed in other members of actinomycins including Y3, Y4 and G6. The α-ring was 
connected to the chromophore through an amide bond since carbonyl group at δC 
169.1 contained HMBC correlations from δH 4.80 (C-2 of Thrα) and δH 7.45 (C-8 of 
chromophore). The β-ring was connected to the chromophore through an ester bond 
as a correlation was observed from the C-4 of Thrβ at δH 4.94 and 5.22 to C-14 on 
the chromophore resonating at δC 167.8. The 18 amu difference between compound 
1 and actinomycin Y3 indicated a loss of H2O in 1, and the significant low field shift of 
H-3 of HThrβ at δH 5.68 compared to actinomycin Y3 at δH 4.57 and Y4 at δH 4.33 
suggested an additional ring structure similar to actinomycin G5 in which chemical 
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shift of H-4 at δH 4.64 and 4.86 shifted to low field significantly compared to G3  at δH 
 
3.23 and 3.76 (77). 
 
 
 
 
 
 
 
Interestingly, while purifying 1, we noticed that this compound was unstable under 
acidic condition. Similar phenomenon was also observed with Y5 (77). Thus the 
degradation product was collected and structurally characterized. 1 underwent 
hydrolysis, and the chromophore-β-peptide ring was opened under 0.1% of TFA 
(pH≈4) to generate actinomycin Y3 (fig 3.3.1). This result further confirmed the 
presence of the bridging macrocycle in 1, and also provided some clue to the 
biosynthetic origin of the third ring: the ring closure is potentially formed by 
nucleophilic attack of the amino group of the chromophore to C-4 of HTHr 
concomitant with dehydration. This observation also provided important information 
for future biochemical characterization of the cyclization reaction, as all acidic 
conditions should be avoided during analysis and reactions can be monitored in real- 
time using difference spectrum analysis. 
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Figure 3.3.1. Simultaneous conversion of 1 to Y3 under acidic condition. (A) 
Conversion of 1 to Y3 under 0.1% TFA. (B) 15% of 1 was converted to Y3 within 1 h. 
Each compound had a signature UV profile. 
The CD spectra of 1 (fig 3.3.4) showed a strong cotton effect at about 210 nm, plus 
the origin from same strain, indicating the absolute configurations of the amino acids 
in 1 were supposed to be identical with actinomycin Y3. Thus, the structure of 
compound 1 was established as a new member of the Y-type actinomycins and 
subsequently named as actinomycin Y6. 
1 
B 
A 
1 
1 Y3 
Y3 
Y3 
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The predicted amino acid stereochemical configuration was confirmed by Marfey’s 
method. The retention times for Marfey’s derivatives of authentic L-Val, D-Val, Sar, L- 
Thr and L-MeVal were 34.2, 39.4, 24.9, 22.9, 38.7 min, respectively. Those for the 
Marfey’s derivatives of D-Val, L-Val, L-Sar, L-Thr and L-MeVal in the hydrolysate of 1 
were 22. (L-Thr), 24.9 (Sar), 38.7 (L-MeVal) and 39.4 (D-Val) min, respectively (fig 
3.3.2). 
 
 
 
 
 
Figure 3.3.2. Chiral amino acid analysis of 1. 
  1   
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Table 3.3.1. NMR data of actinomycin Y6 (1) in CD3OD (1H: 500 MHz, 13C: 100 MHz, 
J in Hz) 
 
Pentapeptidolactones 
α-ring positions δC δH β-ring positions δC δH 
Thr 1 171.8  crHThr 1 165.5  
 2 56.6 4.80 (m)  2 54.6 4.27 (d, 3.5) 
 3 74.7 5.34 (m)  3 64.0 5.68 (m) 
 4 17.2 1.26 (d, 5.9)  4 71.5 4.94 (d, 12.6) 
 NH  8.23 (d, 7.7)    5.22 (d, 12.6) 
D-Val 1 177.2  D-Val 1 175.6  
 2 61.0 3.77 (m)  2 58.3 4.05 (m) 
 3 33.5 2.04 (m)  3 32.9 2.25 (m) 
 4 19.9 1.10 (d, 6.7)  4 19.8 0.89 (d, 6.2) 
 5 19.5 0.92 (d, 7.1)  5 19.2 1.19 (d, 6.6) 
 NH  7.88 (d, 5.5)  NH  8.78 (d, 5.3) 
HMPro 1 172.5  OPro 1 174.9  
 2 69.4 6.29 (s)  2 56.2 6.68 (d, 7.2) 
 3 74.8 4.27 (d, 3.4)  3 42.4 2.38 (m) 
 4 40.4 1.97 (m)    3.42 (m) 
   2.12 (m)  4 209.5  
 5 55.4 4.23 (m)  5 54.2 3.94 (d, 19.0) 
 6 18.9 1.48 (d, 6.0)    4.40 (d, 19.0) 
Sar 1 168.5  Sar 1 168.5  
 2 52.9 4.09 (d, 17.8)  2 52.8 4.09 (d, 17.8) 
   4.80 (d, 17.8)    4.66 (d, 17.8) 
 NMe 35.7 2.84 (s)  NMe 35.4 2.88 (s) 
MeVal 1 169.7  MeAla 1 170.6  
 2 72.1 3.07 (d, 9.4)  2 61.1 3.76 (m) 
 3 28.4 2.60 (m)  3 13.7 1.43 (d, 6.8) 
 4 21.8 1.01 (d, 6.4)  NMe 37.3 2.92 (s) 
 5 19.5 0.82 (d, 6.9)     
 NMe 39.6 3.05 (s)     
Chromophore 
δH 2.25 (s, 3H, 12-H3), 2.55 (s, 3H, 11-H3), 7.45 (d, 7.8, 1H, 8-H), 7.50 (d, 7.9, 1H, 7-H). 
δC 8.3 (CH3, C-12), 15.1 (CH3, C-11), 88.4 (qC, C-1), 116.6 (qC, C-4), 127.1 (CH, C-8), 128.7 
(qC, C-9a), 129.9 (qC, C-6), 132.6 (CH, C-7), 133.0 (qC, C-9), 142.4 (qC, C-5a), 147.2 (qC, 
C-10a), 148.9 (qC, C-4a), 153.4 (qC, C-2), 167.8 (qC, C-14), 169.1 (qC, C-13), 177.4 (qC, C- 
  3).   
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3.3.1.3 Structural elucidation of 2 
 
The molecular formula of compound 2 (obtained as red amorphous powder), was 
determined as C61H82N12O19 from the (+)-HRESIMS (m/z 1287.5857 [M + H]+). The 
UV and NMR data of 2 revealed actinomycin-characteristic features, which were quite 
similar to that of actinomycin Y1 (77). Compared to Y1, the two high-field shifted proton 
signals (δH 3.31 and 3.70, H2-4) of HThr in the β-ring, a much higher chemical shift 
for the C-4 (δC 59.6), and the absence of a chloride atom in 2, indicated a hydroxyl 
substitution at C-4. Further COSY, TOCSY and HMBC correlations were in full 
agreement with compound 2 as a new analog of the actinomycin series and 2 was 
thereby designated as actinomycin Y7. 
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Table 3.3.2. NMR data of actinomycin Y7 (2) in CDCl3 (1H: 500 MHz, 13C: 100 MHz, J 
in Hz) 
 
Pentapeptidolactones 
α-ring positions δC δH β-ring positions δC δH 
Thr 1 169.0  HThr 1 168.2  
 2 55.0 4.61 (m)  2 52.2 4.96 (m) 
 3 74.6 5.23 (m)  3 77.1 5.15 (m) 
 4 17.0 1.15 (d, 6.0)  4 59.6 3.31 (m) 
 NH  7.17 (brs)    3.70 (m) 
     NH  8.15 (d, 6.1) 
D-Val 1 174.2  D-Val 1 173.8  
 2 59.1 3.43 (m)  2 57.0 3.84 (m) 
 3 31.9 2.10 (m)  3 31.9 2.22 (m) 
 4 19.3 1.14 (d, 6.6)  4 19.3 0.94 (d, 6.2) 
 5 18.9 0.94 (d, 6.4)  5 18.8 1.18 (d, 6.5) 
 NH  7.82 (d, 4.6)  NH  8.35 (d, 5.1) 
HMPro 1 170.7  OPro 1 172.6  
 2 68.3 5.87 (s)  2 54.6 6.54 (d, 11.0) 
 3 75.5 4.19 (m)  3 41.8 2.33 (d, 17.7) 
 4 41.0 2.12 (m)    3.93 (m) 
   2.19 (m)  4 208.6  
 5 53.4 4.76 (m)  5 52.8 4.00 (d, 19.0) 
 6 18.8 1.52 (d, 6.0)    4.55 (d, 19.1) 
Sar 1 166.0  Sar 1 165.8  
 2 51.4 3.65 (d, 18.0)  2 51.1 3.65 (d, 17.9) 
   4.72 (d, 18.0)    4.49 (d, 17.9) 
 NMe 35.0 2.90 (s)  NMe 34.7 2.88 (s) 
MeVal 1 167.4  MeAla 1 169.0  
 2 71.2 2.69  2 60.0 3.26 (m) 
 3 27.0 2.67 (m)  3 13.4 1.36 (d, 6.8) 
 4 21.6 0.96 (d, 6.4)  NMe 37.0 2.92 (s) 
 5 19.0 0.75 (d, 6.9)     
 NMe 39.3 2.91 (s)     
Chromophore 
δH 2.12 (s, 3H, 12-H3), 2.53 (s, 3H, 11-H3), 7.36 (d, 7.6, 1H, 7-H), 7.55 (d, 7.8, 1H, 8-H). 
δC 7.7 (CH3, C-12), 14.9 (CH3, C-11), 98.9 (qC, C-1), 113.5 (qC, C-4), 125.9 (CH, C-8), 127.6 
(qC, C-6), 128.7 (qC, C-9a), 130.4 (CH, C-7), 132.7 (qC, C-9), 140.4 (qC, C-5a), 145.2 (qC, 
C-4a), 146.1 (qC, C-10a), 148.3 (qC, C-2), 166.0 (qC, C-13), 168.6 (qC, C-14), 178.2 (qC, C- 
3). 
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3.3.1.4 Structural elucidation of 3 
 
Structurally related to 2, actinomycin Y8 (3) was obtained as red amorphous powder 
and assigned a molecular formula C61H82N12O18 on the basis of (+)-HRESIMS, 
suggestive of a deoxygenated derivative of 2. This deduction was corroborated by 
the NMR data (table 3.3.3), in which the diagnostic methyl signal at C-4 of Thr in β- 
ring (δC 17.4, δH 1.28 (d, J=6.2), showed a COSY correlation with H-3 and an HMBC 
correlation with C-2 and C-3, which indicated the absence of 4-OH in the Thr residue. 
3 was thereby designated as actinomycin Y8. 
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Table 3.3.3. NMR data of actinomycin Y8 (3) in CDCl3 (1H: 400 MHz, 13C: 100 MHz, J 
in Hz) 
 
Pentapeptidolactones 
α-ring positions δC δH β-ring positions δC δH 
Thr 1 168.4  HThr 1 167.8  
 2 54.5 4.49 (dd, 6.9, 3.1)  2 54.7 4.90 (dd, 6.6, 2.6) 
 3 74.5 5.20 (m)  3 75.2 5.22 (m) 
 4 17.0 1.12 (d, 6.1)  4 17.4 1.28 (d, 6.2) 
 NH  6.92 (d, 7.0)  NH  7.72 (d, 6.4) 
D-Val 1 173.9  D-Val 1 173.9  
 2 59.0 3.40 (dd, 10.7, 
4.7) 
 2 56.9 3.83 ( dd, 9.9, 6.6) 
 3 31.9 2.05 (m)  3 31.9 2.17 (m) 
 4 19.3 1.12 (d, 6.0)  4 19.2 0.91 (d, 6.6) 
 5 19.2 0.91 (d, 6.0)  5 18.7 1.15 (d, 6.6) 
 NH  7.64 (d, 5.0)  NH  8.27 (d, 6.2) 
HMPro 1 171.0  OPro 1 172.7  
 2 68.5 5.92 (s)  2 54.4 6.60 (d, 10.4) 
 3 75.8 4.11 (m)  3 41.7 2.31 (d, 18.0) 
 4 41.5 2.10 (m)    3.97 (dd, 17.4, 
11.1) 
   2.20 (m)  4 208.8  
 5 54.0 4.69 (m)  5 52.7 3.97 (d, 19.0) 
 6 18.9 1.51 (d, 5.9)    4.53* 
Sar 1 166.1  Sar 1 165.7  
 2 51.4 3.65 (d, 17.7)  2 51.2 3.61 (d, 17.6) 
   4.75 (d, 17.6)    4.53* 
 NMe 35.0 2.88 (s)  NMe 34.6 2.86 (s) 
MeVal 1 167.4  MeAla 1 168.9  
 2 71.2 2.66*  2 60.5 3.23 (m) 
 3 26.9 2.64 (m)  3 13.5 1.36 (d, 6.8) 
 4 21.6 0.94 (d, 5.9)  NMe 37.2 2.94 (s) 
 5 19.0 0.72 (d, 6.1)     
 NMe 39.4 2.92 (s)     
Chromophore 
δH 2.20 (s, 3H, 12-H3), 2.52 (s, 3H, 11-H3), 7.34 (d, 7.8, 1H, 7-H), 7.54 (d, 7.7, 1H, 8-H). 
δC 7.8 (CH3, C-12), 15.0 (CH3, C-11), 100.8 (qC, C-1), 113.8 (qC, C-4), 125.8 (CH, C-8), 127.6 
(qC, C-6), 128.9 (qC, C-9a), 130.3 (CH, C-7), 132.7 (qC, C-9), 140.5 (qC, C-5a), 145.0 (qC, C- 
  4a), 146.0 (qC, C-10a), 147.3 (qC, C-2), 166.0 (qC, C-13), 167.8 (qC, C-14), 178.6 (qC, C-3).   
* Overlapped signals. 
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3.3.1.5 Structural elucidation of 4 
 
Compound 4, obtained as a red amorphous powder, was assigned to be the 
deoxygenated analogue of 3 by (+)-HRESIMS and NMR data analysis (tables 3.3.4). 
The representative oxygenated methine (δH 5.92) in the 1H NMR of HMPro in the α- 
ring of 3 was absent, and a methylene (δH 1.75 and 2.74) appeared in 4. The 
corresponding methylene signal (δC 29.4) in the 13C NMR of 4 was determined by an 
HSQC experiment. Analysis of the key COSY and HMBC correlations and 
comparison of the data with that of 3 indicated that there was an MPro residue in α- 
ring. Thus, the structure of 4 was confirmed and named actinomycin Y9. 
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Table 3.3.4. NMR data of actinomycin Y9 (4) in CDCl3 (1H: 400 MHz, 13C: 100 MHz, J 
in Hz) 
 
Pentapeptidolactones 
α-ring positions δC δH β-ring positions δC δH 
Thr 1 168.7  HThr 1 168.7  
 2 54.6 4.59 (m)  2 54.9 4.48 (m) 
 3 74.7 5.14 (m)  3 75.4 5.15 (m) 
 4 17.1 1.11 (d, 6.2)  4 17.4 1.25 (d, 6.2) 
 NH  7.14 (d, 7.1)  NH  7.63 (d, 6.0) 
D-Val 1 173.9  D-Val 1 173.2  
 2 59.1 3.51 (dd, 9.6, 
6.0) 
 2 57.0 3.78 (m) 
 3 32.0 2.07 (m)  3 32.3 2.08 (m) 
 4 19.3 1.08 (d, 6.6)  4 19.2 0.88 (d, 7.0) 
 5 19.0 0.91 (d, 6.8)  5 18.7 1.16 (d, 6.6) 
 NH  7.61  NH  8.38 (d, 5.6) 
MPro 1 173.6  OPro 1 172.7  
 2 58.2 6.00 (d, 9.0)  2 54.3 6.57 (d, 10.7) 
 3 29.4 1.75 (m)  3 41.7 2.31 (d, 17.1) 
   2.74 (m)    3.79 (dd, 9.5, 
18.0) 
 4 31.9 1.99 (m) 
2.23 (m) 
 4 208.9  
 5 55.4 4.35 (m)  5 52.8 3.95 (d, 19.0) 
 6 18.8 1.47 (d, 6.0)    4.58 (m) 
Sar 1 166.3  Sar 1 165.6  
 2 51.4 3.62*  2 51.2 3.62* 
   4.64 (d, 16.1)    4.49 (d, 15.8) 
 NMe 34.8 2.86 (s)  NMe 34.6 2.86 (s) 
MeVal 1 167.4  MeAla 1 168.8  
 2 71.3 2.64  2 60.5 3.23 (m ) 
 3 26.8 2.65 (m)  3 13.4 1.36 (d, 6.8) 
 4 21.6 0.93 (d, 6.0)  NMe 37.2 2.92 (s) 
 5 19.0 0.71 (d, 5.8)     
 NMe 39.2 2.90 (s)     
Chromophore 
δH 2.21 (s, 3H, 12-H3), 2.53 (s, 3H, 11-H3), 7.34 (d, 7.7, 1H, 7-H), 7.61 (d, 7.7, 1H, 8-H). 
δC 7.7 (CH3, C-12), 15.0 (CH3, C-11), 101.8 (qC, C-1), 113.5 (qC, C-4), 126.2 (CH, C-8), 
127.7 (qC, C-6), 129.1 (qC, C-9a), 130.1 (CH, C-7), 132.2 (qC, C-9), 140.4 (qC, C-5a), 144.9 
(qC, C-4a), 145.9 (qC, C-10a), 147.3 (qC, C-2), 165.8 (qC, C-13), 168.8 (qC, C-14), 179.0 
  (qC, C-3).   
* Overlapped signals. 
134  
3.3.1.6 Structural elucidation of 5 
 
Compound 5 was obtained as red amorphous powder and had a molecular formula 
of C64H90N12O16 as determined by the pseudo-molecular ion peak at m/z 1283.6666 
[M + H]+ (calcd for C64H91N12O16) by (+)-HRESIMS. Its NMR data showed the 
existence of representative actinoyl chromophore and two identical 
pentapeptidolactone residues which contained Val, MPro, Sar, MeVal and Thr 
moieties (table 3.3.5). Compound 5 differed from actinomycin D at the methylation at 
C-3 of proline, which was confirmed through COSY, TOCSY, HMBC and NOESY 
experiments. By comparison with published structures of known actinomycins, 5 was 
determined to be identical to the known actinomcyin Zp shich was isolated as the 
monomeric protactin and was converted to Zp by ferricyanide oxidation (143). 
However, 5 was, for the first time, isolated as a natural product. 
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Table 3.3.5. NMR data of actinomycin Zp (5) in CDCl3 (1H: 400 MHz, 13C: 100 MHz, J 
in Hz) 
 
Pentapeptidolactones 
α-ring positions δC δH β-ring positions δC δH 
Thr 1 168.4  Thr 1 168.9  
 2 55.1 4.51 (m)  2 54.7 4.65 (m) 
 3 75.0 5.20 (m)  3 75.0 5.20 (m) 
 4 17.4 1.24 (d, 5.3)  4 17.8 1.24 (d, 6.4) 
 NH  7.05 (d, 5.3)  NH  7.61 (d, 6.4) 
D-Val 1 173.4  D-Val 1 173.4  
 2 59.3 3.48*  2 59.2 3.48* 
 3 32.0 2.11 (m)  3 32.0 2.11 (m) 
 4 19.2 1.10*  4 19.2 1.10* 
 5 19.0 0.90 (d, 6.8)  5 19.0 0.88 (d, 6.6) 
 NH  8.39 (d, 5.7)  NH  8.20 (d, 6.0) 
MPro 1 173.4  MPro 1 173.4  
 2 58.0 6.10 (d, 9.0)  2 58.2 6.03 (d, 9.0) 
 3 29.4 1.27 (m)  3 29.6 1.27 (m) 
   1.73 (m)    1.73 (m) 
 4 31.8 1.92 (m)  4 31.8 1.92 (m) 
   2.23 (m)    2.23 (m) 
 5 55.4 4.29 (m)  5 55.2 4.40 (m) 
 6 18.8 1.46 (d, 6.0)  6 18.8 1.46 (d, 6.0) 
Sar 1 166.4  Sar 1 166.5  
 2 51.4 3.58 (d, 11.5)  2 51.4 3.60 (d, 11.5) 
   4.68*    4.68* 
 NMe 34.8 2.87 (s)  NMe 34.8 2.87 (s) 
MeVal 1 167.6  MeVal 1 167.5  
 2 71.3 2.65 (brs)  2 71.3 2.65 (brs) 
 3 26.7 2.68*  3 26.7 2.68* 
 4 21.5 0.95 (d, 5.8)  4 21.6 0.95 (d, 6.1) 
 5 19.1 0.72 (d, 5.8)  5 19.1 0.72 (d, 6.1) 
 NMe 39.2 2.90 (s)  NMe 39.3 2.91 (s) 
Chromophore 
δH 2.22 (s, 3H, 12-H3), 2.52 (s, 3H, 11-H3), 7.32 (d, 7.7, 1H, 7-H), 7.58 (d, 7.7, 1H, 8-H). 
δC 7.7 (CH3, C-12), 15.0 (CH3, C-11), 102.0 (qC, C-1), 113.3 (qC, C-4), 125.7 (CH, C-8), 
127.4 (qC, C-6), 129.1 (qC, C-9a), 130.2 (CH, C-7), 132.9 (qC, C-9), 140.4 (qC, C-5a), 144.9 
(qC, C-4a), 145.7 (qC, C-10a), 147.3 (qC, C-2), 166.1 (qC, C-13), 166.3 (qC, C-14), 179.1 
  (qC, C-3).   
* Overlapped signals. 
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3.3.1.7 Summary of physicochemical properties of novel actinomycins 
 
Actinomycin Y6 (1): red amorphous powder; UV (MeOH) λmax (log ε) 234 (sh, 9.13), 
306 (1.22), 429 (4.30) nm; CD (MeOH) λmax ([θ]) 212 (‒103,949), 244 (7,851), 306 
(14,000), 375 (1,261); 13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: 
m/z 1269.5770 [M + H]+ (calcd for C61H81N12O18, 1269.5792). 
 
Actinomycin Y7 (2): red amorphous powder; UV (MeOH) λmax (log ε) 241 (sh, 7.91), 
441 (3.73) nm; CD (MeOH) λmax ([θ]) 209 (‒94,694), 243 (9,034), 271 (16,047), 306 
(1,664), 378 (5,637); 13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: 
m/z 1287.5918 [M + H]+ (calcd for C61H83N12O19, 1287.5897); m/z 1309.5748 [M + 
Na]+ (calcd for C61H82N12O19Na, 1309.5717). 
 
Actinomycin Y8 (3): red amorphous powder; UV (MeOH) λmax (log ε) 240 (sh, 9.37), 
440 (4.34) nm; CD (MeOH) λmax ([θ]) 215 (‒125,568), 242 (26,967), 267   (56,168), 
379 (20,196); 13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 
1271.5968 [M + H]+ (calcd for C61H83N12O18, 1271.5948); m/z 1293.5788 [M + Na]+ 
(calcd for C61H82N12O18Na, 1293.5768). 
 
Actinomycin Y9 (4): red amorphous powder; UV (MeOH) λmax (log ε) 238 (sh, 8.58), 
440 (3.95) nm; CD (MeOH) λmax ([θ]) 210 (‒67,274), 242 (11,893), 272 (21,000), 381 
(7,255); 13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 1255.5935 
[M + H]+ (calcd for C61H83N12O17, 1255.5999), m/z 1277.5749 [M + Na]+ (calcd for 
C61H82N12O17Na, 1277.5819). 
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Actinomycin Zp (5): red amorphous powder; UV (MeOH) λmax (log ε) 242 (sh, 
9.44), 442 (4.13) nm; CD (MeOH) λmax ([θ]) 212 (‒52,199), 241 (11,713), 269 
(16,359), 380 (5,068); 13C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI- 
MS: m/z 1283.6575 [M + H]+ (calcd for C64H91N12O16, 1283.6676), m/z 1305.6400 [M 
+ Na]+ (calcd for C64H90N12O16Na, 1305.6495). 
 
 
 
 
 
 
Figure 3.3.3. HPLC profile of different actinomycins produced by Streptomyces 
sp. Strain Gö-GS12. 
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The UV/VIS spectra (λmax 238, 429 and 441 nm) of the new actinomycins suggested 
the aminophenoxazinone chromophore was shared by these compounds. An 
additional absorption at 309 nm of 1 suggested the phenoxazinone-fused L-Thr 
congener. Also a red shift at 452 nm was observed for Y4 and Y3 indicating the 
rearrangement of the β-ring also results in a distinct UV-VIS spectrum that is 
diagnostic of this modification (fig 3.3.4). 
 
 
 
 
 
 
Figure 3.3.4 UV/VIS spectra of actinomycins isolated from Streptomyces sp. 
Strain Gö-GS12. 
 
 
 
Actinomycins have a strong negative absorption at 210 nm in the CD spectra. The 
β-ring rearranged actinomycins including 1 and Y4 had two positive absorptions 
around 275 nm and 360 nm, while the other members of actinomycins had a strong 
negative absorption at these wavelengths (fig. 3.3.5). 
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Figure 3.3.5. CD spectra of actinomycins isolated from Streptomyces sp. Strain 
Gö-GS12. 
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Table 3.3.6: Overview on naturally occurring actinomycinsa 
 
 α-ring β-ring 
(1) Actinomycin D as core structure 
Actinomycin D Thr-D-Val-Pro-Sar-MeVal Thr-D-Val-Pro-Sar-MeVal 
(2) N-demethyl actinomycins 
Actinomycin D0 Thr-D-Val-Pro-Sar-MeVal Thr-D-Val-Pro-Gly-MeVal 
N,N'-Didemethyl- 
actinomycin D 
Thr-D-Val-Pro-Gly-MeVal Thr-D-Val-Pro-Gly-MeVal 
(2) C-type actinomycins 
Actinomycin C2 Thr-D-Val-Pro-Sar-MeVal Thr-D-aIle-Pro-Sar-MeVal 
Actinomycin C2a Thr-d-aIle-Pro-Sar-MeVal Thr-D-Val-Pro-Sar-MeVal 
Actinomycin C3 Thr-D-aIle-Pro-Sar-MeVal Thr-D-aIle-Pro-Sar-MeVal 
(3) F-type actinomycins   
Actinomycin F8 Thr-D-Val-Sar-Sar-MeVal Thr-D-Val-Sar-Sar-MeVal 
Actinomycin F9 Thr-D-Val-Sar-Sar-MeVal Thr-D- 
Val-Pro-Sar-MeVal 
Thr-D-Val-Pro-Sar-MeVal 
Thr-D-Val-Sar-Sar-MeVal 
(4) X-type actinomycins 
Actinomycin X0α Thr-D-Val-Sar-Sar-MeVal Thr-D-Val-Hyp-Sar-MeVal 
Actinomycin X0β Thr-D-Val-Pro-Sar-MeVal Thr-D-Val-Hyp-Sar-MeVal 
Actinomycin X0δ Thr-D-Val-Pro-Sar-MeVal Thr-D-Val-aHyp-Sar-MeVal 
Actinomycin X1a Thr-D-Val-Sar-Sar-MeVal Thr-D-Val-OPro-Sar-MeVal 
Actinomycin X2 Thr-D-Val-Pro-Sar-MeVal Thr-D-Val-OPro-Sar-MeVal 
(5) Z-type actinomycins 
Actinomycin Z1 Thr-D-Val-HMPro-Sar-MeVal HThr-D-Val-MOPro-Sar-MeAla 
Actinomycin Z2 Thr-D-Val-HMPro-Sar-MeVal Thr-D-Val-MOPro-Sar-MeAla 
Actinomycin Z3 Thr-D-Val-HMPro-Sar-MeVal ClThr-D-Val-MOPro-Sar-MeAla 
Actinomycin Z4 Thr-D-Val-MPro-Sar-MeVal Thr-D-Val-MOPro-Sar-MeAla 
Actinomycin Z5 Thr-D-Val-MPro-Sar-MeVal ClThr-D-Val-MOPro-Sar-MeAla 
Actinomycin Zp(5) Thr-D-Val-MPro-Sar-MeVal Thr-D-Val-MPro-Sar-MeVal 
(6) G-type actinomycins 
Actinomycin G1 Thr-D-Val-Pro-Sar-MeVal HThr-D-Val-HMPro-Sar-MeAla 
Actinomycin G2 Thr-D-Val-HMPro-Sar-MeVal ClThr-D-Val-Pro-Sar-MeAla 
Actinomycin G3 Thr-D-Val-HMPro-Sar-MeVal HThr-d-Val-Pro-Sar-MeAla 
Actinomycin G4 Thr-D-Val-HMPro-Sar-MeVal Thr-D-Val-Pro-Sar-MeAla 
Actinomycin G5 Thr-D-Val-HMPro-Sar-MeVal cHThr-D-Val-Pro-Sar-MeAla 
Actinomycin G6 Thr-D-Val-HMPro-Sar-MeVal rHThr-D-Val-Pro-Sar-MeAla 
(7) novel Y-type actinomycins 
Actinomycin Y1 Thr-D-Val-HMPro-Sar-MeVal ClThr-D-Val-OPro-Sar-MeAla 
Actinomycin Y2 Thr-D-Val-HMPro-Sar-MeVal ClThr-D-Val-Hyp-Sar-MeAla 
Actinomycin Y3 Thr-D-Val-HMPro-Sar-MeVal rHThr-D-Val-OPro-Sar-MeAla 
Actinomycin Y4 Thr-D-Val-HMPro-Sar-MeVal rHThr-D-Val-Hyp-Sar-MeAla 
Actinomycin Y5 Thr-D-Val-HMPro-Sar-MeVal cThr-D-Val-OPro-Sar-MeAla 
Actinomycin Y6 (1) Thr-D-Val-HMPro-Sar-MeVal crThr-D-Val-OPro-Sar-MeAla 
Actinomycin Y7 (2) Thr-D-Val-HMPro-Sar-MeVal HThr-D-Val-OPro-Sar-MeAla 
Actinomycin Y8 (3) Thr-D-Val-HMPro-Sar-MeVal Thr-D-Val-OPro-Sar-MeAla 
Actinomycin Y9 (4) Thr-D-Val-MPro-Sar-MeVal Thr-D-Val- OPro -Sar-MeAla 
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Differences to actinomycin D are shown in bold letters. All amino acids are L-configurated except when indicated 
otherwise. Abbreviations: MeVal=N-methylvaline, MeAla=N-methyl-L-alanine, aIle=allo-isoleucine, Sar=sarcosine, 
MPro=cis-5-methylproline, HMPro=trans-3-hydroxy-cis-5-methylproline, Hyp=trans-4-hydroxyproline, OPro=4- 
oxoproline, MOPro=cis-5-methyl-4-oxoproline, aHyp=cis-4-hydroxyproline, HThr=4-hydroxythreonine, ClThr=4- 
chlorothreonine, cThr/cHThr=cyclic Thr or HThr, i.e. forming an additional ring closure to the chromophore, rHThr= 
rearrangement of the HThr (β-ring) connectivities. 
a. This table was updated based on previous overview on naturally occurring actinomycins (77). 
 
 
 
 
3.3.2 Biological activity of actinomycins 
 
The biological activities of the novel Y-type actinomycins, along with known isolated 
actinomycins as controls, were evaluated against different Gram-positive and Gram- 
negative strains by using commercial actinomycin D as a clinical reference. Most 
actinomycins showed potent activity against Gram-positive strains except for Y3 and 
Y4. 4 showed the most potent antibacterial activity, followed by 3 and 5. 2 had 
significant decreased activity while 1 was 50-fold less active than 2. 
The results of the antibacterial screen revealed insight into structure-activity 
relationship (SAR) of actinomycins. 5 differed from actinomycin D only in the 5- 
methylproline moiety of the β-ring and showed a 2-fold decrease in activity, indicating 
that methylation of proline had a slight negative impact. When compared with 4, a 
decreased activity of 3 against S. aureus and B. subtilis indicated that introduction of 
an extra hydroxyl group to the methylproline of α-ring was also detrimental to the 
antibacterial activity. Modifications on the threonine moiety of β-ring also significantly 
lowered the activities, since 2 was at least 10-fold less active than 3 which only 
differed by the hydroxyl group on threonine. Another important factor that effected the 
activity was the nature of the cyclization of the β-peptide ring. The connection 
between threonine and alanine of β-ring is typically through an ester bond, and the 
chromophore was attached via an amide. This was not the case for 1, Y3, and Y4 
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which undergo an acyl rearrangement. 1 had significantly decreased activity, while 
Y3 and Y4 showed no appreciable activity suggesting that the β-peptidolactone ring 
played an important role. On the other hand, the fusion of the peptidolactone to the 
phenoxazine had a positive impact on activity since 1 was at least 4-fold more potent 
than Y3. 
As part of our program aimed at rapidly accessing peptide antibiotics, we 
implemented a solid phase synthetic strategy to obtain potential actinomycin 
precursors and derivatives. The synthesized partial 6 and phenol-4 showed no 
appreciable activity against any tested strains. This result indicated that neither the 
peptide chain with altered aromatic moiety nor 4-MHA can provide any antibacterial 
activity. Thus protactin (94) is the minimum bioactive unit (fig 3.3.6). 
 
 
 
Table 3.3.6. In Vitro antimicrobial activities of 1-5 and actinomycins Y1, Y3, Y4 
and D. 
 
MIC ( μM) 
Compound S. 
  aureus   
M. 
luteus   
B. 
subtilis   
M. 
aurum   
  S. 
  cerevisae   S. enterica   E. coli
1 30 7.5 7.5 12 >120 >120 120 
2 6 1.5 1.5 12 >120 >120 >120 
3 0.4 0.04 0.15 12 >120 >120 120 
4 0.15 0.04 0.04 12 >120 >120 120 
5 0.6 0.075 0.075 12 >120 120 >120 
Y1 0.3 0.04 0.02 7.5 >120 >120 60 
Y3 >120 60 >120 >120 >120 >120 >120 
Y4 >120 60 >120 >120 >120 >120 >120 
D 0.075 0.04 0.02 7.5 120 120 60 
C7 >120 >120 >120 >120 >120 >120 >120 
Phenol-4 >120 60 >120 >120 >120 >120 >120 
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Structural modification to actinomycins had parallel impact to antibacterial activity and 
cytotoxicity as noticed in this study. For most cases, actinomycins with higher 
antibacterial potency were more toxic to different cell lines (PC3 and A549 cells were 
used in this study). Importantly, actinomycins with iso-actinomycins such as 5 and 
actinomycin D showed highest toxicity against human cell lines, and this feature 
should be avoid for development of actinomycins as antibacterial agents. 
 
Table 3.3.7. Cytotoxic activity of actinomycins against different tumor cell 
lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Importantly, even though structurally different actinomycins varied in most 
antibacterial activities, their anti-Mycobacteria activity was apparently independent 
from structural modifications. For example, 1 and 2 showed the least cytotoxicity 
against human cancer cell lines and are about 100-fold less toxic than actinomycin 
D, and their activity against S. aureus, M. Iuteus and B. subtilis paralleled the 
decrease in cytotoxicity. Nonetheless, 1 and 2 were still shown to have moderate 
activity against M. aurum with MIC at 12 µM that is comparable to actionomycin D 
(MIC of 7.5 µM). This divergence between toxicity and activity suggests a   possible 
Compound  
  
 
EC50 (nM)    
   PC3 Cells   A549 Cells   
1 76.70 71.48 
2 51.18 119.30 
3 2.77 7.67 
4 0.47 1.54 
5 0.16 0.74 
Y1 0.70 1.10 
Y3 2051 3392 
Y4 1474 3272 
  D   0.61   1.64   
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distinct mechanism of inhibition in M. aurum. This unexpected discovery suggest that 
the actionmycin scaffold may be a good candidate for development of anti- 
Mycobacteria agents, and further structural optimization may enhance this anti- 
mycobacteria activity without compromising drug safety. We are currently testing all 
actinomycins against Mycobacterium tuberculosis, the primary causative agent of TB. 
3.4 Conclusion
The high antibiotic potency and low toxicity of actinomycin Y5 suggested it is possible 
to be a lead compound to achieve an antibiotic-selective actinomycin through 
structural modification. With the goal of expanding the family of actinomycins by 
discovering novel members, we conducted a thorough characterization of the 
metabolic profile of Streptomyces sp. Strain Gö-GS12 strain by LC-MS, and several 
actinomycins were characterized by 1D and 2D NMR. We successfully identified four 
new members of actinomycin family Y6-Y9 (1-4) which differ in the asymmetric (aniso-) 
peptidolactones compared to other actinomycins isolated from Streptomyces sp. 
Strain Gö-GS12, along with actinomycin Zp (5), which was for the first time isolated 
as a natural product. Similar to previously discovered actinomycins from this strain, 
1-4 bear the rare OPro in β-ring and HMPro or MPro in α-ring. 1 also contains two
important structural features including a two-fold acyl shift and an additional ring 
closure. 5 is the only symmetric (iso-) actinomycins produced by this strain, and this 
is also for the first time that iso- and aniso-actinomycins were isolated from the same 
strain. The new members of actinomycins were tested for activity to provide more 
detailed information on antimicrobial/toxicity structure-activity relationship (SAR)   of 
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the actinomycins. The oxidation of proline or threonine moiety diminishes the 
bioactivity in terms of both antibacterial activity and cytotoxicity, and the 
rearrangement of β-ring has a similar negative impact. The additional ring closure of 
1 and Y5 seemed to be the only plausible modification β-ring which leads to significant 
improved antibacterial activity. A structural model of compound 1 containing the 
rearranged β-ring and the additional third ring suggested the β-ring significantly 
changes conformation while the conformation of α-ring showed only minor changes 
(fig. 3.3.6). The differences in conformation of the β-ring may contribute to the binding 
of actinomycins to DNA molecules resulting in various antibacterial activities and 
cytotoxicity. It was interesting to note that the two least toxic actinomycins against 
human cancer cell lines, 1 and 2, maintained potency against M. aurum that was 
comparable to actinomycin D, suggesting divergent activity may be achieved for 
developing an anti-TB agent. 
β-ring 
α-ring 
Chromophore core 
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Figure 3.3.6. Conformational changes of α- and β-ring of actinomycins. The 
structure of actinomycin D (blue line, PDB ID: 4HIV) is shown in blue line. Actinomycin 
Y3 containing a rearranged β-ring was shown in yellow, Y5 and 1 containing the 
additional ring structure were shown as red and green lines, respectively. Structures 
were superimposed by chromophore cores, and the structures of Y3, Y5 and 1 were 
established and optimized using Gaussian program*. 
Streptomyces sp. Strain Gö-GS12 produces at least 10 different actinomycins, from 
actinomycin Y1-Y9 and Zp, with various on both peptide chains and includes almost 
all of the important structural features that have been discovered for different 
actinomycins. The ability of producing a variety of analogues makes this strain a 
perfect candidate to establish a model strain to study SAR and possibly the 
biosynthetic pathway of actinomycins. 
* I am grateful to Prof. Dr. Zhaoyong Yang at Chinese Academy of Medical Science & Peking Union 
Medical College for giving me the remote access to the program in his group. 
                                         Copyright © Wenlong Cai 2015
147 
Chapter 4: Summary 
The discovery of novel antibiotics has dramatically decreased over the last few 
decades while tuberculosis (TB) remains a global major threat to public health. Thus, 
discovery and development of new antibiotics are urgently needed. Capuramycins, a 
class of nucleoside antibiotics, show potent anti-TB activity by inhibiting the bacterial 
MraY, a key enzyme involved in the biosynthesis of peptidoglycan cell wall. The first 
part of this dissertation describes the identification and characterization of the 
biosynthetic gene cluster for A-102395, which is the latest member of capuramycins. 
Bioinformatic analysis of the gene cluster led us to identify 35 putative open reading 
frames (ORF) which were responsible for the biosynthesis and resistance. A series 
of gene inactivations indicate those genes are essential for A-102395 biosynthesis. 
Among the cluster were the genes Cpr19 and Cpr25, two enzymes involved in the 
assembly of the (5’S, 6’S)-5’-C-glycyluridine (GlyU). After this pair of genes was 
coexpressed and was functionally characterized, a shared biosynthesis paradigm for 
uridine-5'-carboxamide (CarU) in uridyl lipopeptide antibiotics was suggested. The 
enzyme conferring self-resistance, Cpr17, was characterized as a 
phosphotransferase, and its substrate promiscuity was explored. Cpr17 transfers the 
γ-phosphate from a nucleoside triphosphate, and GTP was the preferred the 
phosphate donor. Additionally, a validated target- and species-specific high- 
throughput screening model was established, and this model will be used to screen 
natural products and their derivatives to identify new antibacterial therapeutics. 
The second part of this dissertation describes the discovery of novel actinomycins 
via a thorough investigation of the metabolic profile from Streptomyces sp. Strain Gö- 
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GS12. Four new members of actinomycin family Y6-Y9 were isolated and structurally 
elucidated by LC-MS, 1D and 2D NMR. Their anti-TB activity and cytotoxicity were 
determined, and the unexpected divergence between them suggested that the 
actinomycin scaffold may be a good candidate for development of anti-TB agents, 
and further structural optimization may enhance their anti-microbial activity without 
sacrificing drug safety. 
Copyright © Wenlong  2015
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Figure S32. 1H NMR spectrum (CDCl3, 400 MHz) of actinomycin Zp (5) II-34
Figure S33. 13C NMR spectrum (CDCl3, 100 MHz) of actinomycin Zp (5) II-35
Figure S34. HSQC spectrum (CDCl3, 500 MHz) of actinomycin Zp (5) II-36
Figure S35. HMBC spectrum (CDCl3, 500 MHz) of actinomycin Zp (5) II-37
Figure S36. 1H, 1H COSY spectrum (CDCl3, 500 MHz) of actinomycin Zp (5) II-38
Figure S37. (+)-HRESI-MS (positive mode) of actinomycin Zp (5) II-39
Figure S38. 1H NMR spectrum (CDCl3, 500 MHz) of actinomycin Y1 II-40
Figure S39. 13C NMR spectrum (CDCl3, 100 MHz) of actinomycin Y1 II-41
Figure S40. HSQC spectrum (CDCl3, 500 MHz) of actinomycin Y1 II-42
Figure S41. HMBC spectrum (CDCl3, 500 MHz) of actinomycin Y1 II-43
Figure S42. 1H, 1H COSY spectrum (CDCl3, 500 MHz) of actinomycin Y1 II-44
Figure S43. TOCSY spectrum (CDCl3, 500 MHz) of actinomycin Y1 II-45
Figure S44. (+)-HRESI-MS (positive mode) of actinomycin Y1 II-46
Figure S45. 1H NMR spectrum (CDCl3, 500 MHz) of actinomycin Y3 II-47
Figure S46. 13C NMR spectrum (CDCl3, 100 MHz) of actinomycin Y3 II-48
Figure S47. (+)-HRESI-MS (positive mode) of actinomycin Y3 II-49
Figure S48. 1H NMR spectrum (CDCl3, 500 MHz) of actinomycin Y4 II-50
Figure S49. 13C NMR spectrum (CDCl3, 100 MHz) of actinomycin Y4 II-51
Figure S50. (+)-HRESI-MS (positive mode) of actinomycin Y4 II-52
Figure S51. 1H NMR spectrum (CDCl3, 500 MHz) of 6 II-53
Figure S52. 13C NMR spectrum (CDCl3, 100 MHz) of 6 II-54
Figure S53. HSQC spectrum (CDCl3, 500 MHz) of 6 II-55
Figure S54. HMBC spectrum (CDCl3, 500 MHz) of 6 II-56
Figure S55. 1H, 1H COSY spectrum (CDCl3, 500 MHz) of 6 II-57
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